2026 Semi-Annual Report

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Company code: 688606 Company abbreviation: Aotai Biotechnology

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

1/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Important tips

1. The company’s board of directors, directors and senior managers guarantee the authenticity, accuracy and completeness of the contents of the semi-annual report and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.

2. Major Risk Warning

The company has elaborated on the risk factors that may have an adverse impact on the company in Part 4 "Risk Factors" of Section 3 "Management Discussion and Analysis" of this report. Investors are advised to pay attention to investment risks.

3. All directors of the company shall attend the board meeting.

4. This semi-annual report has not been audited.

5. The person in charge of the company, Gao Fei, the person in charge of accounting work Fu Yanping, and the person in charge of the accounting department (accounting supervisor) Fu Yanping declare that they guarantee the authenticity, accuracy and completeness of the financial report in the semi-annual report.

6. There is no profit distribution plan for the reporting period or a plan for converting public reserve funds into share capital passed by the board of directors.

7. Whether there are any important matters such as special arrangements for corporate governance

□Applicable √Not applicable

8. Risk Statement for Forward-Looking Statements

√Applicable □Not applicable

The company's future plans, development strategies and other forward-looking statements involved in this report do not constitute the company's substantive commitment to investors. Investors are advised to pay attention to investment risks.

9. Whether there is any non-operating use of funds by controlling shareholders and other related parties

No

10. Whether there is any violation of the prescribed decision-making procedures in providing external guarantees

No

11. Whether more than half of the directors cannot guarantee the authenticity, accuracy and completeness of the semi-annual report disclosed by the company

12. Others

□Applicable √Not applicable

2/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Directory

Section 1 Interpretation ...................................................................................................................................................... 4

Section 2 Company Profile and Main Financial Indicators .................................................................................................. 6

Section 3 Management Discussion and Analysis................................................................................................................ 9

Section 4 Corporate Governance, Environment and Society .................................................................................................. 32

Section 5 Important Matters...................................................................................................................................... 33

Section 6 Changes in Shares and Status of Shareholders................................................................................................................ 49

Section 7 Bond-related situations...................................................................................................................... 53

Section 8 Financial Report...................................................................................................................................... 54

Financial report signed and stamped by the company’s legal representative, person in charge of accounting work, and person in charge of the accounting department

Document directory for reference

The original copies of all company documents and announcements publicly disclosed on the website designated by the China Securities Regulatory Commission during the reporting period

3/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Section 1 Interpretation

In this report, unless the context otherwise requires, the following words have the following meanings:

Commonly used word definitions

The Company, the Company, Aotai Biotechnology refers to Hangzhou Aotai Biotechnology Co., Ltd. Jingguan Investment refers to Hangzhou Jingguan Investment Management Co., Ltd.

Qunze Investment refers to Hangzhou Qunze Investment Management Co., Ltd.

Saida Investment refers to Hangzhou Saida Investment Partnership (Limited Partnership) Aorui Biotechnology refers to Hangzhou Aorui Biomedical Technology Co., Ltd. Tongzhou Biotechnology refers to Hangzhou Tongzhou Biotechnology Co., Ltd.

Fantian Biotechnology refers to Fantian Biotechnology Co., Ltd.

CitestDiag refers to Citest Diagnostics Inc.

Aokai Biotechnology refers to Hangzhou Aokai Biotechnology Co., Ltd.

Saiye Technology refers to Hangzhou Saiye Technology Co., Ltd.

Tianyu Bio refers to Haining Tianyu Biotechnology Co., Ltd.

AcesoLab refers to Aceso Laboratories Inc.

Ruichi Biotechnology refers to Hangzhou Ruichi Biotechnology Co., Ltd.

Yile Biotechnology refers to Hangzhou Yile Biotechnology Co., Ltd.

Yingxin Medical refers to Zhejiang Yingxin Medical Technology Co., Ltd.

Yinghai Medical refers to Zhejiang Yinghai Medical Supplies Co., Ltd.

RapidLabs refers to Rapid Labs Limited

ACESO PTY refers to ACESO DIAGNOSTICS PTY LTD Shuguang Technology refers to Zhejiang Shuguang Technology Co., Ltd.

Qinzhi Investment refers to Hangzhou Qinzhi Jianyuan Venture Capital Partnership (Limited Partnership) Fanling Biotechnology refers to Fanling Biotechnology (Hangzhou) Co., Ltd. FuXin Medical refers to FuXin Medical Limited

AUSTRALIA ALLTEST refers to AUSTRALIA ALLTEST BIOTECH PTY LTD ABOUNDDiag refers to ABOUND DIAGNOSTICS INC. Yingjian Bio refers to Hangzhou Yingjian Biotechnology Co., Ltd.

Weibo Medical refers to Hangzhou Weibo Medical Technology Co., Ltd. RapidLabs HK refers to RapidLabs HongKong Limited Chaowu Cloud Core refers to Hangzhou Chaowu Cloud Core Technology Co., Ltd.

VIDAQUICK S.L. means VIDAQUICK BIOTECH S.L.

Aceso Consulting,Importation And Distribution Of Health’s Aceso Consulting refers to

Products LTD.

ALLTEST UK means ALLTEST UK LIMITED

Jiesuda refers to Hangzhou Jiesuda Supply Chain Co., Ltd.

Qitianxia Digital Technology refers to Hangzhou Qitianxia Digital Technology Co., Ltd. Future Xinsheng Health Management refers to Hangzhou Future Xinsheng Health Management Co., Ltd. Phamatech refers to Phamatech, Inc.

Shareholders' meeting refers to the shareholders' meeting and board of directors of Hangzhou Aotai Biotechnology Co., Ltd. refers to the board of directors of Hangzhou Aotai Biotechnology Co., Ltd. Company Law refers to the Company Law of the People's Republic of China

Securities Law refers to the Securities Law of the People's Republic of China

The abbreviation of In-Vitro Diagnostics in English refers to a diagnostic method that tests human IVD, blood, body fluid, tissue and other samples outside the human body to determine diseases or body functions.

The abbreviation of Point Of Care Testing in English refers to clinical POCT performed next to the patient, which refers to instant diagnosis.

On-the-bed testing, analysis can be performed immediately at the sampling site, eliminating the need for specimens to be tested in the laboratory.

4/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

It is a new type of method that can quickly obtain test results through time-consuming complex processing procedures.

In the process of in vitro diagnosis, used alone or in conjunction with instruments, in vitro diagnostic reagents refer to reagents, kits, calibrators (materials), quality control materials (materials), etc. for in vitro testing of human samples (various body fluids, cells, tissue samples, etc.).

Substances that can stimulate the body to produce (specific) immune responses and can combine with immune response-generated antigens, antibodies, and sensitized lymphocytes in vivo and in vitro to produce immune effects (specific reactions) are among the core raw materials of in vitro diagnostic reagents.

Under the stimulation of antigens, the body's immune system produces immunoglobulins produced by plasma cells that multiply and differentiate from B lymphocytes or memory cells and can specifically bind to the corresponding antigens. They are one of the core raw materials of in vitro diagnostic reagents.

A highly homogeneous monoclonal antibody secreted by the differentiated and proliferated daughter cells of a B cell.

Antibodies specific for a single epitope.

Polyclonal antibodies produced by different B cell clones against multiple antigenic determinants in antigenic substances refer to

Multiple antibody cocktails.

When chloroauric acid is used as a colloidal gold finger with reducing agents such as white phosphorus, ascorbic acid, sodium citrate, tannic acid, etc., it can polymerize into gold particles of a certain size, and become a stable colloidal state due to electrostatic interaction to form a negatively charged hydrophobic glue solution.

The emerging immune detection technology that emerged in the 1990s is characterized by the application of anti-immune chromatography technology to refer to antigens, antibody immunological reactions and chromatographic reactions, and in the form of dry sheet test paper, to achieve the purpose of rapid and accurate color development to detect the analyte.

The method that combines immunological methods (specific binding of antigens and antibodies) with fluorescent labeling technology, and uses known fluorescent antigen markers or antibody markers to detect the corresponding antibodies or immunofluorescence technology to refer to the antigen is called immunofluorescence. Because fluorescent dyes can not only bind to antibody globulin and be used to detect or locate various antigens, but can also bind to other proteins to detect or locate antibodies.

Combining highly sensitive chemiluminescence measurement technology with highly specific immunoreaction chemiluminescence technology, it is used for the detection and analysis of various antigens, haptens, antibodies, hormones, enzymes, fatty acids, vitamins and drugs.

The abbreviation of Original Design Manufacturer in English means that the manufacturer is entrusted by the purchaser, and the manufacturer is responsible for everything from design to production, while the purchaser is responsible for the sales ODM.

In the production method for sale, the purchaser usually authorizes its brand and allows the manufacturer to produce products bearing the brand.

FDA is the English abbreviation of the U.S. Food and Drug Administration. It is responsible for the safety inspection and approval of drugs, foods, biological products produced and imported in the United States. U.S. FDA registration refers to drugs, cosmetics, veterinary drugs, medical devices, diagnostic supplies and other products. Only products certified by the FDA can enter the U.S. market for sale.

The CE mark (CEMark) is a mandatory mark and is the European Union's certification of imported products. Products that have passed the certification can be affixed with the CE ("CONFORMITE EUROPEENNE" abbreviation) mark, indicating compliance with safety, health, environmental protection and EU CE certification guidelines.

The requirements of a series of European directives such as consumer protection can be freely circulated within the EU single market. If the product that requires the CE mark does not have the CE mark, it shall not be sold in the EU market.

The abbreviation of English Medical Device License, that is, medical device license, is the Canadian MDL certification. It refers to the administrative license issued by Health Canada to allow related medical devices to be marketed in Canada.

TGA is the English abbreviation of Therapeutic Goods Administration (Therapeutic Goods Administration) in Australia. The Australian TGA registration refers to medical products produced, imported and exported in Australia.

All medical supplies (including drugs and medical devices) must be registered and listed in the Australian Register of Medical Goods (ARTG) ("Australian Register of

5/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Therapeutic Goods" abbreviation) can only be supplied to the Australian market.

MHRA is the abbreviation of Medicines and Healthcare products Regulatory Agency. It was registered by the British MHRA on January 1, 2021.

After the end of the Brexit transition period, all medical devices and in vitro diagnostic medical devices will need to be registered with the MHRA before they can be supplied to the British market.

Medical Device Single Audit Program. MDSAP is co-sponsored by members of the International Medical Device Regulatory Agency Forum (IMDRF). The United States, Australia, Brazil, Canada, and Japan refer to the five MDSAP

A new set of audit procedures recognized and joined by the country’s regulatory agencies. This procedure aims to establish a single audit process to meet and unify the audit requirements of the above countries and make the audit more comprehensive and effective.

The English abbreviation of In Vitro Diagnostic Devices Regulations (IVDR Regulations) is a new regulation for in vitro diagnostic medical devices (IVD) that will be officially implemented by the European Union from May 26, 2022.

Reporting period refers to January 1, 2026 to June 30, 2026

Section 2 Company Profile and Main Financial Indicators

1. Basic information of the company

The Chinese name of the company: Hangzhou Aotai Biotechnology Co., Ltd.

The company’s Chinese abbreviation Aotai Biotechnology

The company's foreign name: Hangzhou Alltest Biotech Co.,Ltd

The company's foreign name abbreviation Alltest

The legal representative of the company Gao Fei

Company registration address: No. 550, Yinhai Street, Baiyang Street, Hangzhou Economic and Technological Development Zone, Jianggan District, Hangzhou City, Zhejiang Province

Factory buildings in Building 3, Building 4 and Building 5

On July 11, 2014, the company's registered address was changed from "Room 5A16-5A19, Building 1, No. 452, No. 6 Street, Baiyang Street, Hangzhou Economic and Technological Development Zone" to "The third and fourth floors of Workshop 2, No. 550 Yinhai Street, Baiyang Street, Hangzhou Economic and Technological Development Zone"; on October 18, 2019, the company's registered address was changed from "Room 5A16-5A19, Building 1, No. 452, Baiyang Street, Hangzhou Economic and Technological Development Zone"; on October 18, 2019, the company's registered address was changed from "Room 5A16-5A19, Building 1, No. 452, Baiyang Street, Hangzhou Economic and Technological Development Zone"; 2The third and fourth floor factory building" was changed to "The 4th factory building, Building 3, No. 550, Yinhai Street, Baiyang Street, Hangzhou Economic and Technological Development Zone, Zhejiang Province"; on October 31, 2019, the company's registered address was changed from "Hangzhou, Zhejiang Province "Factory Building No. 3, Building 4, No. 550 Yinhai Street, Baiyang Street, Economic and Technological Development Zone" was changed to "Factory Building No. 5, Building 3, Building 4, No. 550, Yinhai Street, Baiyang Street, Jianggan District, Hangzhou City, Zhejiang Province"

Company office address: No. 383, Qiaoxin Road, Xiasha Street, Qiantang District, Hangzhou City, Zhejiang Province

Postal code for company office address 310018

Company website www.alltests.com.cn

Email [email protected]

Query index for changes during the reporting period None

2. Contact person and contact information

Secretary of the Board of Directors (Domestic Representative for Information Disclosure) Securities Affairs Representative

Name Fu Yanping Pan Haijie

Contact address: No. 383, Qiaoxin Road, Xiasha Street, Qiantang District, Hangzhou No. 383, Qiaoxin Road, Xiasha Street, Qiantang District, Hangzhou Tel: 0571-56207860 0571-56207860

Fax 0571-56267856 0571-56267856

Email [email protected] [email protected]

6/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

3. Brief introduction to changes in information disclosure and storage location

The name of the newspaper selected by the company for information disclosure: Shanghai Securities News, Securities Times

The website address for publishing the semi-annual report is www.sse.com.cn

The company's semi-annual report is prepared at the Secretary's Office of the Board of Directors of Aotai Biotechnology Co., Ltd.

Query index for changes during the reporting period None

4. Brief introduction of company stocks/depository receipts

(1) Brief introduction of company stock

√Applicable □Not applicable

Company Stock Profile

Stock type Stock exchange and sector Stock abbreviation Stock code Stock abbreviation before change RMB Ordinary shares A shares Shanghai Stock Exchange Science and Technology Innovation Board Aotai Biotechnology 688606 Not applicable

(2) Brief introduction to the company’s depositary receipts

□Applicable √Not applicable

5. Other relevant information

√Applicable □Not applicable

Name Grant Thornton Certified Public Accountants LLP (Special General Partnership)

Accountant hired by the company

Office address: 5th Floor, Saite Building, No. 22 Jianguomenwai Street, Chaoyang District, Beijing (domestic)

Name of the signing accountant: Wang Yichong, Luo Jingya

Name Shenwan Hongyuan Securities Underwriting and Sponsoring Co., Ltd.

Performed during the reporting period

Office address: 23rd Floor, Building B, Ping An Financial Center, No. 280 Minxin Road, Shangcheng District, Hangzhou City

Names of the signing sponsor representatives: Liao Yanhua, Zhang Xingzhong

Recommended institutions

Period of continuous supervision 2021.03.25-2024.12.31

Note: As of June 30, 2026, the company's continued supervision period for its initial public offering and listing has expired. In view that the company's previous raised funds have not been fully used, Shenwan Hongyuan Securities Underwriting and Sponsoring Co., Ltd. will continue to pay attention to the use of the company's raised funds and perform supervision responsibilities.

6. The company’s main accounting data and financial indicators

(1) Main accounting data

Unit: Yuan Currency: RMB This reporting period The main accounting data for this reporting period are the same as those for the same period last year

(January to June) Period increase or decrease (%) Operating income 392,144,917.68 429,850,024.75 -8.77 Total profit 54,022,896.75 152,107,387.74 -64.48 Net profit attributable to shareholders of listed companies 50,844,708.31 132,012,694.61 -61.48 Deductions attributable to shareholders of listed companies are not

41,772,372.81 109,435,369.36 -61.83 Net profit from recurring gains and losses

Net cash flow generated from operating activities 52,885,009.00 61,353,635.75 -13.80 The end of this reporting period compared to the end of the previous year The end of this reporting period The end of the previous year

End-of-year increase/decrease (%) in net assets attributable to shareholders of listed companies 3,760,727,808.92 3,946,690,966.34 -4.71

Total assets 3,997,363,870.44 4,242,424,960.67 -5.78

7/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) Main financial indicators

Main financial indicators of this reporting period This reporting period compared with the same period of the previous year

(January to June) Increase/decrease in the same period (%) Basic earnings per share (yuan/share) 0.64 1.67 -61.68 Diluted earnings per share (yuan/share) 0.64 1.67 -61.68 Basic earnings per share after deducting non-recurring gains and losses (yuan/share) 0.53 1.38 -61.59

Decrease 2.05% weighted average return on equity (%) 1.30 3.34

equinox

Decrease by 1.71% Weighted average return on equity after deducting non-recurring gains and losses (%) 1.07 2.77

equinox

Increase the proportion of R&D investment in operating income by 4.19% (%) 15.40 11.21

equinox

Description of the company’s main accounting data and financial indicators

√Applicable □Not applicable

1. Operating income during the reporting period decreased by 8.77% compared with the same period last year. First, due to intensified industry competition, the average sales price of products dropped year-on-year; second, due to the downward impact of the U.S. dollar exchange rate, it had a direct impact on the revenue of related businesses settled in U.S. dollars;

2. During the reporting period, the net profit attributable to shareholders of listed companies and the net profit attributable to shareholders of listed companies excluding non-recurring gains and losses decreased by 61.48% and 61.83% respectively compared with the same period last year. They were affected by multiple factors: first, the operating income declined year-on-year during the reporting period; second, the fluctuation of the U.S. dollar exchange rate Movement, resulting in a significant increase in current exchange losses in financial expenses compared with the same period last year; third, the relevant factories were transferred to fixed assets in the second half of last year, and the depreciation of new fixed assets had a certain impact on current profits; fourth, the company continued to accelerate investment in research and development of the electrochemical technology platform, and related research and development expenses increased compared with the same period last year;

3. The net cash flow generated from operating activities during the reporting period decreased by 13.80% compared with the same period last year, mainly due to the impact of the decline in profits during the reporting period;

4. Earnings per share during the reporting period decreased by 61.68% compared with the same period last year, mainly due to the decrease in net profit during the reporting period.

7. Differences in accounting data under domestic and foreign accounting standards

□Applicable √Not applicable

8. Non-recurring profit and loss items and amounts

√Applicable □Not applicable

Unit: Yuan Currency: RMB Note (if applicable non-recurring profit and loss items Amount

Profit and loss from disposal of non-current assets, including the write-off portion of asset impairment provisions made 48,941.77

Government subsidies included in the current profit and loss, but closely related to the company's normal business operations,

Comply with national policies and regulations, enjoy according to determined standards, and contribute to the company’s profits and losses 2,484,701.69

Except for government subsidies that will continue to affect

In addition to effective hedging business related to the company's normal business operations, non-financial enterprises

Gains and losses from changes in fair value of financial assets and financial liabilities held by the enterprise and disposal 8,153,462.48

Gains and losses arising from financial assets and financial liabilities

Fund occupation fees charged to non-financial enterprises included in current profits and losses

Gains and losses from entrusting others to invest or manage assets

Profit and loss from external entrusted loans

Loss of various assets due to force majeure factors, such as natural disasters

Reversal of impairment provision for accounts receivable that has been individually tested for impairment

8/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Note (if applicable non-recurring profit and loss items Amount

The investment costs for enterprises using) to acquire subsidiaries, associates and joint ventures are less than the cost of acquiring investments.

The investor should enjoy the income generated from the fair value of the identifiable net assets of the investee.

Net profit and loss for the current period from the beginning of the period to the date of merger of subsidiaries resulting from business combinations under common control

Gains and losses on non-monetary asset exchanges

Debt restructuring gains and losses

One-time expenses incurred by the enterprise due to the discontinuation of relevant business activities, such as job placement

labor expenses, etc.

The one-time impact on the current profit and loss due to adjustments to laws and regulations such as taxation and accounting

ring

One-time confirmation of share-based payment expenses due to cancellation or modification of equity incentive plan

For cash-settled share-based payment, after the vesting date, employee benefits payable

Gains and losses arising from changes in fair value

Changes in the fair value of investment real estate using the fair value model for subsequent measurement

Profit and loss incurred

Gains from transactions where the transaction price appears to be unfair

Profit and loss arising from contingencies unrelated to the company's normal business operations

Custody fee income from entrusted operations

Other non-operating income and expenses other than the above items 48,897.19

Other profit and loss items that meet the definition of non-recurring profits and losses

Less: Impact on income tax 1,663,667.63 Impact on minority shareholders’ equity (after tax)

Total 9,072,335.50

If the company identifies items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and is significant in amount, and defines the non-recurring gains and losses listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring gains and losses, the reasons should be stated □ Applicable √ Not applicable

9. Companies with equity incentives and employee stock ownership plans may choose to disclose net profits after deducting the impact of share-based payments.

√Applicable □Not applicable

Unit: Yuan Currency: RMB Main accounting data for this reporting period compared with the same period last year

(January to June) Increase/decrease (%) Net profit after deducting the impact of share-based payment 55,844,900.89 141,691,006.85 -60.59

10. Description of non-business accounting standards performance indicators

□Applicable √Not applicable

Section 3 Management Discussion and Analysis

1. Description of the company’s industry and main business during the reporting period

1. The company’s main business and main products

The company has long been focusing on the POCT point-of-care testing segment in the in vitro diagnostic industry, and its main business focuses on the research and development, production and sales of rapid in vitro diagnostic reagents. At present, eight core technology platforms have been built: biological raw materials, POCT rapid diagnosis, electronic instruments, chemiluminescence, biochemistry, immunoblotting, molecular diagnosis, and biosensing electrochemistry. Based on this, a drug and drug abuse detection system has been formed.

9/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

testing, infectious disease testing, women’s health testing, tumor marker testing, cardiac marker testing and other multi-directional product matrix, covering other

Yu characteristic testing categories. The company has more than 1,600 products on the market, with rich categories and diversified forms. They can be widely used in multiple scenarios such as clinical testing, on-site rapid testing and personal health management, fully meeting the differentiated needs of different customers.

The company's main products are introduced as follows:

Product Category Main Products

Amphetamines, barbiturates, buprenorphine, benzodiazepines, clonazepam, flunitrazepam, cocaine, codeine, cotinine, methadone metabolites, ethyl glucuronide, fentanyl, ketamine, caralone, synthetic marijuana, lysergic acid diethylamide, ecstasy, methylene Dioxypyrovalerone, methamphetamine, morphine, methylphenidate, methazone, methcathinone, methadone, norfentanyl, opium, hydrocodone, phencyclidine, pregabalin, propoxyphene, carisoprodol, tricyclic antidepressants, THC drugs and drug abuse

Phenol, tramadol, synthetic cannabinoids, zolpidem, zopiclone, 6-monoacetylmorphine (6-MAM), fluamine, dimethyltryptamine, according to the detection series

Tomidate, gabapentin, cannabidiol, tapentadol, scopolamine, olanzapine, mirtazapine, mescaline, risperidone, citalopram, celoxibine, xylazine, paroxetine, aripiprazole, dextromethorphan, tiletamine, Tianeptine, papaverine, nizin, diphenoxylin, bupropion, chlorpromazine, repaglinide, modafinil, trihexyphenidyl, nalfurapine, lamotrigine, midazolam, medetomidine, hydrocodone, sertraline, clozapine, naloxone , synthetic cathinone, chlormethcathinone, diphenhydramine and other detection reagents; respiratory disease detection: new coronavirus antibody/antigen/neutralizing antibody/total antibody and other series of detection reagents, Mycoplasma pneumoniae, influenza A/B, adenovirus, respiratory syncytium Viruses, metapneumovirus, rhinovirus, parainfluenza virus, Streptococcus, Legionella pneumophila, tuberculosis, measles virus antibodies, varicella-zoster virus antibodies and other detection reagents, whooping cough, hand, foot and mouth disease, chlamydia pneumoniae, boca virus;

Liver and gastrointestinal disease detection: Hepatitis A/B/C/E, rotavirus, adenovirus, Salmonella typhoid/paratyphoid, Helicobacter pylori, astrovirus, Entamoeba histolytica, Giardia, Cryptosporidium, Clostridium difficile, Vibrio cholerae, norovirus, Campylobacter, Shigella, enterovirus and other detection reagents;

POCT fast infectious disease detection series

Sexually transmitted disease testing products: human immunodeficiency virus (AIDS), human herpes simplex virus, syphilis, chlamydia trachomatis, gonorrhea, rapid diagnostic test

Trichomonas vaginalis, human papillomavirus antigen, Candida albicans, Gardnerella bacilli, Chlamydia trachomatis + Trichomonas vaginalis + Candida albicans test kit

Three-in-one testing reagents;

(Colloidal detection of other insect/mouse/animal borne diseases: malaria, dengue fever, monkeypox virus, Chikungunya, cholera, filariasis, Zika virus, gold) Detection reagents for Leishmania, toxoplasmosis, Chagas disease, scrub typhus, Lyme disease, Leptospira, West Nile virus, Nipah virus antibody, Ebola virus antibody, etc.

Women's Health Testing System Human chorionic gonadotropin, luteinizing hormone, follicle-stimulating hormone, anti-Mullerian hormone, fetal fibronectin, insulin-like growth factor binding protein-1, vaginal pH and other testing reagents.

Tumor marker detection: fecal occult blood, alpha-fetoprotein, carcinoembryonic antigen, transferrin, prostate-specific antigen, CA125, CA15-3, CA19-9, pepsin series, zymogen PG1/PG2, pepsin and other detection reagents.

Cardiac marker detection: cardiac troponin (cTnI&cTnT), myoglobin, creatine kinase isoenzyme, C-reactive protein, procalcitonin, D dimer, cardiac fatty acid binding protein and other detection reagents.

Canine distemper, canine parvovirus, canine coronavirus, canine heartworm, canine leishmania, canine pregnancy, feline leukemia, feline AIDS, feline cupping, feline herpes, feline pregnancy animal/pet detection pregnancy, feline blood group card, African swine fever, bovine viral diarrhea, bovine pregnancy, bovine brucellosis, avian influenza, Newcastle disease, feline blood group, canine blood group, series Veterinary drug abuse detection reagents for peste des petits ruminants, canine Babesia, porcine foot-and-mouth disease, porcine circovirus, camelpox, amphetamine, cocaine, cotinine, methamphetamine, morphine, THC and other veterinary drugs.

Vitamin D (VD), calprotectin, glycated hemoglobin (HbA1c), microalbumin, ferritin, rheumatoid factor, dust mite IgE, and other testing series

Blood type, male fertility, serum amyloid A, celiac disease, hydroenzyme resistance, sickle cell and other testing reagents.

Troponin I, myoglobin, creatine kinase isoenzyme, troponin T, heart-type fatty acid binding protein, troponin I/myoglobin/creatine kinase isoenzyme three-in-one, troponin T/myoglobin/creatine kinase isoenzyme three-in-one, troponin I/D dimer/N cardiac marker series

Quantitative detection reagents such as three-in-one telebrain natriuretic peptide, high-sensitivity troponin I, high-sensitivity troponin T, high-sensitivity N-terminal brain natriuretic peptide, growth-stimulating expression gene 2 protein, and fibrinogen degradation products.

C-reactive protein, procalcitonin, serum amyloid, interleukin-6, calprotectin, myxovirus resistance protein A/C-reactive protein inflammatory marker series

White two-in-one, anti-cyclic citrullinated peptide antibody and other quantitative detection reagents.

Thyroid-stimulating hormone, thyroxine, triiodothyronine, free thyroxine, free triiodothyronine, and thyroglobus thyroid function testing series

Quantitative detection reagents for protein, thyroglobulin antibodies, thyroid peroxidase antibodies, parathyroid hormone, etc.

Beta-human gonadotropin, testosterone, progesterone, prolactin, cortisol, growth hormone, fetal fibronectin/insulin-like hormone detection series

Long factor binding protein-1 two-in-one and other quantitative detection reagents.

Time resolution COVID-19 antigen/antibody, combined influenza A and B, adenovirus, Mycoplasma pneumoniae, respiratory syncytial virus, syncytial/influenza A/influenza B/adenovirus/COVID-19/parainfluenza/pneumonia 7-in-1, pulmonary branch/syncytium/influenza A/influenza B/adenovirus/COVID-19/parainfluenza/pneumonia 8-in-1, dengue fever, malaria immunofluorescence infectious disease detection series

Qualitative detection reagents for viruses, HIV antibodies, rotavirus, norovirus, etc. Helicobacter pylori antigen, tetanus antibody, hepatitis B surface anti-detection reagent

Original quantitative detection reagent.

Prostate specific antigen, alpha-fetoprotein, fecal occult blood, free prostate specific antigen, cytokeratin 19 fragment, carbohydrate antigen tumor marker series

Quantitative detection reagents such as 125, carbohydrate antigen 153, carbohydrate antigen 199, etc.

Acetaminophen, amphetamine, α-pyrrolidinylpentylphenone, barbiturates, benzodiazepines, cocaine, codeine, 2-ethylene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), fentanyl, synthetic cannabinoids, 6-monoacetylmorphine, 3,4-methylenedioxy Drug abuse system methamphetamine, methamphetamine, methadone, morphine, opioids, oxycodone, phencyclidine, tricyclic antidepressants, major More than 30 kinds of fluorescent drug quantitative/qualitative detection reagents (urine/hair/sewage/environment) such as hemp (tetrahydrocannabinol), tiletamine, etomidate, buprenorphine, ecstasy, dextromethorphan, fluamine, propate, isopropate, thiophene, synthetic cathinone, and 15-in-1 fluorescent drug qualitative detection reagent (urine/hair/sewage/environment)

Vitamin D, ferritin, folic acid, vitamin B12, immunoglobulin A, immunoglobulin E, glycation, C-peptide, insulin and other quantitative series

Detection reagents.

10/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Urine analysis of pH, protein, occult blood, specific gravity, glucose, ketone bodies, urobilinogen, nitrate, leukocytes, bilirubin, creatinine, ascorbic acid, urinary calcium, microalbumin, etc.; urine adulteration analysis items such as oxidants, urinary creatinine, pH, nitrite, specific gravity, glutaraldehyde, etc.; Biochemical Diagnosis Dry Chemistry Biochemistry Series

Hemoglobin test, alcohol test, gamma-hydroxybutyric acid, G6PD, zinc test, calcium test, Helicobacter pylori chemical test, bile test reagents, sterol eye interpretation, urine HPV, breath alcohol, cat litter test, lactose intolerance test and other rapid test reagents.

Blood lipid testing series: rapid testing reagents for triglycerides, total cholesterol, high-density lipoprotein, low-density lipoprotein, etc.

Troponin I, myoglobin, creatine kinase isoenzyme, D-dimer, troponin T, N-terminal B-type natriuretic peptide precursor, B-type cardiac marker series

Quantitative detection reagents such as natriuretic peptide, heart-type fatty acid binding protein, and soluble ST2.

Inflammation marker series C-reactive protein, procalcitonin, interleukin-6, serum amyloid and other quantitative detection reagents.

Luteinizing hormone, anti-Mullerian hormone, β-human chorionic gonadotropin, follicle-stimulating hormone, prolactin, progesterone, testosterone, and estrogen detection series

Alcohol and other quantitative detection reagents.

Anemia vitamin testing

Quantitative detection reagents for ferritin, 25-hydroxyvitamin D, folic acid, vitamin B12, etc.

Series

Prostate detection series: quantitative detection reagents such as prostate specific antigen and free prostate specific antigen.

Infectious disease series: Hepatitis B surface antigen antibody, hepatitis C antibody, syphilis antibody, HIV antigen antibody and other detection reagents

chemiluminescence

Intestinal inflammation series calprotectin and other quantitative detection reagents

Detection reagent

Preeclampsia series placental growth factor, soluble tyrosine kinase-1 and other quantitative detection reagents

Allergen series IgE and other quantitative detection reagents

Thyroid function testing: Quantitative testing reagents for thyroid stimulating hormone, thyroxine, triiodothyronine, free thyroxine, free triiodothyronine, and thyroid globule series proteins.

Diabetes testing series: quantitative testing reagents for insulin, C-peptide, glycated hemoglobin, etc.

Alpha-fetoprotein, carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 15-3, carbohydrate antigen-242, carbohydrate antigen cytokeratin 19 fragment, tumor marker detection

Squamous cell carcinoma antigen, gastrin-releasing peptide precursor, carbohydrate antigen 19-9, carbohydrate antigen 72-4, human epididymis protein 4, neuronal series

Specific enolase and other quantitative detection reagents.

Gastric function testing series: pepsinogen I, pepsinogen II, gastrin 17 and other quantitative testing reagents.

Hepatitis B/C antibody, HIV antibody, syphilis antibody, Helicobacter pylori antibody, anti-falciparum HRP-Ⅱ antibody, novel coronavirus antigen/antibody, influenza virus antibody, dengue virus antibody, bovine viral diarrhea antibody, malaria antibody, Treponema pallidum recombinant antigen, AIDS antigen/anti-HIV recombinant antigen, hepatitis C virus recombinant antigen, Mycobacterium tuberculosis recombinant antigen, herpes simplex virus recombinant antigen, macrosomia Cytovirus recombinant antigens, dengue virus recombinant antigens and antibodies, Plasmodium falciparum recombinant antigens and antibodies, Plasmodium vivax recombinant antigens and antibodies, Plasmodium falciparum lactate dehydrogenase recombinant antigens and antibodies, Lyme Borrelia antigens, mouse anti-B flow coated antibodies, mouse anti-B flow labeled antibodies, mixed Plasmodium coated antibodies, mixed Plasmodium labeled antibodies, rabbit anti-E. coli K99 polyclonal antibodies, etc. Amphetamine antigen antibody, methamphetamine antigen antibody, benzodiazepine antigen antibody, cocaine antigen antibody, THC antigen antibody, synthetic cannabinoid antigen antibody, ketamine antigen antibody, fluorine antigen antibody, buprenorphine antigen antibody, fentanyl antigen antibody, morphine antigen antibody, ecstasy antigen antibody, zolpidem Antigen and antibody, zopiclone antigen and antibody, zaleplon antigen and antibody, etomidate antigen and antibody, methadone antigen and antibody, tapentadol antigen and antibody, tramadol antigen and antibody, dimethyltryptamine antigen and antibody, methadone metabolite antigen and antibody, tilidine antigen and antibody, cotinine antigen, kratom antigen, risperidone antigen and antibody, drug antigen/antibody Aripiprazole antigen antibody, carisoprodol antigen antibody, scopolamine antigen antibody, mirtazapine antigen antibody, litarine antigen antibody, citalopram antigen antibody, carbamazepine antigen antibody, tropamide antigen antibody, psilocybin antigen antibody, pethidine antigen antibody, tianeptine antigen antibody, xylazine antigen antibody, papaverine antibody, etizazepam antigen, diphenoxylate antigen, tianeptine antigen biological raw material Antibody, chlorpromazine antigen antibody, dextromethorphan antigen, bupropion antigen antibody, flutomidate antigen, sertraline antibody, phenylephrine series antibody, repaglinide antigen antibody, modafinil antigen antibody, trihexyphenidyl antigen antibody, methcathinone antigen, nalfurapine antigen antibody, medetomidine antigen, estrone sodium sulfate antibody and other raw materials for more than 100 small molecule drugs.

Feline leukemia recombinant antigen, feline leukemia virus antibody, C-reactive protein antibody, human hemoglobin antibody, classical CSFV coated antigen, tumor markers, cardiac swine fever CSFV marker antigen, porcine blue ear virus PRRSV antigen, foot and mouth disease FMDV-O antigen, canine leptovirus recombinant antigen, canine distemper marker, pet virus recombinant antigen, canine parvovirus recombinant antigen, canine coronavirus recombinant antigen, canine adenovirus recombinant antigen, canine parainfluenza virus retest and other antigens/antigens Group antigen, African swine fever P54-30a antigen (marker), African swine fever P54-22b antigen (coating), porcine ring (PCV) antigen, body biological raw materials Tetanus tetanus antigen, recombinant troponin, feline HIV recombinant antigen, Babesia gibsoni recombinant antigen, feline B blood type recombinant antibody, etc.;

Inflammation, glucose metabolism

Insulin-like growth factor binding protein 1, serum amyloid A1, procalcitonin and other antigens and antibodies.

Antigen/Antibody

Enzymes and enzyme antibodies, auxiliary streptavidin SA, SP-10 recombinant protein, recombinant Staphylococcus aureus protein A, biotin-conjugated bovine serum albumin, γ-hydroxy auxiliary antibody raw materials butyrate dehydrogenase, human type II angiotensin-converting enzyme, etc.

Other tests: ovomucoid, cat hair allergen 2 and 1 fusion protein, shrimp tropomyosin

Human allergen IgE antibody detection series, human allergen IgE antibody rapid detection series, animal allergen IgE antibody detection series, animal immunoblotting series

Physical allergen IgE antibody rapid detection series, antinuclear antibody spectrum detection series

Electronic pregnancy test stick, electronic ovulation test pen, hemoglobin analyzer, drug detection urine cup device reader, desktop/handheld gold label reader, electronic instrument series fully automatic chemiluminescence immunoanalyzer, desktop/handheld/semi-automatic dry fluorescence immunoanalyzer, blood lipid analyzer, desktop/handheld urine analyzer, animal gold label reader, animal fluorescence immunoanalyzer, animal urine analyzer.

Blood glucose testing (oxidase method), blood glucose testing (dehydrogenase method), four-in-one testing (blood glucose, blood ketones, blood lipids, and uric acid), blood creatinine testing, biosensing electrochemical series, hemoglobin testing, blood glucose and blood ketone test paper two-in-one testing, blood glucose and uric acid test paper two-in-one testing, continuous dynamic glucose monitoring (CGM), animal two-in-one testing (blood sugar and blood ketones), blood ketone testing (non-medical use), lactate testing (non-medical use)

New coronavirus and Delta variant RT-qPCR reagents, new coronavirus and Omicron variant RT-qPCR reagents, influenza molecular diagnostic series

Virus A/B RT-qPCR reagent, respiratory syncytial virus RT-qPCR reagent, monkeypox RT-qPCR reagent, influenza virus A/B and respiratory

11/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Dow syncytial virus RT-qPCR reagent, novel coronavirus and influenza virus A/B RT-qPCR reagents, novel coronavirus and influenza virus A/B and respiratory syncytial virus RT-qPCR reagents, Neisseria gonorrhoeae/Chlamydia trachomatis/Ureaplasma RT-qPCR reagents, rotavirus and norovirus RT-qPCR reagents , HBV/HCV/HIV RT-qPCR reagent, dengue fever, Zika virus and chikungunya virus nucleic acid detection kit, methicillin-resistant Staphylococcus aureus nucleic acid detection kit, human papillomavirus 16+18 type nucleic acid detection kit.

2. Main business model

The company has been deeply involved in the field of in vitro diagnostic reagents for a long time, focusing on the entire chain layout of R&D, production and sales of in vitro diagnostic products. After years of steady operation and accumulation, an independent and complete business operation system has been established, covering core links such as supply chain procurement, large-scale production, and full-process quality management, forming a sustainable and stable profit model. During the reporting period, the core source of the company's operating income and profits was the sales of in vitro diagnostic products.

(1) Procurement model

The company mainly adopts the "production-based procurement" procurement model: the production planning department combines the current sales forecast, actual orders on hand, comprehensively considers the existing inventory level and the procurement cycle of various materials, scientifically formulates procurement requirements and submits them to the procurement department, which then implements centralized procurement. The company has formulated complete internal management systems such as "Procurement Control Procedures" and "Supplier Evaluation and Selection Procedures", established strict supplier screening, dynamic assessment and access mechanisms, compiled and regularly updated a list of qualified suppliers, and ensured that the quality of raw materials from the source of the supply chain fully complies with the company's established standards.

(2)Production mode

The company's core adopts the lean production operation model of "sales determine production": the production planning department scientifically coordinates and schedules production plans based on customer orders in hand and combined with the periodic sales forecasts issued by the sales department. The production department strictly anchors specific order requirements and organizes full-process production to ensure that orders are delivered on time and respond to customer needs in a timely manner. The entire production process is managed in strict compliance with the relevant specifications and standards of the medical device and in vitro diagnostic reagent industry. Quality inspection links are embedded in the entire production chain. The quality assurance department implements full-process supervision and compliance verification on each process node to ensure the stability and reliability of product quality in an all-round way.

(3)Marketing and management model

The company has built a two-dimensional sales system covering both domestic and overseas markets, which is divided into two independent operating modules: overseas sales and domestic sales.

Overseas sales are mainly based on the ODM sales model. The company adopts the ODM model as the core and the sales strategy of coordinated development of multiple own brands. The company has set up a full-time marketing center with three functional units: marketing department, sales department and customer service department, which respectively bear the core responsibilities of market demand research and judgment, product promotion and sales, and full-cycle order tracking. The marketing team carries out market expansion through multiple channels: conducting in-depth on-site surveys in target areas to accurately capture market demand, proactively visiting customers to build cooperative ties, actively participating in domestic and foreign industry exhibitions to enhance brand exposure, and relying on digital channels to tap potential customer resources. In terms of business processes, after market development personnel complete customer docking and cooperation promotion, they will hand over the entire customer link to the customer service department, who will be responsible for subsequent order follow-up, demand response and customer relationship maintenance, and continue to optimize the customer repurchase process experience.

On the domestic sales side, the company focuses on products that have obtained domestic registration certificates, adopts a sales model dominated by its own brands, accurately matches the market needs of domestic clinical, public health and other diverse scenarios, and provides domestic customers with compliant, high-quality diagnostic products and supporting services.

Added important non-main business information

□Applicable √Not applicable

2. Discussion and analysis of operating conditions

In the first half of 2026, competition in the in vitro diagnostic industry has reached an unprecedented level of intensity, market demand has intensified, and most peer companies are in a difficult climbing and adjustment stage. In the face of a complex and ever-changing macro environment and a challenging market landscape, under the correct leadership of the company's board of directors, the management has established a strategic tone with "persistence" as the core: insisting on innovation-driven development, persisting in global market expansion without slackening efforts, and insisting on high-quality development without lowering standards. All employees worked together as one and demonstrated strong resilience and determination in the face of adversity.

12/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

During the reporting period, the company achieved operating income of 392.1449 million yuan, a decrease of 8.77% from the same period last year; net profit attributable to shareholders of the parent company was 50.8447 million yuan, a decrease of 61.48% from the same period last year; basic earnings per share was 0.64 yuan. As of June 30, 2026, the company's total assets were 3,997.3639 million yuan, a decrease of 5.78% from the beginning of the year; the net assets attributable to shareholders of listed companies were 3,760.7278 million yuan, a decrease of 4.71% from the beginning of the year.

The company’s main work priorities in the first half of 2026 are now summarized as follows:

1. Adhere to innovation-driven and build a strong technological moat

In the context of the industry generally facing performance pressure and cost cutting, the company still insists on a high proportion of R&D investment, aiming to cross the cycle through technological breakthroughs. During the reporting period, the company invested RMB 60.3848 million in R&D, accounting for 15.40% of its operating income. The company continues to focus on core technology research and development, focusing on optimizing product performance to ensure that it maintains its technological leadership in fierce market competition. During the reporting period, the company launched 104 new products and made phased progress in key product lines. It not only consolidated the existing market share, but also reserved sufficient technical momentum for subsequent market recovery.

During the reporting period, the company completed 9 new in vitro diagnostic product registrations under the EU IVDR regulations; as of the end of the reporting period, the company had obtained a total of 340 IVDR product certificates, making it one of the companies in the industry that holds a large number of IVDR compliant products. During the reporting period, the company's independently developed Group A Streptococcus antigen rapid detection product obtained the US FDA 510(k) marketing authorization. It is the company's first infectious disease rapid detection product to obtain US market access qualifications. The approval of this product further enriched the company's in vitro diagnostic product matrix in the US market, improved the company's US market business layout in the field of rapid detection of infectious diseases, and laid a compliance foundation for the subsequent expansion of primary care, community outpatient clinics and other terminal scenarios in the US.

During the reporting period, the company had a total of 43 new authorized patents/software copyrights, including 4 invention patents. As of the end of the reporting period, the company had obtained a total of 293 authorized patents/software copyrights, including 51 invention patents.

2. Persist in market expansion and deepen global channels in adversity

Faced with the current market situation where it is difficult to maintain existing markets and acquire new customers, the company adheres to the "going global" strategy and actively embraces the market. During the reporting period, the company insisted on participating in well-known international and domestic industry exhibitions, focusing on important exhibitions such as Medlab, Hospitalar, and CMEF. Through a global promotion system that combines online digital reach with offline in-depth business docking, the company has effectively hedged against the market expansion pressure brought by the industry downturn cycle. While consolidating the stickiness of the original existing customers, it has bucked the trend and achieved breakthroughs in new customers, and has established long-term and stable cooperative relationships with a number of international and regional core dealers. During the reporting period, a total of nearly 300 new domestic and overseas effective business customers were added, providing solid support for the company to continue to maintain and optimize its global market share.

3. Persist in strengthening shareholder returns and effectively safeguard the company’s intrinsic value

During the reporting period, the company repurchased a total of 2.8887 million shares through centralized bidding transactions, accounting for 3.64% of the company's total share capital, and paid a total of 165 million yuan. At the same time, the company also attaches great importance to shareholders' investment returns and strives to create long-term sustainable value for shareholders. During the reporting period, the company implemented the 2025 annual equity distribution plan and distributed a total of 77,016,414 yuan in cash dividends, truly respecting investors, repaying investors, and protecting investors, and also reflected the company's emphasis on investors' rights and interests and its commitment to market confidence.

Analysis and outlook on changes in non-business accounting standards financial indicators

□Applicable √Not applicable

Major changes in the company's operating conditions during the reporting period, as well as events that occurred during the reporting period that have a significant impact on the company's operating conditions and are expected to have a significant impact in the future

□Applicable √Not applicable

3. Analysis of core competitiveness during the reporting period

(1) Core competitiveness analysis

√Applicable □Not applicable

13/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

1. Significant advantages in biological raw material R&D and preparation technology capabilities

The company independently builds a biological raw material technology platform, and develops and produces bioactive raw materials for diagnostic reagents such as antigens, antibodies, and enzymes in-house. It builds triple barriers of technology, cost, and supply chain to support rapid iteration of the entire product line, ensure stable product performance, and strengthen long-term profitability resilience.

At the technology research and development level, relying on its own biological raw material platform, the company can develop adaptive raw materials in response to the product needs of different technology platforms such as POCT rapid diagnosis, immunofluorescence, chemiluminescence, and molecular diagnosis, significantly shortening the new product development cycle. At the same time, by continuously optimizing core indicators such as specificity, sensitivity, and stability of raw materials, the company can promote the continuous iterative upgrade of the performance of terminal detection products and form differentiated product competitive advantages.

In terms of cost and profitability, the self-production of core biological raw materials for self-use has significantly reduced the company's cost of external procurement of key materials, directly improving the gross profit margin level of the entire series of products, allowing the company to have sufficient profit buffer space in the industry market price competition, and ensuring the stability and resilience of the overall profitability level.

At the supply chain level, the self-owned biological raw material platform has achieved complete independent control of core materials, effectively avoiding external uncertainty risks such as overseas raw material supply interruptions, international logistics fluctuations, and geopolitical policy changes, and providing a solid supply chain guarantee for the company's continuous and stable production.

As of the end of the reporting period, the company had produced and put into use 337 types of biological raw materials. These achievements not only demonstrate the company's leading position in the research and development of biological raw materials, but also lay a solid foundation for the company's future sustainable development.

2. Collaborative layout of multiple technology platforms, continuous R&D innovation capabilities and transformation efficiency build solid barriers

The company has built eight core technology platforms including biological raw materials, POCT rapid diagnosis, electronic instrumentation, chemiluminescence, biochemistry, immunoblotting, molecular diagnosis, and biosensing electrochemistry. Each platform has formed a deeply collaborative and mutually supporting technology ecosystem. It has built differentiated advantages that are difficult to replicate in the industry in multiple dimensions such as product research and development, market expansion, cost control, and risk resistance. Products from different technology platforms can adapt to the needs of different scenarios.

The actual controller of the company, Mr. Gao Fei, has been deeply involved in the POCT industry for more than 30 years, focusing on R&D, production and sales services. He has presided over a number of major national, provincial and municipal science and technology projects, and has an accurate and forward-looking grasp of industry market trends and technological development directions. The company's core technical team is deeply involved in the field of in vitro diagnostic reagents, with profound R&D accumulation and mature industry management experience. The company adheres to both internal training and external introduction, and continues to optimize its talent structure. It has gathered a group of senior technical and management talents covering biological raw materials, POCT and other subdivisions. The R&D team has a reasonable structure and strong stability. At the same time, it links industry experts and customers to carry out joint technical research, laying a solid core foundation for the company's long-term technology iteration and building a differentiated talent competitive advantage.

The company's patents and R&D transformation efficiency are outstanding. As of the end of the reporting period, the company had obtained a total of 293 authorized patents/software copyrights, including 51 invention patents, 106 utility model patents, 121 design patents, and 15 software copyrights. The patents cover core links in the entire chain such as reagent formula optimization, instrument integration innovation, and raw material preparation processes; in the first half of 2026, the company's R&D investment accounted for 15.40% of operating income, and there were 104 new products on the market. The R&D input-output ratio was significantly higher than the industry average. At the same time, the company has established a rapid response mechanism of "clinical needs-R&D transformation", collects actual pain points in front-line diagnosis and treatment scenarios through the global dealer network, and regularly organizes the R&D team to hold joint seminars with customers and experts at home and abroad to directly transform terminal needs into product definitions, significantly reducing the trial and error cost of new product development.

3. Enrich product categories and complete product lines to meet diversified market needs

Relying on a number of core technologies accumulated on the POCT technology platform, the company has successfully developed a series of POCT products. The products cover multiple series such as drug and drug abuse testing, infectious disease testing, women's health testing, tumor marker testing, cardiac marker testing, etc., and can be adapted to all-level testing scenarios such as home self-testing, pharmacies, grassroots clinics, hospitals, and public health screenings.

The company's rich product matrix can be used as a "stepping stone" for market development, and it can quickly enter new customers in the form of combined product packages, greatly reducing the communication costs of new customer development; the same detection direction can provide gradient products with different accuracy and different forms to meet the differentiated needs of different customers and avoid the market limitations of a single product track; the market cycles of different categories of products can form a hedge, and fluctuations in demand for a single category will not have a major impact on the overall performance, improving the company's ability to resist risks.

14/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

In addition to medical products, the company has also completed the research and development of a variety of time-resolved fluorescent immunodiagnostic reagents, which can be used in animal disease detection and other fields to meet the needs of various customers in the international market. The rich product lines provide customers with a variety of choices, helping the company expand market share and improve performance.

4. The advantages of a sound quality system lay the foundation for the company’s high-quality product quality.

The core feature of IVD products "instant-to-use" directly determines that product quality is the absolute lifeline for the survival and development of an enterprise. Its importance runs through the entire chain of compliance access, terminal experience, brand reputation, and long-term operation.

The company attaches great importance to product quality management and control, adopts various advanced international quality management standards, and continues to improve the company's quality system. The company has passed ISO9001:2015 quality management system certification and ISO13485:2016 medical device quality management system certification. In 2018, Zero Defect passed the on-site audit of the US FDA quality management system and obtained the MDSAP Medical Device Single Audit Program (Medical Device Single Audit Program) certification recognized by many countries, including the United States, Canada, Brazil, Japan, Australia, etc., becoming one of the earliest companies in China to pass this certification. In July 2022, the company successfully obtained the EU IVDR quality management system certificate issued by TÜV SÜD of Germany; it also obtained IVDR certification for five products including StrepA, FOB, Rota&Adeno combo, H.Pylori Antibody, and Syphilis. It is one of the first domestic companies to obtain IVDR certificates under the new EU regulations. As of the end of the reporting period, the company and its subsidiaries had obtained a total of 340 IVDR certified products, making it one of the companies with a larger number of IVDR products in the industry. The company has also received multiple inspections and unannounced inspections from provincial and municipal market supervision and administration bureaus, third-party audit agencies and customers, and has met the requirements of relevant quality system assessments.

The company has strictly established a quality management system, formulated a "Quality Manual", clarified quality control objectives, organizational structure and functional distribution, and formulated more than 30 program control documents to control various links. It has formed quality management system documents at all levels based on quality manuals, procedural documents, operating procedures, etc., formulated standard operating procedures for each link of production and research and development and specific products, and carried out strict procedural, process-based and refined management of the entire product process to ensure stable, safe and reliable product quality.

(2) Events that occurred during the reporting period that seriously affected the company's core competitiveness, impact analysis and countermeasures

□Applicable √Not applicable

(3) Core technologies and R&D progress

1. Core technology and its advancement and changes during the reporting period

(1) The core technologies currently owned by the company

The company attaches great importance to technology research and development and independent innovation. After years of technology accumulation, it has built a biological raw material technology platform, a POCT rapid diagnosis technology platform, a biochemical technology platform, a chemiluminescence technology platform, an electronic instrument technology platform, a biosensing electrochemical technology platform, an immunoblotting technology platform, and a molecular diagnostic technology platform. It has eight major technology platforms, including monoclonal antibody preparation technology, small molecule antigen preparation technology, nanoscale immunocolloidal gold labeling technology, time-resolved immunofluorescence technology, dry chemical analysis technology, biosensing electrochemical technology, etc., which are all applied to self-produced products and gradually realized industrialization. The company's core technologies are all obtained through independent research and development. The main details are as follows:

Technology platform Core technology Technology source Maturity level Monoclonal antibody preparation technology, polyclonal antibody preparation technology,

Genetically engineered antigen-antibody recombinant technology and small molecule antigen production technology are mature and have been developed independently as a biological raw material technology platform.

Preparation technology, hapten modification coupling technology, cell serum-free technology to achieve industrialized culture technology and microbial culture technology

Nanoscale immune colloidal gold labeling technology, immune latex labeling

POCT rapid diagnostic technology, immunochromatography technology, and new coronavirus lysis technology have matured

Independent research and development

Platform technology, hemoglobin stabilization technology, streptavidin-biotin industrialized signal multiplication technology, immunoglobulin (M) signal enhancement technology

15/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

technology, heterophilic antibody interference elimination technology, whole blood sample red

Cell capture technology, hair sample drug release technology, time

Interval resolution immunofluorescence technology, chemical-chromatography dual-mode fusion technology

technique, hook effect elimination technology

Mature technology, electronic instrument technology platform, LP micro-optical detection technology, computer vision technology independently developed

Realize industrialization

Mature technology, chemiluminescence technology platform, immunomagnetic bead coating technology, enzyme immunolabeling signal amplification technology, independently developed

Realize industrialization

Dry chemical analysis technology, multi-layer coating technology, wet biotechnology are mature and biochemical technology platforms are independently developed.

Chemical technology and freeze-drying technology to achieve industrialization

Multi-item joint detection detection technology, streptavidin-biotin signal technology is mature and the western blot technology platform is independently developed

Number multiplication technology and single-component substrate preparation technology realize industrialization

Extraction-free fluorescence PCR technology, fast fluorescence PCR technology, mature technology and independent research and development of molecular diagnostic technology platform

Matrix fluorescence PCR technology, fluorescence in situ hybridization technology, etc. to achieve industrialization

Electrochemical biosensor technology, code-free technology, temperature

Biosensing electrochemical technology has matured

Anti-interference technology, oxygen partial pressure anti-interference technology, anti-oxidation technology independently developed

Technology platform to realize industrialized technology and dehydrogenase multiple anti-interference technology

(2) The company’s technological advancement and changes during the reporting period

①Biological raw material technology platform

Biological raw materials are key components of in vitro diagnostic reagents, and their quality directly affects the stability of the reagents, which in turn is related to the competitiveness of the product in the market. Based on this, the company deeply realizes the importance of biological raw materials and attaches great importance to research and development, quality control and cost control. Relying on its independently developed biomaterial technology platform, the company has achieved remarkable results in many aspects. On the one hand, the platform effectively reduces production costs, improves product quality, successfully gets rid of dependence on upstream core raw material suppliers, gives the company's products a unique cost advantage, and significantly enhances market competitiveness. On the other hand, the company can keenly capture market demand and rely on this platform to quickly develop suitable biological raw materials, providing a steady stream of power for continued product innovation and development. It can be said that mastering the biological raw material technology platform plays a decisive role in the development process of new products and is of vital significance for ensuring stable reagent quality and promoting the smooth operation of industrialization.

As of the end of the reporting period, the company had self-produced and put into use 337 types of biological raw materials. These fruitful research and development results not only fully demonstrate the company's leading position in the field of biological raw material research and development, but also lay a solid foundation for the company's future long-term and sustainable development.

② POCT rapid diagnosis technology platform

Point-of-care testing (POCT) has become a rapidly developing and important branch in the field of laboratory medicine. With years of intensive work and continuous innovative research and development in this technology field, the company has mastered a series of advanced core technologies at the forefront of the industry in terms of POCT rapid diagnostic technology, including nanoscale immunocolloidal gold labeling technology, carbon nanoparticle labeling technology, immune latex microsphere labeling, immunochromatography technology, streptavidin-biotin signal multiplication technology, time-resolved immunofluorescence technology, heterophilic antibody interference elimination technology, whole blood sample red Cell capture technology and immunoglobulin (M) signal enhancement technology, new coronavirus lysis technology, hemoglobin stabilization technology, hair sample drug release technology, multi-index joint detection technology, trace substance enrichment detection technology, chemistry-chromatography dual-mode fusion technology, high-dose hook effect elimination technology, etc. These technologies cover many key aspects such as accurate identification of biomarkers, effective amplification of signals, and efficient optimization of sample processing.

The company's industrialization technology platform takes efficient scientific research achievement transformation capabilities as its core competitiveness and has built a complete and mature product development and industrialization chain. From cutting-edge technology research and development breakthroughs, to product design optimization, to actual production and marketing, each

16/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

All links are closely connected and operate efficiently. This complete chain ensures that the company can quickly capture market dynamics, accurately respond to changes in market demand, and quickly transform the latest scientific research results into actual products and introduce them to the market.

During the reporting period, the company relied on this powerful technology platform to achieve continued prosperity in new product research and development. The company continues to launch innovative products, and new products are successfully launched every month, injecting a steady stream of new vitality into the company's product line. As of the end of the reporting period, the number of diagnostic reagents developed based on this platform exceeded 1,600. This huge product matrix fully demonstrates the company's deep technical foundation and outstanding innovation capabilities in the field of point-of-care testing. In the future, the company will continue to adhere to the concept of "innovation-led, quality first, customer service", continue to increase investment in technology research and development, and continuously improve product quality and service levels. With more advanced technology, higher quality products and more considerate services, we will contribute more wisdom and strength to the development of global medical and health undertakings, and help the global medical testing level reach new heights.

③Biochemical technology platform

The company is deeply engaged in the field of biochemical diagnosis and has mastered key technologies such as dry chemistry, multi-layer coating, wet biochemistry and freeze-drying.

Dry chemical analysis technology combines chemistry, enzymology, solid-phase membrane reaction technology, immersion-reading and other modern analysis technologies, and uses enzymes and chemical specific binding reaction principles to perform instant diagnostic detection of target detection substances. The dry chemical analysis technology platform established by the company has the advantages of simultaneous detection of multiple elements, small amount of test specimens, fast speed, good repeatability and high accuracy. On this technology platform, the company has launched urine adulteration detection analysis, alcohol detection analysis, multiple urine analysis reagents, gamma-hydroxybutyric acid (GHB) detection reagents and hemoglobin test strips. The above products have been industrialized and mass-produced. Among them, multiple urine analysis reagent papers can detect 14 indicators such as red blood cells, white blood cells, and urine protein in urine. When paired with standard color comparison cards or urine analyzers, semi-quantitative instant detection can be achieved and can provide reference for a variety of urine diseases. Urine adulteration detection reagents are used in conjunction with drug abuse detection reagents to greatly improve the validity of test results and prevent drug abusers from providing invalid samples. The hemoglobin test strip is mainly used to detect the hemoglobin content in human capillary whole blood and venous whole blood. When used in conjunction with the company's independently developed hemoglobin analyzer, it can accurately achieve quantitative detection of hemoglobin in 15 seconds.

Multi-layer coating technology is to apply multiple reaction reagents on a film base in a specific order, and then use a special drying process to make a dry film for product manufacturing. Dry sheets made using multi-layer coating technology are smoother and more uniform than dry chemical paper sheets, suitable for cooperating with instrument testing projects, and can be accurately quantified.

In addition, the company has also launched a blood lipid detection reagent for use with its self-developed blood lipid analyzer, which can directly detect the total cholesterol (CHOL), high-density lipoprotein (HDL), and triglyceride (TRIG) content in human whole blood, plasma, and serum, and automatically calculate the low-density lipoprotein (LDL) concentration. All the above-mentioned samples can be directly detected without preprocessing, and are easy to operate. The biochemical platform company has also developed a lactose tolerance testing service. This test is crucial for clarifying individual lactose digestion and absorption capabilities. It helps to formulate personalized dietary guidance and treatment plans. It is a key step for patients with lactose intolerance or deficiency to obtain effective management and treatment.

While deepening the application of existing platforms, the company has gradually launched calcium and zinc testing projects, glucose-6-phosphate dehydrogenase (G6PD) testing projects, seven-joint vaginitis testing projects, and Helicobacter pylori testing projects. Calcium and zinc testing projects are designed to evaluate the calcium and zinc metabolism in patients, provide scientific basis for disease diagnosis, treatment and nutritional assessment, and also facilitate individual self-monitoring of calcium and zinc absorption. Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is the most common red blood cell enzymopathy in the world. There are multiple G-6-PD gene variants, primaquinoline-type drug-soluble Blood anemia or favismosis, infection-induced hemolysis, neonatal jaundice, etc., G6PD testing is often used for newborn screening, hemolysis cause investigation or risk assessment before medication, to help disease screening; the seven-joint vaginitis test project comprehensively evaluates the condition of the vagina, effectively prompts each stage of vaginitis infection, and provides more effective help for clinicians to diagnose and cure vaginitis. Helicobacter pylori is a common bacterium that mainly lives in the human gastric mucosa and is recognized as a Class I carcinogen by the World Health Organization and the International Agency for Research on Cancer. Helicobacter pylori infection can cause lower gastrointestinal diseases, such as gastritis, gastric ulcer, duodenal ulcer, and gastric cancer. Helicobacter pylori detection can provide help in etiology diagnosis, treatment guidance, and prevention of transmission.

④Chemiluminescence technology platform

17/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The company's chemiluminescence technology platform mainly relies on the independently developed fully automatic chemiluminescence immunoanalyzer to develop chemiluminescence reagents. The company follows the market development trend and adopts a magnetic particle enzymatic chemiluminescence system. The platform emits light continuously and stably, and its stability, signal-to-noise ratio, sensitivity, and accuracy have been further improved.

The company gives full play to the role of its independently developed immunoassay analyzers, carefully optimizes the reaction mode, and through continuous exploration and improvement, strives to provide customers with fast and accurate quantitative testing results to meet the dual needs of clinical diagnosis for timeliness and accuracy. Based on this technology platform, the company has successfully developed a wealth of testing projects covering multiple fields, including inflammatory markers (such as procalcitonin, interleukin-6, C-reactive protein, serum amyloid A), cardiac markers (such as troponin I, myoglobin, creatine kinase Isoenzymes, D-dimer, troponin T, N-terminal B-type natriuretic peptide precursor, B-type natriuretic peptide, heart-type fatty acid binding protein, soluble ST2, etc.), anemia markers (such as ferritin, 25-hydroxyvitamin D, folic acid, vitamin B12, etc.), hormone markers Substances (such as β-human chorionic gonadotropin, anti-Mullerian hormone, luteinizing hormone, follicle-stimulating hormone, prolactin, testosterone, progesterone, estradiol, etc.), thyroid function (thyroid-stimulating hormone, thyroxine, free thyroxine, triiodothyronine, free triiodine Thyronine, thyroglobulin, etc.), tumor markers (alpha-fetoprotein, carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 19-9, squamous cell carcinoma antigen, carbohydrate antigen 15-3, cancer antigen 242, neuron-specific enolase, carbohydrate antigen 724, cytokeratin 19 fragment, gastrin-releasing peptide precursor, human epididymis protein 4, etc.), diabetes series (e.g. C-peptide, insulin, glycated hemoglobin, etc.), preeclampsia series (placental growth factor, soluble tyrosine kinase-1), etc., gastric disease series (pepsinogen Ⅰ, pepsinogen Ⅱ, gastrin 17, etc.), infectious disease series (hepatitis C Antibodies, hepatitis B surface antigen, syphilis antibodies, HIV antigen antibodies, etc.), allergen series (IgE), prostate health screening series (prostate specific antigen, free prostate specific antigen), etc., most of which are now ready for mass production. At the same time, the company is not satisfied with its current results. The research and development of new biomarker detection reagents is in full swing and continues to expand the application boundaries of chemiluminescence detection to bring more innovative solutions to the medical and health field.

⑤Electronic instrument technology platform

The company has built a diversified and highly innovative electronic instrument technology platform in the field of in vitro diagnostic instruments. With a series of advanced technologies, it has successfully developed a variety of small and professional diagnostic instruments with excellent performance, which are widely used in in vitro diagnosis of humans and animals.

Relying on LP micro-optical detection technology, the company independently developed electronic pregnancy test sticks, electronic ovulation test pens, hemoglobin analyzers, blood lipid meters and other small diagnostic instruments, which are used in conjunction with the company's independently developed reagents. With the help of computer vision technology that integrates image processing, artificial intelligence, pattern recognition and other technologies, the company has independently developed diagnostic instruments such as desktop urine cup readers, desktop gold label readers, and portable readers. Among them, the desktop gold label readers and portable readers are powerful and achieve full coverage of qualitative, semi-quantitative, and quantitative testing of supporting reagents. Based on chemiluminescence technology, the company independently developed a fully automatic chemiluminescence immunoassay analyzer. The instrument is based on the principle of ALP enzymatic chemiluminescence. It cleverly uses the combination of antigen-antibody immune reaction and magnetic particle carrier to excite the enzyme luminescence through the substrate. The photomultiplier tube accurately measures the luminescence, and converts the measured luminescence counts per second of the sample into sample concentration based on the built-in standard curve, which greatly improves the detection sensitivity of the product. Relying on immunofluorescence technology, the company has successfully developed a series of single-channel, portable, and multi-channel fluorescence immunoanalyzers. These instruments use ultraviolet LED light sources to excite fluorescent microsphere-labeled test cards, efficiently collect and in-depth analyze the fluorescence signals emitted by the test cards, and quickly calculate the test results. In the field of urine analysis, the company relies on multi-wavelength reflection technology to independently develop high-speed urine analyzers, medium-speed urine analyzers, and portable urine analyzers. After the multi-link test strips are irradiated by the instrument's light source in sequence, they will produce different reflected lights. These instruments can accurately receive light signals of different intensities and convert them into corresponding electrical signals. After accurate calculation, the reflectance of each test item is calculated, and then compared with the standard curve and then corrected to the measured value. This technology ensures the efficiency and accuracy of urinalysis and provides an important basis for the diagnosis of urinary system diseases. For the animal in vitro diagnostic market, the company has also actively deployed and launched portable and desktop fluorescence immunoassay analyzers and portable, high-speed urine analyzers and other instruments. These instruments are specially designed for animal diagnosis, fully considering the characteristics and detection needs of animal samples, and have the advantages of easy operation and rapid detection.

At present, each of the above series of analyzers has been industrialized and mass-produced and successfully launched on the market. With its excellent performance and reliable quality, it has won wide recognition and good feedback from the market, providing strong technical support for animal health management and disease prevention and control.

18/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

⑥ Western blot technology platform

Immunoblotting, also known as Western blotting, is an efficient method based on the specific binding principle of antigen-antibody for detecting specific proteins in complex samples. With its unique technical advantages, it occupies an important position in the field of biomedical testing. Traditional detection methods often rely on gel electrophoresis, but Western blotting technology uses advanced membrane-splitting technology to cleverly replace the protein. It uses electrotransfer technology to firmly solidify the protein, and then carry out immunological detection. When immunoblotting technology is powerfully combined with streptavidin-biotin signal multiplication technology, the detection sensitivity achieves a qualitative leap and can accurately capture extremely small amounts of target proteins. Western blotting technology has powerful analytical capabilities and can detect multiple different proteins in a sample at the same time, and can perform qualitative and semi-quantitative analysis of proteins. Relying on its profound technological accumulation and excellent innovation capabilities, the company has successfully built an immunoblotting technology platform and formed a complete and mature product R&D and production system. At present, this technology has achieved remarkable results in the fields of allergen-specific antibody detection products and autoantibody detection products. In terms of allergen testing, it has implemented 16 human allergen-specific antibody tests, which can comprehensively screen the human body's allergic reactions to a variety of common allergens; at the same time, it has also carried out 120 and 160 pet allergen antibody tests, providing a rich and diverse range of testing items for accurate diagnosis of pet allergies. In the field of autoantibody detection, 7 ENA antibody tests have been successfully implemented, which helps in the early detection and accurate diagnosis of autoimmune diseases.

Based on the existing immunoblotting technology platform, the company further expanded its innovation and developed immunoblotting chromatography detection technology, which was successfully applied to allergen detection for humans and pets. It not only supports the use of whole blood for testing, greatly simplifying the sample collection and processing process; it also requires very little sample, reducing the pain and inconvenience of patients; even more impressively, the testing time is greatly shortened, and accurate results can be obtained in only 36 minutes, which buys valuable time for rapid diagnosis and timely treatment of allergic patients, and greatly improves clinical diagnosis efficiency and patient medical experience.

⑦Molecular diagnostic technology platform

In the field of molecular diagnosis, the company has vigorously promoted the innovation and upgrading of PCR freeze-dried reagent technology on the original multiplex real-time fluorescence quantitative PCR platform, further strengthening its strategic layout in the molecular diagnosis technology platform.

PCR freeze-dried reagent technology solidifies the key components in the PCR reaction system through a freeze-drying process to form freeze-dried microspheres that are stable at room temperature. This greatly improves the convenience of transportation and storage at room temperature while ensuring performance. With its excellent stability, ready-to-use and broad platform compatibility, this technology can be used in fields such as rapid detection of infectious diseases (such as influenza, COVID-19, etc.), companion diagnosis of tumors, and on-site point-of-care testing (POCT). Relying on the independently developed freeze-drying protective agent system and reaction system optimization technology, it provides solid technical support for the quality improvement of freeze-drying reagents. The freeze-drying protective agent system can effectively protect the biologically active components in the reagents and reduce damage during the freeze-drying process, thus significantly enhancing the anti-interference ability of the freeze-drying reagents and ensuring the accuracy and reliability of the test results. At the same time, reaction system optimization technology further improves the batch-to-batch consistency of reagents, making the performance of reagents produced in different batches stable, reducing the fluctuation of test results, and providing a more reliable basis for clinical diagnosis.

At present, the company has established freeze-dried reagent solutions covering common respiratory, reproductive tract and other viruses, and has achieved standardization and large-scale application of products through pre-packaging design and automated production, promoting the development of molecular diagnostic technology.

⑧Biosensing electrochemical technology platform

The core of the biosensing electrochemical technology platform products focuses on electrochemical biosensors. In practical applications, one of them, the electrochemical enzyme sensor, already has very mature industrialization experience. Currently, the industry generally focuses on the second generation of enzyme sensors.

Based on the technology of the second-generation enzyme sensor, the company uses a unique formula system and precise algorithm to design and develop a new electrochemical biosensor technology, which has been successfully used in all-in-one products for blood glucose, blood ketones, uric acid, and cholesterol, fully meeting the diverse needs of the human testing and animal testing markets. In the future, the company will continue to apply the development ideas of this technology to other detection indicators and expand to more application channels.

The company's electrochemical biosensor technology can be further reflected in innovations in biological enzyme system technology, sensor printing technology, multi-index testing technology, temperature anti-interference technology, oxygen partial pressure anti-interference technology, antioxidant technology, and dehydrogenase multiple anti-interference technology, increasing the market competitiveness of the company's products. At the same time, the company independently innovates the coding-free technology, which simplifies the operation process and avoids unnecessary

19/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The problem of inaccurate test results caused by coding adjustment brings a more convenient and accurate user experience to users. At present, the company has successfully completed part of the registration phase for blood glucose dehydrogenase, blood glucose oxidase, blood ketone, uric acid and cholesterol detection products. The price/performance performance of these products is on par with or surpasses existing mainstream products on the market.

The company attaches great importance to the development of the blood glucose monitoring field and accelerates its in-depth deployment in this field. Currently, the company is independently developing continuous glucose monitoring (CGM) products and has made significant progress in R&D innovation. CGM products can monitor blood sugar levels in real time and continuously, providing diabetic patients with more comprehensive and accurate blood sugar information, helping to better control the disease and improve quality of life.

National Science and Technology Awards

□Applicable √Not applicable

Recognition status of national-level specialized and new “little giant” enterprises and manufacturing “single champions”

□Applicable √Not applicable

2. Research and development results obtained during the reporting period

(1) Domestic registration status

During the reporting period, the parent company added a total of 0 domestic medical device registration/product registration certificates. As of June 30, 2026, the parent company has obtained a total of 44 domestic medical device filing/registration certificates.

Registration classification Number at the beginning of the period Number of new additions Number of failures Number at the end of the period Domestic Class I medical device registration 3 0 0 3

Domestic Class II medical device registration 20 0 0 20

Domestic Class III medical device registration 21 0 0 21

In addition, as of the end of the reporting period, the company had obtained a total of 5 domestic medical device filing/product registration certificates through its wholly-owned subsidiaries.

(2) International registration status

During the reporting period, the parent company added a total of 62 foreign product registration certificates. As of June 30, 2026, the parent company has obtained a total of 3,090 foreign product registration certificates.

Registration classification Number at the beginning of the period Number of new additions Number of lapses Number at the end of the period EU CE certification 1895 9 0 1904

US FDA certification 27 1 0 28

Canadian MDL certification 221 3 0 224

Australian TGA certification 76 1 1 76

British MHRA product certification 810 48 0 858

During the reporting period, the company obtained a total of 81 products certified by Ecuador/Colombia/Bolivia/Saudi Arabia through its wholly-owned subsidiaries, which provided a strong guarantee for the company to expand overseas sales channels in multiple brands and dimensions.

During the reporting period, the parent company registered 9 new IVDR products. As of the end of the reporting period, the parent company and wholly-owned subsidiaries had obtained 340 IVDR product certificates.

(3) Patent situation

20/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

During the reporting period, the company obtained a total of 43 new authorized patents/software copyrights, including 4 invention patents, 7 utility model patents, 28 design patents and 4 software copyrights. As of the end of the reporting period, the company had obtained a total of 293 authorized patents/software copyrights, including 51 invention patents, 106 utility model patents, 121 design patents, and 15 software copyrights.

List of intellectual property rights obtained during the reporting period

The cumulative number of new additions in this period

Number of applications (number) obtained Number (number) of applications obtained Number (number) of invention patents obtained 8 4 110 51

Utility model patent 9 7 132 106

Design patent 14 28 148 121

Software copyright 0 4 15 15

Total 31 43 405 293

Note "Cumulative quantity": As of the end of the reporting period, the company's cumulative patents had terminated 7 times.

The newly authorized patents are as follows:

Preface Patent Registration

Patent name Patent number Grant date Patentee number Type Country

Can specifically bind to creatine kinase isoenzyme

invention

1 China Combined antibodies or antigen-binding fragments and their ZL202211597516.X 2026/6/2 Orui Biotechnology Patent

Application

Invention of an artificial arecoline hapten, artificial

2 China ZL202310633933.3 2026/2/10 Tongzhou Biotechnology Patent Antigen and its preparation method and application

Practical A kind of double-head rod sleeve integrated sampling and detection

3 China ZL202521335886.5 2026/6/16 Tongzhou Biotech’s new device

Appearance

4 China Test Plate ZL202530716409.2 2026/6/2 Tongzhou Biodesign

Appearance

5 China Test Board ZL202530716413.9 2026/6/2 Tongzhou Biodesign

Appearance

6 China Blood Glucose Meter ZL202530301613.8 2026/1/20 Aokai Biodesign

Appearance

7 China Electrodes for biosensor components (2) ZL202530355589.6 2026/1/20 Aokai Biodesign

Appearance

8 China Electrodes for biosensor components (1) ZL202530355586.2 2026/1/23 Aokai Biodesign

Appearance

9 China Biosensor Components (1) ZL202530355581.X 2026/2/24 Aokai Biodesign

Appearance

10 China Biosensor Component (2) ZL202530355582.4 2026/2/24 Aokai Biodesign

Appearance

11 China All-in-one blood glucose meter ZL202530628699.5 2026/5/26 Aokai Biodesign

Appearance

12 China Pet Blood Glucose Meter ZL202530628702.3 2026/5/26 Aokai Biodesign

Invention Liquid sampler and sampler including the same

13 China ZL202211736766.7 2026/5/26 Aotai Biotechnology patented sampling and testing device

Invention of a fentanyl artificial hapten, artificial

14 China ZL202311096208.3 2026/6/2 Aotai Biotechnology Patent Antigen and its preparation method and application

Practical

15 China A specimen sampler ZL202422833473.1 2026/1/20 Aotai Biotech

Practical

16 China A rapid beverage detection device ZL202520165761.6 2026/3/6 Aotai Biotech

Practical

17 China An all-in-one detection device with a single injection hole ZL202520509159.X 2026/4/7 Aotai Biotech

Practical

18 China A device for detecting substances in liquids ZL202520386702.1 2026/4/7 Aotai Biotech

Practical

19 China A saliva sampling and testing device ZL202520602156.0 2026/5/5 Aotai Biotech

21/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Appearance

20 China Stool Sampler ZL202530226645.6 2026/1/27 Aotai Bio-Design

Appearance

21 China Rapid Saliva Stick ZL202530354736.8 2026/2/10 Aotai Biodesign

Appearance

22 United States TEST CUP (Testing Cup) US29/950391 2026/2/10 Aotai Bio-Design

Appearance: Exam tool (an all-in-one double-sided tool

23 Japan JP2025011047 2026/2/13 Aotai Bio-Design Rapid Test Plate)

Appearance Square testing tool (liquid sample testing

24 Japan JP2025014101 2026/2/13 Aotai Biodesign Device (square))

Appearance

25 Japan Utensils for stool sampling (stool sampler) JP2025013586 2026/2/13 Aotai Bio-Design

Appearance Sample dissolving device (a liquid standard

26 Japan JP2025018927 2026/2/13 Aotai Biodesign This lysis detection device)

Appearance Blood test

27 Japan JP2025019511 2026/2/13 Aotai Biodesign Measuring Rod)

Appearance

28 Japan Utensils for stool sampling (stool sampler) JP2025010360 2026/1/26 Aotai Bio-Design

Appearance

29 Japan Container for urine testing (urine testing cup) JP2025010628 2026/1/26 Aotai Biodesign

Appearance

30 China Blood Test Stick ZL202530436943.8 2026/3/10 Aotai Biodesign

Appearance

31 United States ASSAY PLATE (test plate) US29/953640 2026/3/3 Aotai Biodesign

Appearance

32 China Early pregnancy stick ZL202530470606.0 2026/3/24 Aotai Biodesign

Appearance

33 Japan JP2025023198 2026/4/3 Aotai Bio-Design Speed Saliva Stick)

Appearance

34 China Test Stick ZL202530571420.4 2026/5/8 Aotai Biodesign

Appearance Analytical test strips (liquid

35 European Union EU015141345 2026/5/8 Aotai Biodesign Sample Testing Device (square))

Appearance Analytical test strips (slippery

36 European Union EU015142618 2026/5/20 Aotai Biodesign Moving detection board)

Appearance UM

37 Test strip (multi-window detection plate) AU202613817 2026/6/17 Aotai Biodesign Leah

Appearance Tira de teste de sangue (blood

38 Brazil BR302025005895-3 2026/5/12 Aotai Biodesign Liquid Detection Stick)

Practical

39 China A stool sampler ZL202520606652.3 2026/6/23 Aotai Biotech

new type

3. R&D investment status table

Unit: Yuan

Number for the current period Number for the same period last year Change range (%) Expensed R&D investment 60,384,755.92 48,195,711.85 25.29Capitalized R&D investment - - -Total R&D investment 60,384,755.92 48,195,711.85 25.29 Total R&D investment as a proportion of operating income (%) 15.40 11.21 4.19 Proportion of capitalized R&D investment (%) - - -

Reasons for significant changes in total R&D investment compared with the previous year

□Applicable √Not applicable

Reasons for the significant change in the proportion of capitalized R&D investment and its rationale

□Applicable √Not applicable

22/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

4. Current research projects

√Applicable □Not applicable

Unit: Yuanxu Estimated total investment Current investment Cumulative investment Progress or stage Technical level

Project name To be achieved Specific application prospects Number of funding Amount Amount Achievements Level

A number of products have been completed and are widely used in POCT rapid

Product development and storage International POCT Clinical Examination 1 Diagnostic Technology 50,000.00 4,048.52 47,245.85 Continuously enrich the company’s product line

equipment, technology optimization, leading experience, judicial testing and other platforms

and upgrade areas

Ensure the development of biological raw materials for new products. Completed a number of products. Realized self-supply of raw materials, antigens and antibodies domestically.

2 6,200.00 339.96 5,634.34 Launched and launched a sexual technology platform Product development Industrialization and large-scale production Leading

performance and cost advantages

Reduce operator burden and widely used in multiple development projects

The possibility of contamination can meet the requirements of international POCT clinical examination 3 Others 17,500.00 1,650.00 16,062.24 items, all in different

The demand for rapid testing anytime and anywhere leads to the development stage of testing and judicial testing.

Continuously enrich the company’s product lines and field cooperation

/ 73,700.00 6,038.48 68,942.43 / / / /Total

5. R&D personnel

Unit: 10,000 yuan Currency: Basic information on RMB

Number of the current period Number of the company's R&D personnel in the same period last year (person) 244 244 Proportion of the number of R&D personnel to the total number of the company (%) 25.42 25.41 Total salary of R&D personnel 2,277.86 2,053.72 Average salary of R&D personnel 9.34 8.42

education level

Educational composition Number (person) Proportion (%) Doctoral students 1 0.40 Master’s degree 55 22.54 Undergraduate 154 63.12 College 32 13.13 High school and below 2 0.81 Total 244 100

age structure

Age range Number (person) Proportion (%) Under 30 years old (excluding 30 years old) 121 49.59 30-40 years old (including 30 years old, excluding 40 years old) 98 40.17 40-50 years old (including 40 years old, excluding 50 years old) 23 9.43 50-60 years old (including 50 years old, excluding 60 years old) 2 0.81 60 years and above - -

Total 244 100

6. Other instructions

□Applicable √Not applicable

4. Risk factors

√Applicable □Not applicable

23/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(1) Core competitiveness risks

1. New product development risks and registration risks

The company focuses on the POCT subdivision of the in vitro diagnostic industry, which is the fastest-growing technology-intensive track in the in vitro diagnostic industry. Its new product research and development links generally have the core characteristics of large-scale capital investment, long R&D registration cycle, high risk of technology iteration, and outstanding product added value.

In recent years, POCT products have been widely promoted and applied in clinical diagnostic scenarios in many countries and regions around the world, and the downstream market has continued to improve the technical standards, performance indicators, and compliance requirements for in vitro diagnostic reagent products. In order to maintain and strengthen its core competitiveness in the market, the company must continue to promote the research and development of new technologies and new products based on market demand. If the company's promotion speed and industrialization efficiency in new product research and development decline in the future, and it is unable to adapt to the industry's rapid product update and iteration development characteristics, it will have an adverse impact on the company's market competitive position. At the same time, the registration, approval and regulatory policies for IVD products in major countries and regions around the world are in the process of continuous adjustment and optimization. In the future, there will still be potential risks of individual products under development failing to obtain relevant registration certificates in time, resulting in the corresponding products not being able to be marketed as scheduled.

(2) Business risks

1. The risk of a relatively high proportion of foreign sales revenue

The company mainly provides rapid in vitro diagnostic reagents to overseas medical device brands or manufacturers, and export revenue is the main source of the company's income. In 2024, 2025 and the first half of 2026, the company's foreign sales revenue accounted for 94.98%, 92.80% and 93.72% of its main business revenue respectively, and the company's future development still depends on the expansion of overseas markets. However, because the export business is affected by many factors such as national export policies, import policies and political environment of the country where the customer is located, international trade environment, currency exchange rates, and market competition for rapid in vitro diagnostic reagents, higher requirements have been placed on the company's management capabilities. If the company cannot effectively manage overseas business or cannot achieve its overseas market expansion goals as scheduled, it will have a certain impact on the company's performance.

2. Risks of ODM business model

The company's in vitro diagnostic reagent product sales are mainly based on the ODM model. In 2024, 2025 and the first half of 2026, the company's ODM business will account for 65.58%, 70.42% and 70.61% of its main business revenue respectively. The proportion of ODM brand sales is still relatively high, and the company's main business income is greatly affected by changes in ODM model risks. In the future, if the company's main ODM customers experience significant declines in revenue scale, poor management and other problems, or the company cannot meet the needs of ODM customers in terms of product quality, supply capacity, etc. in the future, it may lead to the loss of customers, which will have an adverse impact on the company's operations.

(3) Industry risks

1. Risks of industry regulation and policy changes

The in vitro diagnostic industry is a key regulatory area under the medical and health systems of various countries around the world. The relevant policies and regulations on industry access, production specifications, market circulation and other relevant policies and regulations formulated by domestic and foreign regulatory agencies for the in vitro diagnostic industry will have a significant impact on the compliant production and market sales of enterprise products. The company's main business is centered on export sales. During the reporting period, products accounting for more than 90% of the company's operating income were mainly exported to many countries and regions such as Europe, Asia, and the Americas.

In recent years, the international economic and trade environment has shown a complex and ever-changing trend, and uncertainties such as trade barriers and adjustments to cross-border regulatory rules have increased significantly. If there are major adverse changes in the import trade policies, tariff rules, access licensing requirements or product certification standards for in vitro diagnostic products in the above-mentioned major exporting countries and regions in the future, the company's export business may face related risks such as blocked market access and increased operating costs. At the same time, as the reform of the domestic medical and health system continues to deepen, the regulatory system, centralized procurement policies, quality control standards and other rules of the domestic in vitro diagnostic industry are also constantly being updated and improved. Subsequently introduced new industry regulatory policies may also have a certain impact on the company's production and operation activities.

2. The risk that the new EU regulation IVDR may affect the company’s future operations

24/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The company's overseas revenue accounts for a relatively high proportion, and the EU region is the company's most important overseas target market. During the reporting period, the company’s in vitro diagnostic reagent products exported to the EU were originally subject to the EU’s In Vitro Diagnostic Medical Devices Directive (IVDD, 98/79/EC) for compliance registration and market sales. In May 2017, the European Union officially promulgated a new version of the "In Vitro Diagnostic Medical Device Regulations" (IVDR, EU 2017/746), and released phased implementation details in December 2021: Among them, Class A non-sterile products have entered the mandatory implementation stage from May 2022, and Class D, Class C, Class B and Class A The mandatory compliance deadlines for sterilization products are May 2025, May 2026 and May 2027 respectively.

The new regulation IVDR makes the IVD product classification rules more complex and strict, resulting in an extension of the registration cycle and an increase in registration fees after the product is reclassified. At the same time, the new regulation IVDR imposes stricter requirements on manufacturers, further emphasizing manufacturer responsibility and strengthening post-market supervision requirements for products. The full implementation of IVDR will have a significant impact on the company's existing ODM business model. For some ODM customers who have the ability to continue to be "legal manufacturers", they will face more stringent qualification review and regulatory requirements; for some ODM customers with small business scale and limited compliance capabilities, it will be difficult for them to continue to meet all legal responsibilities and obligations corresponding to manufacturers. There is a probability that the cooperation model will be adjusted and transformed into importers or distributors to conduct business with the company; in addition, some small and medium-sized customers with insufficient technical reserves and weak financial strength will not be able to meet the rigid compliance threshold of IVDR, and will be difficult to continue operating in the in vitro diagnostic reagent industry, and will gradually be cleared by the market. In the overall environment where EU IVDR supervision continues to become stricter, there are still certain risks of uncertainty as to whether existing ODM customers can continue to meet the full range of regulatory requirements such as document systems and quality systems required as "legal manufacturers", and whether the cooperation model with the company can maintain long-term stability after the relevant customers transform into importers or distributors.

(4) Financial risks

1. Exchange rate fluctuation risk

During the reporting period, more than 90% of the company's main business income came from overseas sales, and the pricing and settlement currency for overseas product sales was mainly US dollars. Affected by the international political and economic environment, the global foreign exchange market has significantly increased volatility, and the exchange rate of RMB against the US dollar may experience periodic and substantial two-way fluctuations. The resulting exchange gains or losses will have a certain impact on the company's operating performance in each reporting period.

2. Bad debt risk of accounts receivable

At the end of the reporting period, the company's accounts receivable balance was relatively large, accounting for a high proportion of both current assets and current operating income. Currently, the overall aging structure of the company's accounts receivable is healthy, with most of the accounts receivable being aged within one year. Moreover, credit sales cooperation customers are mainly partners with long-term stability and good credit status. The overall risk of bad debts under normal operating conditions is at a low level.

Since the company's business is focused on export, there are a large number of overseas customers and they are widely distributed in different countries and regions around the world. The pace of customer payment and performance capabilities are greatly affected by the international trade environment, the foreign exchange reserves of the host country, and cross-border payment policies. If there are major adverse changes in global macroeconomic trends and international trade patterns in the future, or if some debtors' own operating conditions and financial health deteriorate significantly, the company will face the credit risk that accounts receivable cannot be collected on time or even in full.

3. Financial interest income reduces risk

As the company's external investment layout continues to advance, the scale of investment in production infrastructure expands, and the capital expenditures superimposed on daily operations continue to increase, the company's book monetary capital scale shows a gradual downward trend. At the same time, affected by the multiple reductions in RMB deposit interest rates in recent years, the company's interest income corresponding to RMB deposits has narrowed; combined with the risk of possible fluctuations in U.S. dollar deposit interest rates in the future, and under the combined effect of multiple factors, the company's overall interest income will face continued pressure.

5. Main business conditions during the reporting period

For details, please refer to “II. Discussion and Analysis of Operating Conditions” in “Section 3 Management Discussion and Analysis” of this report.

25/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(1) Main business analysis

1. Analysis table of changes in relevant accounts of financial statements

Unit: Yuan Currency: RMB account Number for the current period Number for the same period last year Change ratio (%) Operating income 392,144,917.68 429,850,024.75 -8.77 Operating costs 183,954,455.35 186,926,166.19 -1.59 Sales expenses 30,564,898.56 38,436,383.21 -20.48Administrative expenses 39,777,220.08 34,605,227.94 14.95Financial expenses 19,660,254.50 -13,092,384.58 Not applicable R&D expenses 60,384,755.92 48,195,711.85 25.29 Net cash flow from operating activities 52,885,009.00 61,353,635.75 -13.80 Net cash flow from investing activities 997,087,405.02 246,079,358.86 305.19 Net cash flow from financing activities -242,846,328.86 -118,139,971.31 -105.56 Reasons for changes in operating income: Mainly due to product price reductions caused by intensified industry competition and the decline in revenue settled in U.S. dollars due to the decline in the U.S. dollar exchange rate;

Explanation of reasons for changes in operating costs: Mainly due to the decrease in revenue during the reporting period;

Explanation of reasons for changes in sales expenses: Mainly due to the decrease in market and service fees and equity incentive expenses during the reporting period;

Explanation of reasons for changes in administrative expenses: Mainly due to the increase in depreciation and amortization of factory buildings during the reporting period;

Explanation of reasons for changes in financial expenses: Mainly due to the decline in the US dollar exchange rate during the reporting period, which led to a significant increase in exchange losses for the current period compared with the same period last year; Explanation of reasons for changes in R&D expenses: Mainly due to the increase in product testing fees and product material fees for new research and development projects during the reporting period; Explanation of reasons for changes in net cash flow generated from operating activities: Mainly due to the decrease in income during the reporting period;

Explanation of reasons for changes in net cash flows generated from investing activities: Mainly due to redemption of financial products during the reporting period;

Explanation of reasons for changes in net cash flow generated from financing activities: Mainly due to share repurchases and annual dividends during the reporting period.

2. Detailed description of major changes in the company’s business type, profit composition or profit sources during this period

□Applicable √Not applicable

(2) Explanation of significant changes in profits caused by non-main business

□Applicable √Not applicable

(3) Analysis of assets and liabilities

√Applicable □Not applicable

1. Assets and liabilities status

Unit: Yuan

The closing amount of the current period is % of the ending amount of the previous year. The ending amount of this period is less than

Project name Closing amount of the current period Proportion of total assets Last year’s closing amount Proportion of total assets Last year’s closing change ratio Description of the situation

(%) (%) Example (%)

Monetary funds 1,847,967,875.13 46.23 1,067,266,075.69 25.16 73.15

Mainly due to financing assets resulting from redemption of the company's wealth management trading funds 276,186,261.64 6.91 1,324,890,081.11 31.23 -79.15

Other receivables Mainly due during the reporting period 8,684,803.56 0.22 5,979,081.69 0.14 45.25

Due to the increase in rent collection

Mainly due to the Fanling production and construction project under construction 39,001,920.92 0.98 15,336,809.11 0.36 154.30

The increase in transactional funds is mainly due to changes in the U.S. dollar exchange rate.

12,145,021.00 0.30 19,809,014.00 0.47 -38.69

Due to the impact of financial liabilities

Mainly due to accounts payable during the reporting period 82,299,803.67 2.06 120,045,617.81 2.83 -31.44

Increase in payment to suppliers

Mainly due to advance payment from rent collection 2,055,784.10 0.05 872,190.32 0.02 135.70

Payable to employees Mainly due to expenses during the reporting period 16,563,758.20 0.41 26,067,168.25 0.61 -36.46

Salary: bonus paid last year

26/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Other payables Mainly due to increase during the reporting period 1,421,941.02 0.04 910,334.89 0.02 56.20

The deposit will arrive within one year after adding the deposit

Mainly due to non-currents due within one year 868,962.89 0.02 544,672.40 0.01 59.54

Liabilities arising from increases in leases

Mainly due to other domestic flows during the reporting period

530,034.75 0.01 316,151.15 0.01 67.65 Sales advance payment balance to liabilities

The increase in balance at the beginning of the year was mainly due to the decrease in shares during the reporting period: treasury shares 212,421,258.46 5.31 47,406,740.77 1.12 348.08

Minority shareholders due to ticket repurchase Mainly due to losses of subsidiaries -579,971.04 -0.01 -352,022.72 -0.01 64.75

Other explanations due to rights and interests

None

2. Overseas assets

√Applicable □Not applicable

(1) Asset scale

Among them: overseas assets are 7,099.00 (unit: 10,000 yuan, currency: RMB), accounting for 1.78% of total assets.

(2) Relevant explanations on the high proportion of overseas assets

□Applicable √Not applicable

Other instructions

None

3. Restrictions on major assets as of the end of the reporting period

□Applicable √Not applicable

4. Other instructions

□Applicable √Not applicable

27/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(4) Investment status analysis

1. Overall analysis of external equity investment

√Applicable □Not applicable

Unit: RMB 10,000 Currency: RMB Investment amount during the reporting period (RMB 10,000) Investment amount during the same period last year (RMB 10,000) Range of change

690.25 2,000.00 down 65.49%

(1) Significant equity investment

√Applicable □Not applicable

Unit: Yuan Currency: RMB

As of the end of the reporting period, disclosure date and name of the invested company, main business, investment method, investment amount, shareholding ratio, source of funds, investment profit and loss for the current period.

Progress Index (if any) Research and Development, Manufacturing, Sales and Services Medical

Device products (including video laryngoscopes,

Weisbo Medical Acquisition 22,058,000.00 22.00 Own funds Completed -155,961.21 No electronic bronchoscope, image processor

etc.)

Sales of power electronic components; electronic products

Chaowu Yunxin Product sales; daily household appliances retail; chemical industry New establishment 20,000,000.00 25.0745 Own funds Completed -73,925.00 No product sales, etc.

Internet sales (except sales that require a license

Qitianxia Digital Technology Capital increase 40,000,000.00 34.78 Own funds Not completed, see remarks - None

products)

Future Health Management Health Consultation Services (excluding medical services

Capital increase 20,000,000.00 40.00 Own funds Completed -97,560.00 Unreasonable)

Total / / 102,058,000.00 / / / -327,446.21 /

Notes: 1. According to the requirements of the capital increase agreement between Hangzhou Saiye Technology Co., Ltd. and Hangzhou Qitianxia Digital Technology Co., Ltd., the investment by subsidiary Saiye Technology in the joint venture Hangzhou Qitianxia Digital Technology Co., Ltd. is divided into two rounds of delivery. The subsidiary Saiye Technology has committed to invest 50 million yuan, and has actually invested 40 million yuan in total. Subsequently, based on the annual audit report issued by Qitianxia Digital Technology, the subsidiary Saiye Technology will fulfill the remaining investment commitment of 10 million yuan.

28/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) Significant non-equity investments

□Applicable √Not applicable

(3) Financial assets measured at fair value

√Applicable □Not applicable

Unit: Yuan Currency: RMB Accumulation included in equity

Fair value for the current period Less provision for the current period Sales/redemption for the current period

Asset category Beginning balance Change in fair value Purchase amount in the current period Other changes Closing balance Gains and losses from changes Value Amount

move

Others 1,360,737,937.71 -15,669,319.47 0.00 0.00 1,696,902,500.00 2,723,034,500.00 0.00 318,936,618.24Total 1,360,737,937.71 -15,669,319.47 0.00 0.00 1,696,902,500.00 2,723,034,500.00 0.00 318,936,618.24

Securities investment situation

□Applicable √Not applicable

Derivatives investment situation

□Applicable √Not applicable

(4) Investment status of private equity investment funds

√Applicable □Not applicable

Unit: Yuan Currency: Is RMB controlled?

reporting period

Investment agreement Reporting period As of the reporting period, whether the fund exists. Private equity fund investment during the reporting period. Accounting verification. Accumulated interest agreement signed. Total planned investment. No funds or funds invested. Assets at the related level. Profit impact name. Purpose. Share. Proportion. Accounting items. Profit impact time point. Amount.

influence

Hangzhou Qinzhi mainly invests

Other non-

Jianyuan Entrepreneurship 2023 Professional Limited Joint Venture in Life

30,000,000 0 18,000,000 60.00 No Liquidity No - -Investment Partnership February Investment Partner Technology

Financing assets

Enterprise (Limited Institution, etc. Healthy

29/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

partnership) resources, investment

Capitalized on

new science

Skills

Head

Total / / 30,000,000 0 18,000,000 / 60.00 / / / / - -

Other instructions

None

(5) Major assets and equity sales

□Applicable √Not applicable

(6) Analysis of major holding and participating companies

√Applicable □Not applicable

Information about major subsidiaries and joint-stock companies that affect the company's net profit by more than 10%

√Applicable □Not applicable

Unit: RMB 10,000 Currency: RMB Company name Company type Main business Registered capital Total assets Net assets Operating income Operating profit Net profit AcesoLab Subsidiary R&D, production 20 million RMB 52,537.90 -1,541.97 561.65 -1,328.14 -1,328.48 AcesoLab subsidiary R&D, production, sales USD 1 million 6,773.02 -360.42 3,003.72 1,796.26 1,796.26

Acquisition and disposal of subsidiaries during the reporting period

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

30/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(7) Structured entities controlled by the company □ Applicable √ Not applicable

6. Other disclosure matters

□Applicable √Not applicable

31/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Section 4 Corporate Governance, Environment and Society

1. Changes in directors, senior managers and core technical personnel of the company

□Applicable √Not applicable

Description of changes in the company’s directors, senior managers and core technical personnel

□Applicable √Not applicable

Description of the identification of the company’s core technical personnel

□Applicable √Not applicable

2. Profit distribution or capital reserve conversion plan

The profit distribution plan and the plan for converting public reserve funds into share capital prepared in the semi-annual period

Whether to allocate or convert to increase No Number of bonus shares for every 10 shares (shares) 0 Number of dividends for every 10 shares (yuan) (tax included) 0 Number of convertible shares for every 10 shares (shares) 0 Description of the profit distribution or capital reserve conversion plan

None

3. The situation and impact of the company’s equity incentive plan, employee stock ownership plan or other employee incentive measures

(1) Applicable if relevant equity incentive matters have been disclosed in temporary announcements and there is no progress or change in subsequent implementation √Not applicable

(2) Incentives not disclosed in temporary announcements or with subsequent progress

Equity incentives

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

Employee stock ownership plan status

□Applicable √Not applicable

Other incentives

□Applicable √Not applicable

4. Environmental information of listed companies and their major subsidiaries included in the list of companies that disclose environmental information in accordance with the law □Applicable √Not applicable

Other instructions

□Applicable √Not applicable

5. Consolidate and expand the results of poverty alleviation, rural revitalization and other work specific situations

□Applicable √Not applicable

32/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Section 5 Important Matters

1. Fulfillment of commitments

(1) Commitments made by the company’s actual controller, shareholders, related parties, acquirers and the company and other relevant parties during the reporting period or continuing into the reporting period

√Applicable □Not applicable

Yes Yes If not possible

No No Timely performance of commitments and If failed to be performed in time, the commitment should be stated Commitment Commitment Promise Time Fulfillment on time Should be performed by the party to the commitment Commitment time Performance Commitment period Clearly unfinished Type Content Strict Explain the next line Fulfillment conditions Specific step plan period

Reason for fulfillment of limit

Other Actual Controllers Acting in Concert Agreement: Both parties agree that Gao Fei and Zhao Huafang, as parties to the company's concerted action April 2, 2019 Yes Not Applicable Not Applicable Acting in Concert Agreement, through the equity and capabilities of Aotai Biotech held/controlled by them. The agreement is valid until Aotai

Controlled directors and supervisors of Aotai Biotechnology (referred to in the "Concert Acting Persons Agreement") Aotai Biotechnology achieved its first

with

"Controllable directors and supervisors" refers to the directors and supervisors nominated by them, who have been publicly issued by Aotai Biotech and

first

Directors and supervisors elected by the shareholders’ meeting) for Aotai Biotech’s strategic planning and listing from the date of listing 36

times

Business plans, business strategies, financial policies, personnel plans and other related matters Months, not allowed during this period

Public

When deliberating and voting on issues, they should act in unison. "Consistent Cancellation"

open

The "Moving Agreement" is valid until Aotai Biotech achieves its initial public offering and listing.

send

It is 36 months from the date and is irrevocable during this period. Within 30 days before the expiration date,

OK

If either party does not raise any written objection, the Agreement on Persons Acting in Concert will automatically

phase

Renewal, each automatic renewal period is 12 months. For details, please refer to the company’s announcement in 2021

close

"Section 5-7/(5)" of the "Prospectus" announced on March 19, 2019

of

/1. The main terms of the "Concerted Acting Persons Agreement" signed by the actual controller.

inherit

Shares Controlling shareholder, 1) Within 36 months from the date of listing of the company's shares ("lock-up period"), initial public offering Yes Date of initial listing Yes Not applicable Not applicable No.

Restricted Sale Actual Controller Do not transfer or entrust others to manage the stock directly and/or indirectly within 42 months before this issuance.

1. Directors do not directly and/or indirectly repurchase the company's shares directly held by the company.

The shares issued before the company's public issuance of shares held by the chief executive and general manager. 2) The company goes public

33/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Yes

Yes If not possible

No

No Timely performance of commitments and If failed to be performed in time, the commitment should be made. Commitment Commitment. Timely performance. Commitment time. Commitment period. Clear unfinished type. Content. Strict. Explain the next line. Implementation conditions. Details of the step plan period.

shoes

Limitation reason

OK

If the closing price of the company's stock for 20 consecutive trading days within the next 6 months is lower than

The issue price of technical personnel is high, or the closing price at the end of 6 months after listing is lower than the issue price.

The lock-in period of the company's shares held by the person is automatically extended for 6 months. 3) in

During my tenure as a director, supervisor, and senior manager of the company, I

The company shares transferred in a year do not exceed the total number of company shares held by the person

25%. If I resign from the company, I will not transfer the job within 6 months after resigning.

Let me hold the company shares. For details, please see the company’s announcement on March 19, 2021

"Section 10-5/(1)/2." of the "Prospectus" announced on the

The company’s controlling shareholder, one of the actual controllers, chairman and general manager, core

Technicians fly high on promises.

Actual controller of shares 1) Within 36 months from the date of listing of the company's stocks ("lock-up period"), the initial public offering Yes The date of initial listing Yes Not applicable Not applicable Restriction on sales One, director shall not transfer or entrust others to manage the shares I directly and/or indirectly share before the issuance Within 42 months from before

Zhao Huafang indirectly holds the company's shares, nor will the company repurchase the company's shares directly and/or indirectly.

Shares held by a company that have been issued before a public offering of stock. 2) The company goes public

In the next 6 months, if the closing price of the company's stock for 20 consecutive trading days is lower than

The issue price, or the closing price at the end of the 6-month period after listing is lower than the issue price, the

The lock-in period of the company's shares held by the person is automatically extended for 6 months. 3) in

During my tenure as a director, supervisor, and senior manager of the company, I

The company shares transferred in a year do not exceed the total number of company shares held by the person

25%. If I resign from the company, I will not transfer the job within 6 months after resigning.

Let me hold the company shares. For details, please see the company’s announcement on March 19, 2021

“Section 10-5/(1)/3, Company Prospectus” announced on the

Zhao Huafang, one of the company’s actual controllers and director, promised.

34/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Yes

Yes If not possible

No

No Timely performance of commitments and If failed to be performed in time, the commitment should be made. Commitment Commitment. Timely performance. Commitment time. Commitment period. Clear unfinished type. Content. Strict. Explain the next line. Implementation conditions. Details of the step plan period.

shoes

Limitation reason

OK

Shares Company shareholders 1) Within 36 months from the date of listing of the company's stocks ("lock-up period"), the initial public offering Yes The date of initial listing Yes Not applicable Not applicable Sales restrictions Da Investment shall not transfer or entrust others to manage the partnership directly and within 36 months before the issuance of shares.

/ Or indirectly hold the company's shares, nor will the company repurchase the partnership directly

Directly and/or indirectly held shares issued before the company's public offering of shares.

For details, please refer to the “Prospectus” announced by the company on March 19, 2021.

“Section 10-5/(1)/4. The company’s shareholder Saida Investment Commitment.

Shares Controlling shareholder, 1) Within 36 months from the date of listing of the company's shares ("lock-up period"), the initial public offering Yes The date of initial listing Yes Not applicable Not applicable Restriction on sales Actual controller Will not transfer or entrust others to manage I directly and/or indirectly stock before this issuance Within 42 months

1. Directors do not directly and/or indirectly repurchase the company's shares directly held by the company.

The shares held by the chief executive and general manager that have been issued before the company's public offering of shares. 2) The company goes public

Gao Fei's spouse If the closing price of the company's stock for 20 consecutive trading days in the next 6 months is lower than

Wu Weiqun If the issue price, or the closing price at the end of 6 months after listing is lower than the issue price, the

The lock-in period for company shares held by a person is automatically extended for 6 months. See details

The "Prospectus" announced by the company on March 19, 2021

Section 10-5/(1)/5. One of the company’s controlling shareholders and actual controllers,

Wu Weiqun, the spouse of chairman and general manager Gao Fei, promised.

Shares Holding company shares 1) Within 12 months from the date of listing of the company's shares ("lock-up period"), the company's directors shall not transfer or entrust others to manage the shares that I directly and/or indirectly held before the issuance of the shares within 18 months from the date of initial public offering.

The company's shares held by the general manager and senior management will not be repurchased by the company directly and/or indirectly.

Shares issued before the company's public issuance of shares held by management personnel and auditors. 2) Shares in the company

From the date of listing of the core technical personnel, if the company stocks held by me are 2 days after the expiration of the lock-up period,

If Lu Weike reduces his holdings during the year, the reduction price shall not be lower than the issue price; the company is listed

In the next 6 months, if the closing price of the company's stock for 20 consecutive trading days is lower than

35/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Yes

Yes If not possible

No

No Timely performance of commitments and If failed to be performed in time, the commitment should be made. Commitment Commitment. Timely performance. Commitment time. Commitment period. Clear unfinished type. Content. Strict. Explain the next line. Implementation conditions. Details of the step plan period.

shoes

Limitation reason

OK

The issue price, or the closing price at the end of the 6-month period after listing is lower than the issue price, the

The lock-in period of the company's shares held by the person is automatically extended for 6 months. 3) in

During my tenure as a director, supervisor, and senior manager of the company, I

The company shares transferred in a year do not exceed the total number of company shares held by the person

25%. If I resign from the company, I will not transfer the job within 6 months after resigning.

Let me hold the company shares. For details, please see the company’s announcement on March 19, 2021

"Section 10-5/(1)/7. Holding" of the "Prospectus" announced on

Directors, senior managers and core technical personnel of the company who own shares in the company

Lu Weike promised.

Shares Holding company shares 1) Within 12 months from the date of listing of the company's stocks ("lock-up period"), the initial public offering Yes The date of initial listing Yes Not applicable Not applicable Restricted shares of the company shall not be transferred or entrusted to others to manage the shares I directly and/or indirectly held before the issuance Within 18 months from before the issuance

The company's shares directly held by senior management personnel will not be repurchased by the company directly and/or indirectly.

The shares held by Fu Yanping that have been issued before the company's public offering of shares. 2) Shares in the company

From the date of listing of the shares, if the company stocks held by me expire 2 days after the lock-up period,

If the holding is reduced during the year, the reduction price shall not be lower than the issue price; the company is listed

In the next 6 months, if the closing price of the company's stock for 20 consecutive trading days is lower than

The issue price, or the closing price at the end of the 6-month period after listing is lower than the issue price, the

The lock-in period of the company's shares held by the person is automatically extended for 6 months. 3) in

During my tenure as a director, supervisor, and senior manager of the company, I

The company shares transferred in a year do not exceed the total number of company shares held by the person

25%. If I resign from the company, I will not transfer the job within 6 months after resigning.

Let me hold the company shares. For details, please see the company’s announcement on March 19, 2021

"Section 10-5/(1)/8" of the "Prospectus" announced on the

36/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Yes

Yes If not possible

No

No Timely performance of commitments and If failed to be performed in time, the commitment should be made. Commitment Commitment. Timely performance. Commitment time. Commitment period. Clear unfinished type. Content. Strict. Explain the next line. Implementation conditions. Details of the step plan period.

shoes

Limitation reason

OK

Fu Yanping, a senior executive of the company who owns shares in the company, promised.

Others Intention of holding and reducing shareholding of the company's controlling shares: 1) The company will strictly abide by the commitments made regarding the share sales restriction arrangements and voluntary lock-in of the company's shares held by the company. 2) Before the stock, two days after the expiration of the lock-up period

Capital and Qunze Investment. If the company reduces its holdings of Aotai Biotechnology shares, it shall do so three trading days in advance within the year.

Report information in a timely and accurate manner in accordance with laws, regulations and normative documents.

Accurately perform notification, filing and information disclosure obligations. held by the company

Within two years after the expiration of the lock-up period of Tai Biotech shares, the Company plans to reduce its holdings in Tai Biotech

For shares of a property, the reduction price shall not be lower than the initial public offering of shares of Aotai Biotech.

The issue price (from the listing of Aotai Biotech to the period of shareholding reduction, such as Aotai Biotech

Distribution of dividends, bonus shares, capital increase, issuance of new shares or rights issue, etc.

In case of ex-dividend or ex-rights behavior, the above price will be adjusted accordingly); 3)

Since the company and persons acting in concert with the company (if any) hold the company’s shares

When the number of shares is less than 5% of the company's total share capital, the company may no longer comply with the above

Commitment.

Others Intention of holding and reducing holdings of the company's controlling shares: 1) I will strictly abide by the commitments I have made regarding the initial public offering Yes Controlling shareholder's shares Yes Not applicable Not applicable The share restriction arrangement and voluntary lock-up of the company's shares held by the actual controlling shareholder. 2) Before the stock, two days after the expiration of the lock-up period

After the lock-in period for the company's shares held by me, one of the shareholders, expires, I plan to reduce my company's shares within the year

Chairman and CEO will strictly abide by laws, regulations and the China Securities Regulatory Commission

Managers, core committees, and relevant regulations of the Shanghai Stock Exchange (hereinafter referred to as “laws, laws and regulations”)

Technical personnel "high standards and normative documents"), prudently formulate a reduction plan, and pass laws,

Fly gradually reduce holdings in trading methods permitted by laws and regulatory documents; 3) I

If the company's shareholding is reduced, it shall be announced three trading days in advance and shall be

The provisions of laws, regulations and normative documents shall be implemented promptly and accurately.

37/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Yes

Yes If not possible

No

No Timely performance of commitments and If failed to be performed in time, the commitment should be made. Commitment Commitment. Timely performance. Commitment time. Commitment period. Clear unfinished type. Content. Strict. Explain the next line. Implementation conditions. Details of the step plan period.

shoes

Limitation reason

OK

notification, filing and information disclosure obligations. Lock-in of company shares held by oneself

Within two years after the expiration, if I plan to reduce my holdings of the company's shares, the reduction price shall not be low.

The issue price of the company's initial public offering of shares (from the date of the company's listing to the

During the holding period, if the company distributes dividends, sends bonus shares, converts shares into capital, increases

In the event of ex-dividend or ex-rights actions such as the issuance of new shares or allotment of shares, the above price will be

Adjust accordingly).

Others The company's actual intention to control and reduce shareholding: 1) I will strictly abide by the commitments I have made regarding the initial public offering Yes Controlling shareholder's shares Yes Not applicable Not applicable One of the controlling shareholders, the share sales restriction arrangement and voluntary locking of the company's shares held. 2) Before the stock, two days after the expiration of the lock-up period

Director Zhao Huafang After the lock-up period of the company shares I hold expires, I plan to reduce the company shares within the year

Those who do not do so will strictly abide by laws, regulations and the China Securities Regulatory Commission

The relevant provisions of the Shanghai Stock Exchange and the Shanghai Stock Exchange (hereinafter referred to as “laws, laws and regulations”)

regulations and normative documents"), prudently formulate shareholding reduction plans, and adopt laws,

The trading methods allowed by regulations and normative documents will gradually reduce holdings; 3) I

If the company's shareholding is reduced, it shall be announced three trading days in advance and shall be

The provisions of laws, regulations and normative documents shall be implemented promptly and accurately.

notification, filing and information disclosure obligations. Lock-in of company shares held by oneself

Within two years after the expiration, if I plan to reduce my holdings of the company's shares, the reduction price shall not be low.

The issue price of the company's initial public offering of shares (from the date of the company's listing to the

During the holding period, if the company distributes dividends, sends bonus shares, converts shares into capital, increases

In the event of ex-dividend or ex-rights actions such as the issuance of new shares or allotment of shares, the above price will be

Adjust accordingly).

Others Intention of holding and reducing shareholding of the company's controlling shares: 1) I will strictly abide by the commitments I have made regarding the initial public offering Yes Controlling shareholder's shares Yes Not applicable Not applicable The share restriction arrangement and voluntary lock-up of the company's shares held by the actual controlling shareholder. 2) Before the stock, after the lock-up period expires and

38/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Yes

Yes If not possible

No

No Timely performance of commitments and If failed to be performed in time, the commitment should be made. Commitment Commitment. Timely performance. Commitment time. Commitment period. Clear unfinished type. Content. Strict. Explain the next line. Implementation conditions. Details of the step plan period.

shoes

Limitation reason

OK

As one of the shareholders, after the lock-up period of the company shares held by me expires, I plan to reduce the company shares within two years after expiration.

Chairman and CEO will strictly abide by laws, regulations and the China Securities Regulatory Commission

Manager Gao Fei’s committee and the relevant provisions of the Shanghai Stock Exchange (hereinafter referred to as the “Laws, Laws and Regulations”)

Spouse Wu Weiqun ("Regulations and Normative Documents"), carefully formulate a shareholding reduction plan, and pass laws,

The trading methods allowed by regulations and normative documents will gradually reduce holdings; 3) I

If the company's shareholding is reduced, it shall be announced three trading days in advance and shall be

Promptly and accurately implement the provisions of laws, regulations and normative documents

notification, filing and information disclosure obligations. Lock-in of company shares held by oneself

If I plan to reduce my shareholding in the company within two years after the expiration, the reduction price shall not be low.

The issue price of the company's initial public offering of shares (from the date of the company's listing to the

During the holding period, if the company distributes dividends, sends bonus shares, converts shares into capital, increases

In the event of ex-dividend or ex-rights actions such as the issuance of new shares or allotment of shares, the above price will be

Adjust accordingly).

Other companies, holdings Commitment to stabilize stock price: Within three years after the company's listing, the company's stock has been lower than the company's most recent fiscal year's audited stock price for 20 consecutive Initial Public Offerings Yes Date of IPO Yes Not Applicable Not Applicable Shareholders, actual closing prices of each trading day are lower than the company's most recent fiscal year Audited Stock Within 36 months

The net assets per share of the controller and directors, the company will repurchase the company's shares or the controlling shareholder,

Directors (excluding independent directors, the same below) and senior managers increase their holdings in the company

Except for things), stock price stabilization measures will be initiated in the form of stocks. For details, please refer to the company’s announcement in March 2021

Senior Manager "Section 10-5/(2) Stability" of the "Prospectus" announced on the 19th

Member price measures and commitments.

Other companies, companies There are no false records, misleading statements or major omissions in information disclosure. Initial public offering No When it occurs Yes Not applicable Not applicable Not applicable Shareholders, actual omissions: For example, if there are false records, misleading statements in the company's prospectus. Before the stock

Controllers, public guidance statements or major omissions are important for determining whether the company complies with legal requirements.

39/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Yes

Yes If not possible

No

No Timely performance of commitments and If failed to be performed in time, the commitment should be made. Commitment Commitment. Timely performance. Commitment time. Commitment period. Clear unfinished type. Content. Strict. Explain the next line. Implementation conditions. Details of the step plan period.

shoes

Limitation reason

OK

The issuance conditions of directors, supervisors and senior management constitute a significant and substantial impact. 1) The company’s commitment: This

Core Technical Personnel The company will determine the relevant illegal facts from the date when the China Securities Regulatory Commission and other competent authorities determine the relevant illegal facts.

members and repurchase all new shares issued by the company in accordance with the law within 30 days from this time;

If the sponsorship of the issuance causes investors to suffer losses in the issuance and trading of securities, the company will

People and Securities Services shall compensate investors for their losses. 2) The company’s controlling shareholder and actual controller promises:

The company/I will urge the company to obtain certification from the China Securities Regulatory Commission and other competent authorities.

Repurchase the company's initial public offering in accordance with the law within 30 days from the date of relevant illegal facts

all new shares; causing investors to suffer losses in the issuance and trading of securities,

The company/I will compensate investors for their losses in accordance with the law. 3) All directors of the company,

Supervisors and senior managers promise: to enable investors to participate in the issuance and trading of securities

If Yizhong suffers losses, I will compensate investors for their losses in accordance with the law. 4) Company insurance

Recommended agency commitment: Because this sponsor is responsible for the company’s initial public offering of stocks and

Documents produced and issued for listing on the Science and Technology Innovation Board contain false records and misleading statements

If any statement or major omission causes losses to investors, the sponsor will

Compensate investors for losses in accordance with the law. 5) The company’s accounting firm promises:

Produced and issued documents for the company's initial public offering and listing on the Science and Technology Innovation Board

The documents contain false records, misleading statements or major omissions, which may cause investment

If investors cause losses, they will compensate investors for their losses in accordance with the law. 6) Corporate lawyers

The firm promises: There are no relevant legal documents produced and issued for this issuance and listing.

False records, misleading statements or major omissions. Such as this time

Failure to perform duties diligently during the issuance and listing process resulted in a public legal notice issued by the Exchange.

Legal documents make false records and misleads about important matters that are contrary to the truth.

sexual statements, or major omissions in disclosing information, causing the company to be inconsistent with

40/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Yes

Yes If not possible

No

No Timely performance of commitments and If failed to be performed in time, the commitment should be made. Commitment Commitment. Timely performance. Commitment time. Commitment period. Clear unfinished type. Content. Strict. Explain the next line. Implementation conditions. Details of the step plan period.

shoes

Limitation reason

OK

meet the conditions for this issuance and listing stipulated by relevant laws and cause problems to investors.

In case of direct economic losses, the Exchange will compensate investors for their losses in accordance with the law. See the public for details

The "Tenth Prospectus" announced by the company on March 19, 2021

Section 5/(7) Commitment to bear compensation or liability in accordance with the law.

Other companies, holdings Commitment to repurchase shares for fraudulent issuance and listing: 1. I/the company guarantee the initial public offering No When it occurs Yes Not applicable Not applicable Shareholders and actual The company's public issuance of stocks and the shares on the Shanghai Stock Exchange's Science and Technology Innovation Board

The controller is the city, and there is no fraudulent issuance. 2. If the company does not meet the issuance requirements

Listing conditions, where issuance registration is obtained by deception and has been issued and listed,

I/our company will confirm the last five working hours with the China Securities Regulatory Commission and other competent authorities.

The share repurchase procedure will be initiated within the next working day and all shares of the company’s public offering will be repurchased.

Department of new shares.

Other companies’ measures and commitments on making up for diluted immediate returns: For details, please refer to the company’s initial public offering No in the year of raising funds Yes Not applicable Not applicable “Section 10-5 of the Prospectus announced on March 19, 2021 Before shares

/ (5) Measures and commitments to make up for diluted immediate returns.

Other companies' commitment to profit distribution policy: For details, please refer to "Section 10-5/(6) Profit Distribution Policy" of the Prospectus of the company's Initial Public Offering Yes Date of IPO Yes Not Applicable Not Applicable 36 months from the date of the announcement of the company's shares on March 19, 2021

policy commitment.

Solution The company's controlling shares Commitment to avoid horizontal competition: For details, please refer to the "Section 10-5/(8) Other Undertaken Stocks" in the "Prospectus" announced by the company's initial public offering on March 19, 2021 No Continuous Yes Not applicable Not applicable to the same industry shareholders and actual controlling shareholders

Competition and restraint Commitment/1. Commitment to avoid competition within the same industry.

Resolution Controlling shareholder, commitment on reducing related transactions: For details, please refer to "Section 10-5/(8) Other Undertakings" in the "Prospectus" announced by the company on March 19, 2021. No Continuous Yes Not applicable Not applicable Related Actual Controller

Transaction and Wu Weiqun Commitment/2. Commitment to reduce related transactions.

41/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

2. Non-operating capital occupation by controlling shareholders and other related parties during the reporting period □ Applicable √ Not applicable

3. Illegal guarantee situation

□Applicable √Not applicable

42/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

4. Audit status of semi-annual report

□Applicable √Not applicable

5. Changes and handling of matters involved in non-standard audit opinions in last year’s annual report □ Applicable √ Not applicable

6. Matters related to bankruptcy and reorganization

□Applicable √Not applicable

7. Major litigation and arbitration matters

□The company has major litigation and arbitration matters during this reporting period √The company has no major litigation and arbitration matters during this reporting period

8. Listed companies and their directors, senior managers, controlling shareholders, and actual controllers are suspected of violating laws and regulations, and have been punished and rectified

situation

□Applicable √Not applicable

9. Explanation of the integrity status of the company, its controlling shareholders and actual controllers during the reporting period □ Applicable √ Not applicable

10. Major related transactions

(1) Related transactions related to daily operations

1. Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable

2. Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable

3. Matters not disclosed in temporary announcements

□Applicable √Not applicable

(2) Related transactions arising from asset acquisition or equity acquisition or sale

1. Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable

2. Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable

3. Matters not disclosed in temporary announcements

□Applicable √Not applicable

4. If a performance agreement is involved, the performance achievement during the reporting period should be disclosed □Applicable √Not applicable

43/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(3) Major related transactions of joint external investments

1. Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable

2. Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable

3. Matters not disclosed in temporary announcements

□Applicable √Not applicable

(4) Related credit and debt transactions

1. Matters that have been disclosed in temporary announcements and have no progress or changes in subsequent implementation □Applicable √Not applicable

2. Matters that have been disclosed in temporary announcements but have subsequent progress or changes in implementation □ Applicable √ Not applicable

3. Matters not disclosed in temporary announcements

□Applicable √Not applicable

(5) Financial business between the company and related financial companies, company-controlled financial companies and related parties □ Applicable √ Not applicable

(6) Other major related transactions

□Applicable √Not applicable

(7) Others

□Applicable √Not applicable

11. Major contracts and their performance

(1) Custody, contracting and leasing matters

□Applicable √Not applicable

(2) Major guarantees performed and not yet completed during the reporting period □ Applicable √ Not applicable

(3) Other major contracts

□Applicable √Not applicable

44/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

12. Instructions on the progress of use of raised funds

√Applicable □Not applicable

(1) Overall use of raised funds

√Applicable □Not applicable

Unit: Yuan As of the reporting period As of the reporting period

Prospectus or fundraising statement Investment this year

Cumulative as of the end of the reporting period, including: raised funds as of the end of the reporting period, excess raised funds at the end of the year, raised funds with changed uses, raised funds in the statement when the raised funds are in place, total excess raised funds (3) Amount invested during the year, proportion of the amount

Total amount of raised funds Net amount of raised funds (1) Total amount of raised funds invested Cumulative investment of excess raised funds at the end of the year

=(4)/(1) =(5)/(3)

First public release

March 19, 2021

Development Bank 1,804,545,000.00 1,643,266,906.25 398,382,200.00 1,244,884,706.25 1,438,904,389.91 1,058,692,749.43 87.56 85.04 165,178,089.97 10.05 0

day

stocks

Total / 1,804,545,000.00 1,643,266,906.25 398,382,200.00 1,244,884,706.25 1,438,904,389.91 1,058,692,749.43 / / 165,178,089.97/0

Other instructions

□Applicable √Not applicable

(2) Details of fundraising projects

√Applicable □Not applicable

1. Detailed use of raised funds

√Applicable □Not applicable

Unit: Yuan Item can be

The nature of the prospectus is that the project will be invested in

Is it true that as of the end of the reporting period, this project has raised funds? Or has the amount of funds raised as of the end of the reporting period reached the predetermined level? Whether the investment progress has not been reached

Project Name Project Involving Planned Investment of Raised Funds Cumulative Investment Progress Achieved Effects This Year Major Change Fund Set Description Amount of Investment This Year Total Raised Funds Invested Available Specific Original Savings Amount Already Complied with the Plan

Name Nature Change Total (1) (%) Benefits or research, as in source book (2) Status date Reason for project progress

Investment direction (3)＝(2)/(1) If the result is yes, please tell us the length of commitment and investment period

Specify specific capital projects

situation

Add new year

First time production 2.65

Disclosure 100 million servings Production 1,450.95 16,571.27

Yes No 213,950,600.00 - 205,972,811.99 96.27 2023.06 Yes Yes Not Applicable Not Applicable 7,977,788.01 Issuance of Extracorporeal Clinic Construction Ten Thousand Yuan Ten Thousand Yuan

Stock off reagent

industry

45/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Upgrading

Technical reform

construction project

first time

IVD R&D

public

Center construction R&D Yes No 88,554,800.00 - 84,084,079.65 94.95 2023.12 Yes Yes Not applicable Not applicable Not applicable Not applicable 4,470,720.35 issued

Set up project

stocks

First time marketing network

public network center

Others Yes No 40,876,800.00 - 36,047,259.25 88.19 2025.12 Yes Yes Not applicable Not applicable Not applicable Not applicable 4,829,540.75 issuance construction project

stock item

first time

public supplementary stream

Others Yes No 55,000,000.00 - 54,107,489.59 98.38 Not applicable Yes Yes Not applicable Not applicable Not applicable Not applicable Not applicable Issuance of working capital

stocks

Annual output 2

100 million servings

in vitro diagnosis

first time

breaking reagent

Public production 558.06 5,598.11

In production No No 247,136,300.00 - 221,158,041.67 89.49 2023.12 Yes Yes Not applicable Not applicable 25,978,258.33 Issuance Construction Ten thousand yuan Ten thousand yuan

Care and research

stocks

Development Center

Construction items

Head

Hangzhou Ao

Kai Biology

Technology has

Ltd.

First annual production 4

Disclosure 100 million servings Production 1.4510 1.451 million

No No 640,000,000.00 - 497,284,124.92 77.70 2025.12 Yes Yes Not applicable Not applicable 142,715,875.08 Issuance of in vitro diagnostic construction Ten thousand yuan stock Diagnostic reagent

Production research

Development Center

Construction items

Head

first time

Public repurchase of shares

Others No No 175,072,492.87 - 175,072,492.87 100 Not applicable Yes Yes Not applicable Not applicable Not applicable Not applicable Not applicable Issue 1

stocks

first time

Public repurchase of shares

Others No No 200,000,000.00 165,178,089.97 165,178,089.97 82.59 Not applicable No Yes Not applicable Not applicable Not applicable Not applicable Not applicable Issue 2

stocks

2,154.11 22,314.40Total / / / / 1,660,590,992.87 165,178,089.97 1,438,904,389.91 86.65 / / / / / 185,972,182.52

Ten thousand yuan Ten thousand yuan Note: The total planned investment of raised funds is greater than the net amount of raised funds, mainly due to the bank interest generated during the period when the raised funds are held and used.

46/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

2. Detailed usage of excess raised funds

√Applicable □Not applicable

Unit: Yuan As of the end of the reporting period, the accumulated investment has exceeded the amount raised. As of the end of the reporting period, the accumulated investment has exceeded

Purpose Nature Total amount of excess funds to be invested (1) Remarks

Total funds (2) Degree (%) (3) = (2)/(1)

In vitro diagnostic reagent production center with an annual output of 200 million doses and research and development in progress

Projects under construction 247,136,300.00 221,158,041.67 89.49 Completed core construction projects

Hangzhou Aokai Biotechnology Co., Ltd. has an annual output of 400 million human body parts

Projects under construction 640,000,000.00 497,284,124.92 77.7 Completed diagnostic reagent production R&D center construction project

Repurchase of shares 1 Repurchase 175,072,492.87 175,072,492.87 100 Completed repurchase of shares 2 Repurchase 200,000,000.00 165,178,089.97 82.59 Unclosed as of the end of the reporting period

Total / 1,262,208,792.87 1,058,692,749.43 //Explanation: The total amount of over-raised funds planned to be invested is greater than the total amount of over-raised funds, mainly due to the bank interest generated during the period of holding and using the over-raised funds.

3. Details of re-evaluation of investment projects during the reporting period

□Applicable √Not applicable

(3) Changes or termination of investment during the reporting period

□Applicable √Not applicable

47/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(4) Other use of raised funds during the reporting period

1. Advance investment and replacement of raised funds in investment projects

□Applicable √Not applicable

2. Use idle raised funds to temporarily supplement working capital

□Applicable √Not applicable

3. Cash management of idle raised funds and investment in related products

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB raised funds

Funds used for the reporting period Maximum during the period

Cash Management Ending Cash Balance Whether the Board of Directors Review Date Start Date End Date

There is a reasonable management margin that exceeds the authorized review limit.

Quota

June 30, 2025 48,000 June 30, 2025 June 29, 2026 1,887.00 No

Other instructions

The company on June 30, 2025 The 13th meeting of the third session of the Board of Directors was held on the 13th, and the "Proposal on the Use of Temporarily Idle Raised Funds for Cash Management" was reviewed and approved. It was agreed that the company would use the maximum balance without affecting the construction of investment projects with raised funds and the use of raised funds as well as the normal business development of the company. Temporarily idle raised funds (including super-raised funds) not exceeding RMB 480 million (including the original amount) can be used to purchase investment products with high security, good liquidity, and a term of no more than 12 months (including but not limited to agreement deposits, structured deposits, time deposits, notice deposits, certificates of deposit, etc.). Within the above quota, the funds can be used on a rolling basis, and the use period is valid for 12 months from the date of review and approval by the board of directors.

4. Others

√Applicable □Not applicable

The company held the 19th meeting of the third board of directors and the first extraordinary shareholders' meeting of 2026 on January 21, 2026 and February 6, 2026 respectively, and reviewed and approved:

(1) "Proposal on "Closing Part of the Investment Projects with Raised Funds and Investment Projects with Super Raised Funds and Using the Surplus Raised Funds to Permanently Supplement Working Capital", the raised funds investment project "Marketing Network Center Construction Project" and the super raised fund investment project "Hangzhou Aokai Biotechnology Co., Ltd." Co., Ltd.'s annual production capacity of 400 million doses of in vitro diagnostic reagents production and R&D center construction project" was completed. After the completion of the above-mentioned projects, 210,462,700 yuan of raised funds were saved (the actual amount is based on the balance of the special raised funds account on the day when the funds were transferred out), which the company intends to use to permanently replenish working capital.

(2) "Proposal on the "Plan to Repurchase the Company's Shares through Centralized Bidding Transactions"", the company plans to use the excess funds raised from the initial public offering of stocks to conduct share repurchases through centralized bidding transactions. All repurchased shares will be used to cancel or reduce registered capital. The repurchase price shall not exceed 85 yuan/share (inclusive) and shall not exceed 150% of the average trading price of the company's stock in the 30 trading days before the board of directors passed the resolution to repurchase shares. The total amount of repurchase funds shall not be less than RMB 100 million (inclusive) and shall not exceed RMB 200 million (inclusive). The specific total repurchase funds shall be subject to the total amount of funds actually used.

(5) Explanation of the intermediary agency’s abnormal verification of the storage and use of raised funds

□Applicable √Not applicable

(6) Subsequent rectification of unauthorized changes in the use of raised funds and illegal occupation of raised funds

□Applicable √Not applicable

48/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

13. Description of other major matters

□Applicable √Not applicable

Section 6 Changes in Shares and Shareholders

1. Changes in share capital

(1) Statement of changes in shares

1. Statement of changes in shares

During the reporting period, the total number of common shares and share capital structure of the company did not change.

2. Description of changes in shares

□Applicable √Not applicable

3. The impact of changes in shares between the reporting period and the disclosure date of the semi-annual report on financial indicators such as earnings per share and net assets per share (if any)

□Applicable √Not applicable

4. Other content that the company deems necessary or required to be disclosed by securities regulatory authorities

□Applicable √Not applicable

(2) Changes in restricted shares

□Applicable √Not applicable

2. Shareholder situation

(1) Total number of shareholders:

Total number of ordinary shareholders (households) as of the end of the reporting period 5,587 Total number of preference shareholders (households) with voting rights restored as of the end of the reporting period 0 Total number of shareholders (households) holding shares with special voting rights as of the end of the reporting period 0

Number of depositary receipt holders

□Applicable √Not applicable

(2) Shareholding status of the top ten shareholders and the top ten shareholders without selling restrictions as of the end of the reporting period

Situation in which the top ten shareholders guarantee their shareholding in securities accounts through both ordinary securities accounts and securities company customer credit transactions √ Applicable □ Not applicable

Among the top 10 shareholders, Ningbo Wenye Venture Capital Partnership (General Partnership) holds 790 shares of the company's shares through ordinary securities accounts and 659,577 shares of the company's shares through customer credit transaction guaranteed securities accounts of securities companies.

Unit: Shareholding status of the top ten shareholders (excluding shares lent through refinancing)

Holding includes transfer pledge, shareholder name, number of shares held at the end of the reporting period, limited financing loan mark or shareholder ratio (%)

(Full name) Increase or decrease in quantity, terms of sale, freezing status of shares sold, status of restricted sales of nature shares

49/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Number of shares Number of shares

shares

quantity quantity

number of copies

state quantity

state

Hangzhou Jingguan Investment Domestic Non-state-owned Law

0 18,492,600 23.33 0 0 None 0

Management Co., Ltd. Person: Hangzhou Qunze Investment Domestic non-state-owned law

0 15,022,000 18.95 0 0 None 0

Management Co., Ltd. Ren Gaofei 0 6,216,000 7.84 0 0 None 0 Domestic natural person Xu Jianming -146,000 3,817,843 4.82 0 0 None 0 Domestic natural person Lu Weike 0 2,648,832 3.34 0 0 None 0 Domestic natural person Hangzhou Saida Investment

Domestic non-state-owned legal partnership (limited) 0 2,092,935 2.64 0 0 None 0

partnership)

Fu Yanping 0 1,058,062 1.33 0 0 None 0 Domestic natural person HKSCC

-738,285 1,013,037 1.28 0 0 None 0 Other limited companies

Feng Mingyan + 1 6 1 , 4 8 0 7 5 0 , 0 0 0 0 . 9 5 0 0 None 0 Domestic Natural People Ningbo Wenye Entrepreneurship

Domestic non-state-owned legal investment partnerships 0 660,367 0.83 0 0 None 0

Person (general partnership)

Shareholding status of the top ten shareholders without selling restrictions (excluding shares lent through refinancing)

Type and number of shares held without selling restrictions

Name of shareholder Conditional tradable shares

Type Quantity

quantity

Hangzhou Jingguan Investment Management Co., Ltd. 18, 492, 600 RMB ordinary shares 18, 492, 600 Hangzhou Qunze Investment Management Co., Ltd. 15,022,000 RMB ordinary shares 15,022,000 Gaofei 6,216,000 RMB ordinary shares 6,216,000 Xu Jianming 3,817,843 RMB ordinary shares 3,817,843 Lu Weike 2,648,832 RMB ordinary shares 2,648,832 Hangzhou Saida Investment Partnership (Limited Partnership) 2,092,935 RMB ordinary shares 2,092,935 Fu Yanping 1,058,062 RMB ordinary shares 1,058,062 Hong Kong Securities Clearing Company Limited 1, 0 1 3, 0 3 7 RMB Ordinary shares 1, 0 1 3, 0 3 7 Feng Mingyan 7 5 0, 0 0 0 RMB Ordinary shares 7 5 0, 0 0 0 Ningbo Wenye Venture Capital Partnership (General Partnership) 6 6 0 , 3 6 7 RMB Ordinary shares 6 6 0 , 3 6 7

As of June 30, 2026, the company's repurchase accounts among the top ten shareholders held 3,481,233 shares, of which: 592,531 shares were used for employee holdings.

stock or equity incentive plan; 2,888,702 shares were used for share cancellation. Explanation of the above-mentioned shareholders’ entrusted voting rights, entrusted voting rights, and abstention from voting. The Company does not have the above-mentioned shareholders’ entrusted voting rights, entrusted voting rights, or abstention from voting.

50/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Jingguan Investment is a company controlled by the actual controller Zhao Huafang; Qunze Investment and Saida Investment are companies controlled by the actual controller Gao Fei. Gao Fei directly holds 7.84% of the company's shares, indirectly controls 18.95% of the company's shares through Qunze Investment, indirectly controls 2.64% of the company's shares through Saida Investment, and controls 29.43% of the company in total. Explanation of the above-mentioned shareholders' related relationships or concerted actions

Zhao Huafang indirectly controls 23.33% of the company's shares through Jingguan Investment. The two control a total of 52.76% of the company's shares through direct and indirect methods. They have signed the "Concert Acting Persons Agreement" and are the actual controllers of the company. Apart from this, there is no related relationship between the above shareholders.

Explanation of preference shareholders whose voting rights have been restored and the number of shares they hold. The company does not have any preference shareholders.

Shareholders holding more than 5% of the shares, the top ten shareholders and the top ten shareholders of unrestricted tradable shares participating in the refinancing business and lending shares

□Applicable √Not applicable

The top ten shareholders and the top ten shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□Applicable √Not applicable

Number of shares held by the top ten shareholders subject to selling restrictions and conditions for selling restrictions

□Applicable √Not applicable

As of the end of the reporting period, the company’s top ten domestic custodial receipt holders are as follows:

□Applicable √Not applicable

Depositary receipt holders holding more than 5% of the shares, the top ten depositary receipt holders and the top ten depositary receipt holders with no selling conditions participating in the refinancing business and lending shares

□Applicable √Not applicable

The top ten holders of depositary receipts and the top ten holders of unrestricted depositary receipts have changed from the previous period due to refinancing lending/returning.

□Applicable √Not applicable

The number and sales restrictions held by the top ten holders of restricted depositary receipts

□Applicable √Not applicable

(3) Table of top ten shareholders by number of voting rights as of the end of the reporting period

√Applicable □Not applicable

Unit: Number of shares held Voting rights

During the reporting period

Preface Voting rights Name of restricted shareholder Special voting Number of voting rights Increase in voting rights

No. Ordinary shares Proportional equity shares Less

Kuang Hangzhou Jingguan Investment

1 18,492,600 0 18,492,600 23.33 0 Unmanaged Limited Company

Hangzhou Qunze Investment

2 15,022,000 0 15,022,000 18.95 0 Unmanaged Limited Company

3 Gao Fei 6,216,000 0 6,216,000 7.84 0 None 4 Xu Jianming 3,817,843 0 3,817,843 4.82 -146,000 None 5 Lu Weike 2,648,832 0 2,648,832 3.34 0 No Hangzhou Saida Investment

6 2,092,935 0 2,092,935 2.64 0 No partnership (limited

51/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

partnership)

7 Fu Yanping 1,058,062 0 1,058,062 1.33 0 No HKSCC

8 1,013,037 0 1,013,037 1.28 -738,285 No Limited Company

9 Feng Mingyan 7 5 0 , 0 0 0 0 7 5 0 , 0 0 0 0 . 9 5 + 1 6 1 , 4 8 0 None

Ningbo Wenye Entrepreneurship

10 Investment partnership 660,367 0 660,367 0.83 0 None

(general partnership)

combine

/ 51,771,676 0 51,771,676 / / /Total

(4) Strategic investors or general legal persons become the top ten shareholders due to the placement of new shares/depositary receipts □Applicable √Not applicable

3. Directors, senior managers and core technical personnel

(1) Changes in shareholdings of current and departing directors, senior managers and core technical personnel during the reporting period □Applicable √Not applicable

Other situation description

□Applicable √Not applicable

(2) Equity incentives granted to directors, senior managers and core technical personnel during the reporting period

1. Stock options

□Applicable √Not applicable

2. Class I restricted stocks

□Applicable √Not applicable

3. Class II restricted stocks

□Applicable √Not applicable

(3) Other instructions

□Applicable √Not applicable

4. Changes in controlling shareholders or actual controllers

□Applicable √Not applicable

5. Implementation and changes of relevant arrangements for depositary receipts during the reporting period □ Applicable √ Not applicable

6. Special voting rights shares

□Applicable √Not applicable

7. Information related to preference shares

□Applicable √Not applicable

52/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Section 7 Bond-Related Information

1. Corporate bonds (including corporate bonds) and non-financial corporate debt financing instruments □ Applicable √ Not applicable

2. Convertible corporate bonds

□Applicable √Not applicable

53/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Section 8 Financial Report

1. Audit report

□Applicable √Not applicable

2. Financial statements

Consolidated Balance Sheet

June 30, 2026

Prepared by: Hangzhou Aotai Biotechnology Co., Ltd.

Unit: Yuan Currency: RMB

Item Notes June 30, 2026 Current assets as of December 31, 2025:

Monetary funds 1,847,967,875.13 1,067,266,075.69 Settlement reserves

Loan funds

Trading financial assets 276,186,261.64 1,324,890,081.11 Derivative financial assets

Notes receivable

Accounts receivable 145,117,261.47 159,047,825.16 Accounts receivable financing

Prepayments 13,066,554.38 14,129,812.12 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 8,684,803.56 5,979,081.69 Including: interest receivable

Dividends receivable

Buy financial assets under resale agreements

Inventory 192,494,033.82 176,689,306.84 Including: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 84,161,121.51 83,757,355.81

Total current assets 2,567,677,911.51 2,831,759,538.42 Non-current assets:

Grant loans and advances

debt investment

Other debt investments

long-term receivables

Long-term equity investment 98,400,797.52 98,728,243.73 Other equity instrument investment 24,750,356.60 17,847,856.60 Other non-current financial assets 18,000,000.00 18,000,000.00 Investment real estate 74,740,675.49 61,919,957.58 Fixed assets 970,728,665.42 994,456,083.70 Construction in progress 39,001,920.92 15,336,809.11

54/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

productive biological assets

oil and gas assets

Right-of-use assets 6,947,594.01 7,889,108.04 Intangible assets 133,919,356.19 136,818,845.76 Including: data resources

development expenditure

Among them: data resources

goodwill

Long-term deferred expenses 19,238,185.31 16,490,866.54 Deferred income tax assets 21,782,561.97 22,049,411.30 Other non-current assets 22,175,845.50 21,128,239.89 Total non-current assets 1,429,685,958.93 1,410,665,422.25

Total assets 3,997,363,870.44 4,242,424,960.67 Current liabilities:

short term borrowing

Borrow from the central bank

borrowing funds

Trading financial liabilities 12,145,021.00 19,809,014.00 Derivative financial liabilities

Notes payable

Accounts payable 82,299,803.67 120,045,617.81 Advance receipts 2,055,784.10 872,190.32 Contract liabilities 39,250,193.85 35,023,065.15 Financial assets sold under repurchase

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 16,563,758.20 26,067,168.25 Taxes payable 74,207,474.06 83,056,346.73 Other payables 1,421,941.02 910,334.89 Including: interest payable

Dividends payable

Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year 868,962.89 544,672.40 Other current liabilities 530,034.75 316,151.15

Total current liabilities 229,342,973.54 286,644,560.70 Non-current liabilities:

insurance contract reserves

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 6,162,637.11 6,867,318.10 Long-term payables

Long-term employee benefits payable

Estimated liabilities

55/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Deferred income 1,710,421.91 2,574,138.25 Deferred income tax liabilities

Other non-current liabilities

Total non-current liabilities 7,873,059.02 9,441,456.35

Total liabilities 237,216,032.56 296,086,017.05 Owners’ equity (or shareholders’ equity):

Paid-in capital (or share capital) 79,280,855.00 79,280,855.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 1,685,190,409.78 1,680,354,501.42 Less: treasury shares 212,421,258.46 47,406,740.77 Other comprehensive income 32,556,215.97 32,169,058.37 Special reserves

Surplus reserve 266,191,150.02 266,191,150.02 General risk reserve

Undistributed profits 1,909,930,436.61 1,936,102,142.30 Attributable to the owner’s equity of the parent company (or shareholders

3,760,727,808.92 3,946,690,966.34 equity) total

Minority shareholders' equity -579,971.04 -352,022.72 Total owners' equity (or shareholders' equity) 3,760,147,837.88 3,946,338,943.62 Liabilities and owners' equity (or shareholders' equity)

3,997,363,870.44 4,242,424,960.67 profit) total

Person in charge of the company: Gao Fei Person in charge of accounting work: Fu Yanping Person in charge of the accounting department: Fu Yanping

Parent company balance sheet

June 30, 2026

Prepared by: Hangzhou Aotai Biotechnology Co., Ltd.

Unit: Yuan Currency: RMB

Item Notes June 30, 2026 Current assets as of December 31, 2025:

Monetary funds 1,597,495,564.82 828,174,704.98 Trading financial assets 276,186,261.64 1,324,890,081.11 Derivative financial assets

Notes receivable

Accounts receivable 302,014,490.39 297,023,822.67 Accounts receivable financing

Prepayments 9,618,759.42 10,656,149.82 Other receivables 859,904,434.30 804,199,211.82 Including: interest receivable

Dividends receivable

Inventory 154,336,343.82 138,899,475.01 Including: data resources

contract assets

Assets held for sale

Non-current assets due within one year

56/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Other current assets 4,074,816.99 631,535.54

Total current assets 3,203,630,671.38 3,404,474,980.95 Non-current assets:

debt investment

Other debt investments

long-term receivables

Long-term equity investment 131,179,963.50 130,521,969.69 Other equity instrument investments -

Other non-current financial assets 18,000,000.00 18,000,000.00 Investment real estate 14,304,445.14 12,979,325.70 Fixed assets 193,518,765.90 202,251,091.97 Construction in progress 1,028,668.14 144,628.32 productive biological assets

oil and gas assets

Right-of-use asset -

Intangible assets 22,897,215.81 23,508,148.52 Including: data resources

development expenditure

Among them: data resources

goodwill

Long-term deferred expenses 595,037.65 1,553,659.19 Deferred income tax assets 17,939,489.49 18,824,470.68 Other non-current assets - -

Total non-current assets 399,463,585.63 407,783,294.07

Total assets 3,603,094,257.01 3,812,258,275.02 Current liabilities:

short term borrowing

Trading financial liabilities 12,145,021.00 19,809,014.00 Derivative financial liabilities

Notes payable

Accounts payable 48,227,519.81 58,532,902.07 Advance receipts 706,514.00 52,448.00 Contract liabilities 32,865,007.76 28,730,945.72 Employee benefits payable 13,647,423.30 22,253,840.12 Taxes payable 2,016,835.43 4,414,547.36 Other payables 256,866.00 60,530.00 Including: interest payable

Dividends payable

Liabilities held for sale

Non-current liabilities due within one year -

Other current liabilities 425,421.68 209,428.75

Total current liabilities 110,290,608.98 134,063,656.02 Non-current liabilities:

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liability –

57/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

long-term payables

Long-term employee benefits payable

Estimated liabilities

Deferred income 1,164,882.31 2,022,679.59 Deferred income tax liabilities

Other non-current liabilities

Total non-current liabilities 1,164,882.31 2,022,679.59

Total liabilities 111,455,491.29 136,086,335.61 Owners’ equity (or shareholders’ equity):

Paid-in capital (or share capital) 79,280,855.00 79,280,855.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 1,685,880,469.24 1,681,044,560.88 Less: treasury shares 212,421,258.46 47,406,740.77 Other comprehensive income

special reserve

Surplus reserve 266,191,150.02 266,191,150.02 Undistributed profits 1,672,707,549.92 1,697,062,114.28 Total owners’ equity (or shareholders’ equity) 3,491,638,765.72 3,676,171,939.41 Liabilities and owners’ equity (or shareholders’ rights

3,603,094,257.01 3,812,258,275.02 profit) total

Person in charge of the company: Gao Fei Person in charge of accounting work: Fu Yanping Person in charge of the accounting department: Fu Yanping

consolidated income statement

January-June 2026

Unit: Yuan Currency: RMB Item Notes 2026 Half Year 2025 Half Year

1. Total operating income 392,144,917.68 429,850,024.75 Including: operating income 392,144,917.68 429,850,024.75 Interest income

Premiums earned

Fee and commission income

2. Total operating costs 345,033,080.78 299,110,577.78 Including: operating costs 183,954,455.35 186,926,166.19 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 10,691,496.37 4,039,473.17 Sales expenses 30,564,898.56 38,436,383.21 Management expenses 39,777,220.08 34,605,227.94 Research and development expenses 60,384,755.92 48,195,711.85

58/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Financial expenses 19,660,254.50 -13,092,384.58 Including: interest expenses 158,237.55 100,232.85 Interest income 13,474,004.03 13,241,292.78 Plus: other income 2,729,397.96 5,537,749.40 Investment income (losses are listed with "-") -5,519,581.89 6,084,326.45 Including: investment in associates and joint ventures

-327,446.21 -215,248.83 capital income

Financial assets measured at amortized cost

Derecognition of income (losses are listed with "-")

Exchange gains (losses are listed with "-")

Net exposure hedging income (losses are filled in with "-"

column)

Gains from changes in fair value (losses are marked with a “-”

13,345,598.16 15,823,882.70 fill in the column)

Credit impairment losses (losses are listed with "-") -2,735,269.54 -4,996,527.44 Asset impairment losses (losses are listed with "-") -1,006,923.80 -608,005.17

Asset disposal income (losses are listed with "-") 65,174.37 -

3. Operating profit (losses are listed with "-") 53,990,232.16 152,580,872.91 plus: non-operating income 169,603.53 0.30

Less: Non-operating expenses 136,938.94 473,485.47

4. Total profits (total losses are listed with "-") 54,022,896.75 152,107,387.74

Less: Income tax expense 3,380,763.64 20,005,582.88

5. Net profit (net loss is listed with "-") 50,642,133.11 132,101,804.86

(1) Classification by business continuity

1. Net profit from continuing operations (net loss is marked with "-"

50,642,133.11 132,101,804.86 fill in the column)

2. Net profit from discontinued operations (net loss is marked with "-"

Fill in the column)

(2) Classification according to ownership ownership

1. Net profit (net loss) attributable to shareholders of the parent company

50,844,708.31 132,012,694.61 (please fill in the list with "-")

2. Profit and loss of minority shareholders (net loss is filled in with "-"

-202,575.20 89,110.25 columns)

6. Net after-tax amount of other comprehensive income 361,784.48 -647,348.27

(1) Other comprehensive income attributable to owners of the parent company

387,157.60 -644,840.25 net profit after tax

1. Other comprehensive income that cannot be reclassified into profit or loss

(1) Remeasurement of changes in defined benefit plan

(2) Other comprehensive income that cannot be transferred to profit or loss under the equity method

(3) Changes in fair value of other equity instrument investments

(4) Changes in the fair value of the company’s own credit risk

2. Other comprehensive income that will be reclassified into profit and loss 387,157.60 -644,840.25 (1) Other comprehensive income that can be converted into profit and loss under the equity method

(2) Changes in fair value of other debt investments

(3) Financial assets are reclassified and included in other comprehensive income

Amount

(4) Credit impairment provisions for other debt investments

(5) Cash flow hedging reserve

(6) Translation difference of foreign currency financial statements 387,157.60 -644,840.25

59/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(7) Others

(2) Other comprehensive income attributable to minority shareholders

-25,373.12 -2,508.02 net amount after tax

7. Total comprehensive income 51,003,917.59 131,454,456.59

(1) Comprehensive income attributable to owners of the parent company

51,231,865.91 131,367,854.36 total

(2) Total comprehensive income attributable to minority shareholders -227,948.32 86,602.23

8. Earnings per share:

(1) Basic earnings per share (yuan/share) 0.64 1.67

(2) Diluted earnings per share (yuan/share) 0.64 1.67

If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0 yuan, and the net profit realized by the merged party in the previous period is: 0 yuan.

Person in charge of the company: Gao Fei Person in charge of accounting work: Fu Yanping Person in charge of the accounting department: Fu Yanping

Parent company income statement

January-June 2026

Unit: Yuan Currency: RMB

Item Notes 2026 Half Year 2025 Half Year

1. Operating income 334,892,564.38 398,894,776.54 Less: Operating costs 167,234,572.68 182,436,741.01 Taxes and surcharges 9,746,965.98 3,596,035.86 Sales expenses 25,663,614.33 24,311,408.31 Administrative expenses 17,197,851.39 18,220,832.77 Research and development expenses 46,851,966.63 38,923,439.56 Financial expenses 18,268,067.46 -9,064,561.38 Including: interest expenses - 71,148.52

Interest income 12,091,230.79 9,329,677.24 plus: other income 2,670,417.41 4,956,222.66 Investment income (losses are listed with "-") -5,935,836.64 6,021,499.05 Including: investment in associates and joint ventures

-155,961.21 -215,248.83 income

Financial assets measured at amortized cost

No income has been recognized (losses are listed with "-")

Net exposure hedging income (losses are listed with a “-” sign)

Gains from changes in fair value (losses are filled in with a “-” sign

13,345,598.16 15,823,882.70 columns)

Credit impairment loss (losses are listed with "-") -2,565,146.18 -4,684,518.68 Asset impairment losses (losses are listed with "-") -956,325.84 -608,005.17 Asset disposal income (losses are listed with "-") 65,174.37 1,246,278.36

2. Operating profit (losses are listed with "-") 56,553,407.19 163,226,239.33 plus: non-operating income 169,600.18 -

Less: Non-operating expenses 130,264.23 440,334.95

3. Total profits (total losses are listed with "-") 56,592,743.14 162,785,904.38 Less: income tax expenses 3,930,893.50 19,447,219.94

4. Net profit (net loss is listed with "-") 52,661,849.64 143,338,684.44

(1) Net profit from continuing operations (net loss is represented by “-” 52,661,849.64 143,338,684.44

60/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(Fill in the number)

(2) Net profit from discontinued operations (net loss is represented by “-”

(Fill in the number)

5. Net amount of other comprehensive income after tax

(1) Other comprehensive income that cannot be reclassified into profit or loss

1. Remeasure the changes in defined benefit plan

2. Other comprehensive income that cannot be transferred to profit or loss under the equity method

3. Changes in fair value of other equity instrument investments

4. Changes in the fair value of the company’s own credit risk

(2) Other comprehensive income that will be reclassified into profit and loss

1. Other comprehensive income that can be converted to profit or loss under the equity method

2. Changes in fair value of other debt investments

3. Financial assets are reclassified and included in other comprehensive income

Amount

4. Credit impairment provisions for other debt investments

5. Cash flow hedging reserve

6. Translation differences of foreign currency financial statements

7.Others

6. Total comprehensive income 52,661,849.64 143,338,684.44

7. Earnings per share:

(1) Basic earnings per share (yuan/share) - -

(2) Diluted earnings per share (yuan/share) - -

Person in charge of the company: Gao Fei Person in charge of accounting work: Fu Yanping Person in charge of the accounting department: Fu Yanping

Consolidated cash flow statement from January to June 2026 Unit: Yuan Currency: RMB

Item Notes 2026 Half Year 2025 Half Year

1. Cash flow generated from operating activities:

Cash received from sales of goods and provision of services 409,281,237.77 406,781,612.87 Net increase in customer deposits and interbank deposits

Net increase in borrowing from the central bank

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

Tax returns received 30,042,818.55 22,560,355.25 Other cash received related to operating activities 25,925,382.42 21,636,906.42

Subtotal of cash inflows from operating activities 465,249,438.74 450,978,874.54 Cash paid for purchasing goods and receiving services 228,105,883.42 196,560,468.32 Net increase in customer loans and advances

Net increase in deposits with central banks and inter-banks

61/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 89,985,805.84 90,667,788.36 Various taxes and fees paid 38,392,866.17 23,025,629.44 Cash paid for other operating activities 55,879,874.31 79,371,352.67 Subtotal of cash outflows from operating activities 412,364,429.74 389,625,238.79

Net cash flow generated from operating activities 52,885,009.00 61,353,635.75

2. Cash flow generated from investing activities:

Cash received from recovery of investment 1,198,703,819.47 1,323,366,810.53 Cash received from investment income 1,184,256.32 7,053,526.66 Cash received from disposal of fixed assets, intangible assets and other long-term assets

218,294.22 9,799,934.04 times net cash

Net cash received from disposal of subsidiaries and other business units

Um

Other cash received related to investing activities

Subtotal of cash inflows from investing activities 1,200,106,370.01 1,340,220,271.23 Expenses for purchase and construction of fixed assets, intangible assets and other long-term assets

42,655,558.15 120,754,290.25 paid in cash

Cash paid for investment 157,597,286.84 973,386,622.12 Net increase in pledged loans

Net cash paid to acquire subsidiaries and other business units

Um

Cash payments related to other investing activities 2,766,120.00 -

Subtotal of cash outflows from investing activities 203,018,964.99 1,094,140,912.37

Net cash flow generated from investing activities 997,087,405.02 246,079,358.86

3. Cash flow generated from financing activities:

Cash received from investments - 3,396.29 Including: Cash received from subsidiaries absorbing investment from minority shareholders - 3,396.29 Cash received from borrowings

Other cash received related to financing activities 286,068.78 -

Subtotal of cash inflows from financing activities 286,068.78 3,396.29 Cash paid to repay debts

Cash paid for distribution of dividends, profits or repayment of interest 77,016,414.00 116,801,088.61 Including: dividends and profits paid by subsidiaries to minority shareholders

Other cash payments related to financing activities 166,115,983.64 1,342,278.99 Subtotal of cash outflows from financing activities 243,132,397.64 118,143,367.60

Net cash flow generated from financing activities -242,846,328.86 -118,139,971.31

4. Impact of exchange rate changes on cash and cash equivalents -29,135,405.72 -630,750.50

5. Net increase in cash and cash equivalents 777,990,679.44 188,662,272.80 plus: opening balance of cash and cash equivalents 1,062,762,726.91 900,336,955.59

6. Balance of cash and cash equivalents at the end of the period 1,840,753,406.35 1,088,999,228.39

Person in charge of the company: Gao Fei Person in charge of accounting work: Fu Yanping Person in charge of the accounting department: Fu Yanping

Parent company cash flow statement

January-June 2026

62/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Unit: Yuan Currency: RMB

Item Notes 2026 Half Year 2025 Half Year

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 329,716,787.68 337,070,219.51 Tax refunds received 21,580,996.16 15,614,588.53 Cash received from other operating activities 14,311,938.76 15,767,419.72

Subtotal of cash inflows from operating activities 365,609,722.60 368,452,227.76 Cash paid for purchasing goods and receiving services 186,166,288.66 172,745,618.53 Cash paid to and for employees 69,933,501.80 71,928,755.25 Various taxes paid 31,469,386.67 15,470,419.75 Other cash paid related to operating activities 89,162,866.11 167,076,241.38

Subtotal of cash outflows from operating activities 376,732,043.24 427,221,034.91 Net cash flow from operating activities -11,122,320.64 -58,768,807.15

2. Cash flow generated from investing activities:

Cash received from recovery of investment 1,198,703,819.47 1,323,366,810.53 Cash received from investment income 596,516.57 6,990,699.26 Disposal of fixed assets, intangible assets and other long-term assets

213,854.10 5,163,269.04 Net cash recovered from property

Disposal of cash received from subsidiaries and other business units

Net amount of money

Other cash received related to investing activities

Subtotal of cash inflows from investing activities 1,199,514,190.14 1,335,520,778.83 Purchase and construction of fixed assets, intangible assets and other long-term assets

1,002,589.30 2,768,460.63 Cash paid for property

Cash paid for investment 150,694,786.84 962,963,414.19 Cash paid for acquisition of subsidiaries and other business units

Net amount of money

Other cash payments related to investing activities

Subtotal of cash outflows from investing activities 151,697,376.14 965,731,874.82

Net cash flow generated from investing activities 1,047,816,814.00 369,788,904.01

3. Cash flow generated from financing activities:

Cash received from investment -

Obtain cash received from borrowing money

Other cash received related to financing activities 286,068.78 -

Subtotal of cash inflows from financing activities 286,068.78 -

Cash paid to repay debt

Cash paid for distribution of dividends, profits or repayment of interest 77,016,414.00 116,802,501.00 Cash paid for other financing activities 165,582,370.69 1,268,190.00 Subtotal of cash outflows from financing activities 242,598,784.69 118,070,691.00

Net cash flow generated from financing activities -242,312,715.91 -118,070,691.00

4. Impact of exchange rate changes on cash and cash equivalents -25,178,417.61 -6,791.69

5. Net increase in cash and cash equivalents 769,203,359.84 192,942,614.17 Plus: opening balance of cash and cash equivalents 827,888,636.20 632,411,542.88

6. Balance of cash and cash equivalents at the end of the period 1,597,091,996.04 825,354,157.05

Person in charge of the company: Gao Fei Person in charge of accounting work: Fu Yanping Person in charge of the accounting department: Fu Yanping

63/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Consolidated Statement of Changes in Owner's Equity

January-June 2026

Unit: Yuan Currency: RMB 2026 Half Year

Owner's equity attributable to parent company

Other equity work 1

Item Specific General Minority shareholders Owner's equity Paid-in capital Other comprehensive Items Risks Other equity Total superior capital reserve Less: treasury shares Surplus reserve Undistributed profits Subtotal (or share capital) Other income Reserves Insurance Others Continued

He is ready

stocks bonds

Prepare

1. Previous year period

79,280,855.00 1,680,354,501.42 47,406,740.77 32,169,058.37 266,191,150.02 1,936,102,142.30 3,946,690,966.34 -352,022.72 3,946,338,943.62 Ending balance

Add: Accounting

policy change

Early stage

error correction

Others

2. Current year

79,280,855.00 1,680,354,501.42 47,406,740.77 32,169,058.37 266,191,150.02 1,936,102,142.30 3,946,690,966.34 -352,022.72 3,946,338,943.62 Initial balance

3. Added in this issue

Less working capital

Amount (reduced by 4,835,908.36 165,014,517.69 387,157.60 - - - -26,171,705.69 - -185,963,157.42 -227,948.32 -186,191,105.74 "-"

column)

(1) Comprehensive

• • 387,157.60 50,844,708.31 51,231,865.91 -202,575.20 51,029,290.71Total income

(2) All

Investors’ investment and 5,000,192.58 165,014,517.69 - -160,014,325.11 -25,373.12 -160,039,698.23 Capital reduction

1． owner

Common shares invested - 165,014,517.69 - -165,014,517.69 - -165,014,517.69 shares

2. Other rights

beneficial tool support

• -Those who have input

capital

3． Share-based expenses 5,000,192.58 5,000,192.58 5,000,192.58

64/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Amount paid included in owner's equity

4. Others - -25,373.12 -25,373.12

(3) Profit

• -77,016,414.00 -77,016,414.00 -77,016,414.00 allocation

1． Withdraw profit

-Excess reserve

2. Extract general risk reserves - reserves

3． Distribution to owners (or shareholders) 4. Others - -

(4) Part of owner’s equity -164,284.22 -164,284.22 - -164,284.22 is carried forward

1． Conversion of capital reserves to capital (or share capital)

2. Conversion of surplus reserves into capital (or share capital)

3． Surplus reserve to cover losses

4. The amount of changes in the defined benefit plan is carried forward to retained earnings 5. Other comprehensive income carried forward to retained earnings

5. Others -164,284.22 -164,284.22 -164,284.22

(5) Special reserves

1． Extract this period

2. This issue makes

65/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

use

(6) Others

4. This issue

79,280,855.00 - - - 1,685,190,409.78 212,421,258.46 32,556,215.97 - 266,191,150.02 - 1,909,930,436.61 - 3,760,727,808.92 -579,971.04 Ending balance of 3,760,147,837.88

2025 half year

Owner's equity attributable to parent company

Other equity work 1

Items Specific General Minority shares Owners’ equity Paid-in capital Other comprehensive Items Risks Other owners’ equity Total preferred capital reserve Less: treasury shares Surplus reserve Undistributed profits Subtotal (or share capital) Other income Reserves Insurance Others

Continue first

He is ready

stocks bonds

Prepare

1. Closing balance of the previous year 79,280,855.00 1,707,661,785.48 113,011,953.53 32,499,360.87 266,191,150.02 1,911,019,965.65 3,883,641,163.49 -220,860.60 3,883,420,302.89 plus: changes in accounting policies

Early error update

Right

Others

2. Balance at the beginning of the year 79,280,855.00 1,707,661,785.48 113,011,953.53 32,499,360.87 266,191,150.02 1,911,019,965.65 3,883,641,163.49 -220,860.60 3,883,420,302.89

3. Increases and decreases in this period

Amount (reduced with "-" - - 9,678,312.24 - -644,840.25 - - - 15,210,193.61 - 24,243,665.60 92,762.10 24,336,427.70)

(1) Total comprehensive income

-644,840.25 132,012,694.61 131,367,854.36 86,602.23 131,454,456.59

(2) Owner’s investment

9,678,312.24 9,678,312.24 6,159.87 9,684,472.11 and reduction in capital

1． invested by the owner

-Common shares

2. Other equity instruments

-The holder invests capital

3． Share-based payment included

Owner’s equity 9,678,312.24 9,678,312.24 9,678,312.24

4. Others 6,159.87 6,159.87

(3) Profit distribution -116,802,501.00 -116,802,501.00 -116,802,501.00 1. Withdrawal from surplus reserve

2. Extract general risk

Prepare

66/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

3． to the owner (or

-116,802,501.00 -116,802,501.00 -116,802,501.00 Distribution from shareholders)

4. Others

(4) Owner’s equity

internal carry forward

1． Capital reserve transfer to increase

capital (or equity)

2. Transfer of surplus reserve to increase

capital (or equity)

3． Make up surplus reserve

Loss

4. defined benefit plan

Changes carried forward and retained

income

5. other comprehensive income

Carry forward retained earnings

6. Others

(5) Special reserves

1． Extract this period

2. Used in this issue

(6) Others

4. Ending balance of the current period 79,280,855.00 1,717,340,097.72 113,011,953.53 31,854,520.62 266,191,150.02 1,926,230,159.26 3,907,884,829.09 -128,098.50 3,907,756,730.59

Person in charge of the company: Gao Fei Person in charge of accounting work: Fu Yanping Person in charge of the accounting department: Fu Yanping

Statement of changes in owner's equity of the parent company

January to June 2026 Unit: Yuan Currency: RMB Other equity instruments for the first half of 2026

Item Paid-in capital (or shares Other comprehensive special items Owner’s equity and priority Perpetual capital reserve less: treasury shares Surplus reserve Undistributed profits) Total income reserves

stocks debt him

1. Closing balance of the previous year 79,280,855.00 1,681,044,560.88 47,406,740.77 266,191,150.02 1,697,062,114.28 3,676,171,939.41 Add: changes in accounting policies

Early error correction

Others

67/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

2. Balance at the beginning of the year 79,280,855.00 1,681,044,560.88 47,406,740.77 266,191,150.02 1,697,062,114.28 3,676,171,939.41

3. Amount of increase or decrease in the current period (minus

• • • • 4,835,908.36 165,014,517.69 - - - -24,354,564.36 -184,533,173.69 (please fill in with "-")

(1) Total comprehensive income 52,661,849.64 52,661,849.64

(2) Owner’s investment and capital reduction

5,000,192.58 165,014,517.69 -160,014,325.11

1． Ordinary shares invested by owners 165,014,517.69 -165,014,517.69 2. Investments from other equity instrument holders

-Capital

3． Share-based payments are included in owners’ equity

5,000,192.58 Amount of 5,000,192.58

4. Others -

(3) Profit distribution -77,016,414.00 -77,016,414.00 1. Withdrawal from surplus reserve - 2. Distribution to owners (or shareholders)

-77,016,414.00 -77,016,414.00 matching

3． Others -

(4) Internal carryover of owners’ equity -164,284.22 -164,284.22 1. Conversion of capital reserves into capital (or shares)

-Ben)

2. Conversion of surplus reserves into capital (or shares)

-Ben)

3． Surplus reserve to cover losses - 4. Carrying forward changes in defined benefit plans

-Retained earnings

5. Other comprehensive income carried forward and retained

-Benefit

6. Others -164,284.22 -164,284.22

(5) Special reserves - 1. Extraction of this issue - 2. Used in this issue -

(6) Others -

4. Ending balance of the current period 79,280,855.00 - - - 1,685,880,469.24 212,421,258.46 - - 266,191,150.02 1,672,707,549.92 3,491,638,765.72

68/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

2025 half year

Other equity instruments

Items Paid-in capital (or shares Other comprehensive special reserves Owners’ equity and priority Perpetual capital reserves less: treasury shares Surplus reserves Undistributed profits) Income provision

stocks debt him

1. Closing balance of the previous year 79,280,855.00 1,708,135,235.68 113,011,953.53 266,191,150.02 1,625,234,172.10 3,565,829,459.27 Add: changes in accounting policies

Early error correction

Others

2. Opening balance of the year 79,280,855.00 1,708,135,235.68 113,011,953.53 266,191,150.02 1,625,234,172.10 3,565,829,459.27

3. Amount of increase or decrease in the current period (decrease by

9,678,312.24 26,536,183.44 36,214,495.68 (Fill in “-”)

(1) Total comprehensive income 143,338,684.44 143,338,684.44

(2) Owner’s investment and capital reduction 9,678,312.24 9,678,312.24 1. Common stock invested by owners

2. Capital invested by other equity instrument holders

3． Share-based payment included in owner’s equity

9,678,312.24 9,678,312.24 amount

4. Others

(3) Profit distribution -116,802,501.00 -116,802,501.00 1. Withdrawal from surplus reserve

2. Distribution to owners (or shareholders) -116,802,501.00 -116,802,501.00 3. Others

(4) Internal carryover of owners’ equity

1． Conversion of capital reserves to capital (or share capital)

2. Conversion of surplus reserves into capital (or share capital)

3． Surplus reserve to cover losses

4. Changes in defined benefit plans are carried forward and retained

income

5. Other comprehensive income carried forward to retained earnings

6. Others

(5) Special reserves

1． Extract this period

2. Used in this issue

(6) Others

69/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

4. Ending balance of the current period 79,280,855.00 1,717,813,547.92 113,011,953.53 266,191,150.02 1,651,770,355.54 3,602,043,954.95 Person in charge of the company: Gao Fei Person in charge of accounting work: Fu Yanping Person in charge of accounting department: Fu Yanping

70/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

3. Basic situation of the company

1. Company profile

√Applicable □Not applicable

Hangzhou Aotai Biotechnology Co., Ltd. (hereinafter referred to as the "Company" or the "Company") is a joint-stock company established on the basis of the original Hangzhou Aotai Biotechnology Co., Ltd.. The registered capital at the time of establishment was 38.99 million yuan, and the total share capital was 38.99 million shares (RMB 1 per share). The company was approved and registered by the Hangzhou Administration for Industry and Commerce on April 17, 2009, and now has a unified social credit code: 91330101685842840Y. The company's headquarters is located in Building 3, Building 4, Building 5, No. 550, Yinhai Street, Baiyang Street, Hangzhou Economic and Technological Development Zone, Jianggan District, Hangzhou City, Zhejiang Province.

According to the resolution of the company's first extraordinary shareholders' meeting in 2020 and approved by the China Securities Regulatory Commission's Securities Regulatory Commission (2021) No. 495, the company issued 13,500,000 RMB ordinary shares (A shares) to the public for the first time. The company actually issued 13,500,000 shares with a par value of RMB 1 per share and an issue price of RMB 133.67 per share. As approved by the Shanghai Stock Exchange’s “Self-regulatory Supervision Decision ([2021] No. 122)”, the company’s shares were listed and traded on the Shanghai Stock Exchange’s Science and Technology Innovation Board. The securities abbreviation is “Aotai Bio” and the stock code is “688606”. It was listed on the Shanghai Stock Exchange on March 25, 2021. After the issuance, the company's registered capital increased to RMB 53,904,145.00.

According to the provisions of the revised Articles of Association in 2023, the company applied for additional registered capital of RMB 25,376,710.00. The company used the total share capital of 53,904,145 shares as the base, deducted the number of shares in the special securities account for repurchase of 1,036,000 shares, and transferred the capital reserve to all shareholders at the rate of 4.8 shares for every 10 shares, totaling 25,376,710.00 shares. shares, with a face value of 1 yuan per share, a total increase in share capital of 25,376,710.00 yuan. After this transfer, the company's registered capital changed to RMB 79,280,855.00.

The main business activities of the company and its subsidiaries are the research and development, production and sales of in vitro diagnostic reagents. The main products are rapid diagnostic reagents; the production and sales of non-medical biological raw materials.

The actual controllers of the company are Gao Fei and Zhao Huafang.

These financial statements and notes to the financial statements have been approved for issuance at the 21st meeting of the third session of the Board of Directors of the Company on August 28, 2026.

4. Basis for preparation of financial statements

1. Basics of preparation

The company's financial statements are prepared on a going concern basis.

2. Continuous operation

√Applicable □Not applicable

This report has the ability to continue operating within 12 months from the end of the reporting period, and there are no major events that affect the ability to continue operating.

5. Important accounting policies and accounting estimates

Specific accounting policies and accounting estimation tips:

□Applicable √Not applicable

1. Statement on compliance with corporate accounting standards

The financial statements prepared by the company comply with the requirements of the Accounting Standards for Business Enterprises and truly and completely reflect the company's financial status, operating results, changes in shareholders' equity, cash flow and other relevant information.

2. Accounting period

The company's fiscal year begins on January 1 and ends on December 31 of the Gregorian calendar.

71/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

3. Business cycle

√Applicable □Not applicable

The company's operating cycle is 12 months.

4. Accounting standard currency

The Company and its domestic subsidiaries use RMB as their functional currency for accounting. The company's overseas subsidiaries determine US dollars and pounds as their accounting functional currencies based on the currency of the main economic environment in which they operate. The currency used by the Company in preparing these financial statements is RMB.

5. Determination method and selection basis of materiality criteria

√Applicable □Not applicable

Project Materiality Criteria

Important individual provision for bad debt provisions The amount of individual provision accounts for more than 5% of the total amount of various types of receivables and the amount is greater than 200 million yuan of receivables

The write-off of receivables whose individual write-off amount accounts for more than 5% of the total bad debt provisions of various types of receivables and whose amount is important in the current period

More than 2 million yuan

Important projects under construction: the project amount accounts for more than 5% of total assets and the amount is greater than 100 million yuan

The net assets of a subsidiary account for more than 5% of the group's net assets, or a non-wholly owned subsidiary where a single subsidiary's minority shareholders are important

The equity accounts for more than 1% of the group's net assets and the amount is greater than 20 million yuan

A single investment activity represents an important investment activity item that accounts for the receipt or payment of cash inflows or outflows related to investment activities.

More than 50% of the total amount and the amount is greater than 100 million yuan

6. Accounting treatment methods for business combinations under the same control and those not under the same control

√Applicable □Not applicable

(1) Business merger under common control

For business mergers under common control, the assets and liabilities of the merged party acquired by the merging party during the merger shall be measured based on the book value of the merged party in the consolidated financial statements of the ultimate controlling party on the merger date. The difference between the book value of the merger consideration and the book value of the net assets obtained in the merger is adjusted to the capital reserve. If the capital reserve is insufficient for offset, the retained earnings are adjusted.

The merger of enterprises under the same control is realized step by step through multiple transactions.

The assets and liabilities of the merged party acquired by the merging party during the merger are measured based on their book values in the consolidated financial statements of the ultimate controlling party on the merger date; the difference between the book value of the investments held before the merger plus the book value of the new consideration paid on the merger date and the book value of the net assets acquired during the merger is adjusted to the capital reserve. If the capital reserve is insufficient for offset, the retained earnings are adjusted. For long-term equity investments held by the merging party before acquiring control of the merged party, relevant profits and losses, other comprehensive income and other changes in owner's equity have been recognized between the date of acquisition of the original equity and the date when the merging party and the merged party are under the final control of the same party, whichever is later, to the date of merger, and shall be offset against the opening retained earnings or current profits and losses of the comparative statement period respectively.

(2) Business combination not under common control

For business combinations not under common control, the combination cost is the fair value of the assets paid, liabilities incurred or assumed, and equity securities issued to obtain control of the purchased party on the acquisition date. On the purchase date, the acquired assets, liabilities and contingent liabilities of the purchased party are recognized at fair value.

The difference between the merger cost and the fair value share of the acquiree's identifiable net assets obtained in the merger is recognized as goodwill, and subsequent measurement is carried out at cost less accumulated impairment reserves; the difference between the merger cost and the fair value share of the acquiree's identifiable net assets obtained in the merger is included in the current profit and loss after review.

72/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The merger of enterprises not under common control is realized step by step through multiple transactions.

The merger cost is the sum of the consideration paid on the purchase date and the fair value of the purchased party's equity held before the purchase date on the purchase date. The equity of the purchased party that has been held before the purchase date will be remeasured according to the fair value of the equity on the purchase date, and the difference between the fair value and its book value will be included in the investment income of the current period; the equity of the purchased party that has been held before the purchase date involves other comprehensive income, other owners Changes in equity are converted into current income on the date of purchase, except for other comprehensive income arising from the investee's remeasurement of changes in net liabilities or net assets of the defined benefit plan and other comprehensive income related to investments in non-trading equity instruments originally designated as measured at fair value and whose changes are included in other comprehensive income.

(3) Treatment of transaction costs in business mergers

Intermediary fees such as auditing, legal services, evaluation and consulting, and other related management fees incurred for business mergers are included in the current profit and loss when incurred. The transaction costs of equity securities or debt securities issued as consideration for the merger shall be included in the initial recognition amount of the equity securities or debt securities.

7. Judgment standards for control and preparation methods of consolidated financial statements

√Applicable □Not applicable

(1) Judgment criteria for control

The scope of consolidation in consolidated financial statements is determined based on control. Control means that the company has power over the invested unit, enjoys variable returns by participating in the relevant activities of the invested unit, and has the ability to use its power over the invested unit to affect its return amount. The Company will reassess when changes in relevant facts and circumstances result in changes in the relevant elements involved in the definition of control.

When judging whether to include a structured entity into the scope of consolidation, the company evaluates whether it controls the structured entity based on comprehensively considering all facts and circumstances, including assessing the purpose and design of the structured entity, identifying the type of variable returns, and whether it assumes part or all of the return variability by participating in its related activities.

(2) Preparation method of consolidated financial statements

The consolidated financial statements are based on the financial statements of the Company and its subsidiaries, and are prepared by the Company based on other relevant information. When preparing consolidated financial statements, the accounting policies and accounting period requirements of the Company and its subsidiaries are consistent, and significant inter-company transactions and balances are eliminated.

Subsidiaries and businesses that are added due to business combinations under the same control during the reporting period are deemed to be included in the company's consolidation scope from the date they are both controlled by the ultimate controlling party, and their operating results and cash flows from the date they are both controlled by the ultimate controlling party are included in the consolidated income statement and consolidated cash flow statement respectively.

For subsidiaries and businesses added during the reporting period due to business combinations not under common control, the income, expenses and profits of the subsidiaries and businesses from the date of acquisition to the end of the reporting period are included in the consolidated income statement, and their cash flows are included in the consolidated cash flow statement.

The part of the subsidiary's shareholders' equity that is not owned by the company is listed separately as minority shareholders' equity under the shareholders' equity in the consolidated balance sheet; the share of the subsidiary's current net profit and loss that is minority shareholders' equity is listed as "minority shareholders' profits and losses" under the net profit item in the consolidated income statement. If the losses of a subsidiary shared by minority shareholders exceed the minority shareholders' share of the opening owner's equity of the subsidiary, the balance will still offset the minority shareholders' equity.

(3) Purchase minority shareholders’ equity in subsidiaries

The difference between the cost of the newly acquired long-term equity investment due to the purchase of minority shares and the share of the subsidiary's net assets calculated based on the new shareholding ratio calculated continuously from the date of purchase or merger, as well as the disposal price obtained from the partial disposal of the equity investment in the subsidiary without losing control and corresponding to the disposal of the long-term equity investment, the share of the subsidiary's net assets from the date of purchase or merger.

73/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The difference between the continuously calculated net asset shares will be adjusted to the capital reserve in the consolidated balance sheet. If the capital reserve is insufficient for offset, the retained earnings will be adjusted.

(4) Treatment of loss of control of subsidiaries

If control of the original subsidiary is lost due to the disposal of part of the equity investment or other reasons, the remaining equity shall be remeasured according to its fair value on the date of loss of control; the sum of the consideration obtained for the disposal of the equity and the fair value of the remaining equity, minus the sum of the share of the book value of the original subsidiary's net assets calculated continuously from the date of purchase and the goodwill calculated based on the original shareholding ratio, shall be included in the investment income in the current period when control is lost.

Other comprehensive income related to the equity investment of the original subsidiary will be accounted for on the same basis as the original subsidiary's direct disposal of relevant assets or liabilities when control is lost. Other changes in owner's equity related to the original subsidiary that are accounted for under the equity method will be transferred to the current profit and loss when control is lost.

8. Classification of joint arrangements and accounting treatment of joint operations

□Applicable √Not applicable

9. Determination standards for cash and cash equivalents

Cash equivalents refer to investments held by an enterprise that have a short term (generally due within three months from the date of purchase), are highly liquid, are easily convertible into known amounts of cash, and have little risk of value changes.

10. Foreign currency business and foreign currency statement conversion

√Applicable □Not applicable

(1) Foreign currency business

When the Company conducts foreign currency business, it shall use an exchange rate determined in accordance with a systematic and reasonable method that is similar to the spot exchange rate on the date of the transaction to convert it into the amount in the recording currency.

On the balance sheet date, foreign currency monetary items are converted using the spot exchange rate on the balance sheet date. The exchange difference arising from the difference between the spot exchange rate on the balance sheet date and the spot exchange rate at the time of initial recognition or the previous balance sheet date is included in the current profit and loss; foreign currency non-monetary items measured at historical cost are still converted using the spot exchange rate on the date of the transaction; For foreign currency non-monetary items measured at fair value, they are converted using the spot exchange rate on the date when the fair value is determined. The difference between the converted accounting functional currency amount and the original accounting functional currency amount is included in the current profit and loss or other comprehensive income according to the nature of the non-monetary item.

(2) Conversion of foreign currency financial statements

On the balance sheet date, when translating the foreign currency financial statements of overseas subsidiaries, the asset and liability items in the balance sheet are translated using the spot exchange rate on the balance sheet date. Except for "undistributed profits", shareholders' equity items are translated using the spot exchange rate on the date of occurrence.

Income and expense items in the income statement are translated using an exchange rate determined in a systematic and reasonable manner that is similar to the spot exchange rate on the date of the transaction.

All items in the cash flow statement are translated at an exchange rate determined in a systematic and reasonable manner that is close to the spot exchange rate on the date when the cash flow occurs. The impact of exchange rate changes on cash is regarded as an adjustment item and is reflected in the "Impact of exchange rate changes on cash and cash equivalents" separately in the cash flow statement.

Differences arising from the translation of financial statements are reflected in the "other comprehensive income" item under the shareholders' equity item in the balance sheet.

When an overseas operation is disposed of and control is lost, the translation difference of foreign currency statements listed under the shareholders' equity item in the balance sheet and related to the overseas operation shall be transferred to the current profit and loss of the disposal in full or in proportion to the disposal of the overseas operation.

74/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

11. Financial instruments

√Applicable □Not applicable

A financial instrument is a contract that forms a financial asset of one party and a financial liability or equity instrument of another party.

(1) Recognition and derecognition of financial instruments

The Company recognizes a financial asset or financial liability when it becomes a party to a financial instrument contract.

Financial assets shall be derecognized if they meet one of the following conditions:

①The contractual right to receive cash flows from the financial asset terminates;

②The financial asset has been transferred and meets the following conditions for derecognition of financial asset transfer.

If the current obligation of a financial liability has been discharged in whole or in part, the financial liability or part of it shall be derecognised. If the company (debtor) and its creditor sign an agreement to replace existing financial liabilities by assuming new financial liabilities, and the contract terms of the new financial liabilities are substantially different from the existing financial liabilities, the existing financial liabilities will be derecognised and the new financial liabilities will be recognized at the same time.

When financial assets are bought and sold in a regular manner, accounting recognition and derecognition will be carried out based on the transaction date.

(2) Classification and measurement of financial assets

Upon initial recognition, the Company divides financial assets into the following three categories based on the business model for managing financial assets and the contractual cash flow characteristics of financial assets: financial assets measured at amortized cost, financial assets measured at fair value with changes included in other comprehensive income, and financial assets measured at fair value with changes included in current profits and losses.

Financial assets are measured at fair value upon initial recognition. For financial assets measured at fair value and whose changes are included in the current profit and loss, the relevant transaction costs are directly included in the current profit and loss; for other types of financial assets, the relevant transaction costs are included in the initial recognition amount. For receivables arising from the sale of products or provision of services that do not include or take into account significant financing components, the amount of consideration that the company is expected to be entitled to receive shall be regarded as the initial recognition amount.

Financial assets measured at amortized cost

The Company will classify financial assets that meet the following conditions and are not designated as measured at fair value through profit or loss for the current period as financial assets measured at amortized cost:

The company's business model for managing this financial asset is aimed at collecting contractual cash flows;

The contractual terms of the financial asset provide that the cash flows generated on a specific date are solely payments of principal and interest based on the outstanding principal amount.

After initial recognition, such financial assets are measured at amortized cost using the effective interest rate method. Gains or losses arising from financial assets that are measured at amortized cost and are not part of any hedging relationship are included in the current profit and loss when they are derecognized, amortized according to the effective interest method, or impairment is recognized.

Financial assets measured at fair value through other comprehensive income

The Company will classify financial assets that meet the following conditions and are not designated as measured at fair value through profit or loss for the current period as financial assets measured at fair value through other comprehensive income:

The company's business model for managing this financial asset aims at both collecting contractual cash flows and selling the financial asset; the contractual terms of this financial asset stipulate that the cash flow generated on a specific date is only the payment of principal and interest based on the outstanding principal amount.

75/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

After initial recognition, such financial assets are subsequently measured at fair value. Interest, impairment losses or gains and exchange gains and losses calculated using the effective interest rate method are included in the current profit and loss, and other gains or losses are included in other comprehensive income. When derecognition is terminated, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in the current profit and loss.

Financial assets measured at fair value with changes included in current profits and losses

Except for the above-mentioned financial assets measured at amortized cost and at fair value with changes included in other comprehensive income, the Company classifies all remaining financial assets as financial assets measured at fair value with changes included in current profits and losses. At the time of initial recognition, in order to eliminate or significantly reduce accounting mismatches, the Company irrevocably designates some financial assets that should have been measured at amortized cost or at fair value through other comprehensive income as financial assets at fair value through profit or loss for the current period.

After initial recognition, such financial assets are subsequently measured at fair value, and the resulting gains or losses (including interest and dividend income) are included in the current profits and losses, unless the financial assets are part of a hedging relationship.

However, for investments in non-trading equity instruments, the Company irrevocably designates them as financial assets at fair value through other comprehensive income upon initial recognition. This designation is made on an individual investment basis and the underlying investment meets the definition of an equity instrument from the issuer's perspective.

After initial recognition, such financial assets are subsequently measured at fair value. Dividend income that meets the conditions is included in profit or loss, and other gains or losses and changes in fair value are included in other comprehensive income. Upon derecognition, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in retained earnings.

The business model for managing financial assets refers to how the company manages financial assets to generate cash flow. The business model determines whether the source of cash flow from the financial assets managed by the company is collection of contractual cash flow, sale of financial assets or both. The Company determines the business model for managing financial assets based on objective facts and specific business objectives for managing financial assets determined by key management personnel.

The Company evaluates the contractual cash flow characteristics of financial assets to determine whether the contractual cash flows generated by the relevant financial assets on a specific date are only payments of principal and interest based on the outstanding principal amount. Among them, principal refers to the fair value of the financial asset at the time of initial recognition; interest includes consideration for the time value of money, the credit risk associated with the outstanding principal amount in a specific period, and other basic lending risks, costs and profits. In addition, the Company evaluates contract terms that may cause changes in the time distribution or amount of contractual cash flows of financial assets to determine whether they meet the requirements of the above contractual cash flow characteristics.

Only when the company changes its business model for managing financial assets, all affected related financial assets will be reclassified on the first day of the first reporting period after the change in business model. Otherwise, financial assets shall not be reclassified after initial recognition.

(3) Classification and measurement of financial liabilities

The Company's financial liabilities are classified upon initial recognition into: financial liabilities measured at fair value with changes included in current profits and losses, and financial liabilities measured at amortized cost. For financial liabilities that are not classified as measured at fair value and whose changes are included in current profits and losses, relevant transaction costs are included in their initial recognition amount.

Financial liabilities measured at fair value through profit or loss for the current period

Financial liabilities at fair value through profit or loss include trading financial liabilities and financial liabilities designated as fair value through profit or loss upon initial recognition. For such financial liabilities, subsequent measurement is carried out at fair value, and gains or losses arising from changes in fair value, as well as dividends and interest expenses related to such financial liabilities, are included in the current profits and losses.

Financial liabilities measured at amortized cost

Other financial liabilities adopt the actual interest rate method and are subsequently measured at amortized cost. Gains or losses arising from derecognition or amortization are included in the current profits and losses.

76/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The difference between financial liabilities and equity instruments

Financial liabilities refer to liabilities that meet one of the following conditions:

①Contractual obligation to deliver cash or other financial assets to other parties.

② Contractual obligations to exchange financial assets or financial liabilities with other parties under potentially adverse conditions.

③ Non-derivative contracts that must or can be settled with the enterprise's own equity instruments in the future, and the enterprise will deliver a variable number of its own equity instruments according to the contract.

④ Derivative contracts that must or can be settled with the enterprise's own equity instruments in the future, except for derivative contracts that exchange a fixed number of its own equity instruments for a fixed amount of cash or other financial assets.

Equity instruments refer to contracts that prove ownership of the remaining equity in the assets of an enterprise after deducting all liabilities.

If the Company cannot unconditionally avoid delivering cash or other financial assets to fulfill a contractual obligation, the contractual obligation meets the definition of a financial liability.

If a financial instrument must or can be settled with the company's own equity instruments, it is necessary to consider whether the company's own equity instruments used to settle the instrument are used as a substitute for cash or other financial assets, or to enable the holder of the instrument to enjoy the remaining interest in the issuer's assets after deducting all liabilities. If it is the former, the instrument is the company's financial liability; if it is the latter, the instrument is the company's equity instrument.

(4) Derivative financial instruments and embedded derivatives

The Company's derivative financial instruments include bank financial products, foreign exchange option contracts, etc. The derivative transaction contract is initially measured at its fair value on the date when the contract is signed, and subsequently measured at its fair value. Derivative financial instruments with a positive fair value are recognized as an asset, and derivative financial instruments with a negative fair value are recognized as a liability. Any gains or losses arising from changes in fair value that do not comply with the hedging accounting regulations are directly included in the current profits and losses.

For hybrid instruments containing embedded derivatives, such as if the main contract is a financial asset, the relevant provisions on the classification of financial assets shall apply to the hybrid instrument as a whole. If the main contract is not a financial asset, and the hybrid instrument is not measured at fair value and its changes are included in the current profit and loss for accounting treatment, and the embedded derivative is not closely related to the main contract in terms of economic characteristics and risks, and the conditions are the same as the embedded derivative, and the stand-alone instrument meets the definition of a derivative, the embedded derivative is separated from the hybrid instrument and treated as a separate derivative financial instrument. If the embedded derivative cannot be measured separately at the time of acquisition or subsequent balance sheet dates, the hybrid instrument as a whole is designated as a financial asset or financial liability at fair value through profit or loss for the current period.

(5) Fair value of financial instruments

Fair value refers to the price that can be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date.

The Company measures relevant assets or liabilities at fair value and assumes that an orderly transaction to sell assets or transfer liabilities is conducted in the main market for the relevant assets or liabilities; if there is no main market, the Company assumes that the transaction is conducted in the most favorable market for the relevant assets or liabilities. The main market (or the most advantageous market) is the trading market that the company can enter on the measurement date. The Company adopts the assumptions used by market participants to maximize their economic interests when pricing the asset or liability.

For financial assets or financial liabilities that have an active market, the Company determines their fair value using quotes in the active market. If there is no active market for a financial instrument, the Company uses valuation techniques to determine its fair value.

When measuring non-financial assets at fair value, the ability of market participants to use the asset for its best purpose to generate economic benefits is considered, or the ability to sell the asset to other market participants who can use it for its best purpose to generate economic benefits.

77/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The Company adopts valuation techniques that are applicable under the current circumstances and supported by sufficient available data and other information, giving priority to the use of relevant observable input values. Only when observable input values cannot be obtained or are impractical to obtain, unobservable input values will be used.

For assets and liabilities measured or disclosed at fair value in financial statements, the fair value level to which they belong is determined based on the lowest level input value that is significant to the overall fair value measurement: the first level input value is the unadjusted quoted price in the active market for the same asset or liability that can be obtained on the measurement date; the second level input value is the directly or indirectly observable input value of the relevant assets or liabilities in addition to the first level input value; the third level input value is the unobservable input value of the relevant asset or liability.

At each balance sheet date, the Company reassesses the assets and liabilities recognized in the financial statements that continue to be measured at fair value to determine whether there is a transition between fair value measurement levels.

(6) Impairment of financial assets

Based on expected credit losses, the company performs impairment accounting on the following items and recognizes loss provisions:

Financial assets measured at amortized cost;

Receivables and investments in debt instruments measured at fair value through other comprehensive income;

Contract assets as defined in "Accounting Standards for Business Enterprises No. 14 - Revenue";

lease receivables;

Financial guarantee contracts (except those that are measured at fair value and whose changes are included in current profits and losses, the transfer of financial assets does not meet the conditions for derecognition, or the financial assets continue to be involved in the transferred financial assets).

Measurement of expected credit losses

Expected credit losses refer to the weighted average of the credit losses of financial instruments with the risk of default as the weight. Credit loss refers to the difference between all contractual cash flows receivable under the contract and all cash flows expected to be received by the company, discounted at the original actual interest rate, that is, the present value of all cash shortfalls.

The company considers reasonable and well-founded information about past events, current conditions and predictions of future economic conditions, weights the risk of default, calculates the probability-weighted amount of the present value of the difference between the cash flow receivable in the contract and the cash flow expected to be received, and recognizes expected credit losses.

The Company measures the expected credit losses of financial instruments at different stages respectively. If the credit risk of a financial instrument has not increased significantly since initial recognition, it is in the first stage, and the Company will measure loss provisions based on the expected credit losses within the next 12 months; if the credit risk of a financial instrument has increased significantly since initial recognition but no credit impairment has occurred, it is in the second stage, and the Company will measure loss provisions based on the expected credit losses throughout the entire duration of the instrument; if a financial instrument has experienced credit impairment since initial recognition, it is in the third stage, and the Company will measure loss provisions based on the expected credit losses throughout the entire duration of the instrument.

For financial instruments with low credit risk on the balance sheet date, the company assumes that its credit risk has not increased significantly since initial recognition, and measures loss provisions based on expected credit losses within the next 12 months.

Lifetime expected credit losses refer to the expected credit losses caused by all possible default events that may occur during the entire expected life of a financial instrument. Expected credit losses within the next 12 months refer to the expected credit losses caused by default events on financial instruments that may occur within 12 months after the balance sheet date (if the expected duration of the financial instrument is less than 12 months, the expected duration), and are part of the expected credit losses throughout the duration.

When measuring expected credit losses, the maximum period that the company needs to consider is the longest contract period for which the enterprise faces credit risk (including consideration of renewal options).

78/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

For financial instruments in the first and second stages and with lower credit risk, the company calculates interest income based on its book balance before impairment provisions and actual interest rate. For financial instruments in the third stage, interest income is calculated based on its book balance minus the amortized cost and actual interest rate after impairment provisions have been made.

For receivables such as accounts receivable and other receivables, if the credit risk characteristics of a certain customer are significantly different from those of other customers in the portfolio, or the credit risk characteristics of the customer change significantly, the company will make a separate provision for bad debts for the receivables. In addition to the receivables for which bad debt provisions are made individually, the Company divides the receivables into combinations based on credit risk characteristics and calculates bad debt provisions on a combination basis.

Notes receivable and accounts receivable

For notes receivable and accounts receivable, regardless of whether there is a significant financing component, the Company always measures its loss provisions at an amount equivalent to the expected credit losses during the entire duration.

When a single financial asset cannot assess expected credit losses at a reasonable cost, the company divides notes receivable and accounts receivable into combinations based on credit risk characteristics, and calculates expected credit losses on the basis of the combination. The basis for determining the combination is as follows:

A. Notes receivable

Notes Receivable Portfolio 1: Bank Acceptance Bill

Notes Receivable Portfolio 2: Commercial Acceptance Bill

B. Accounts receivable

Accounts receivable portfolio 1: foreign customers

Accounts Receivable Portfolio 2: Domestic Customers

Accounts receivable portfolio 3: Related parties within the scope of consolidation

For notes receivable divided into portfolios, the Company refers to historical credit loss experience, combines current conditions and predictions of future economic conditions, and calculates expected credit losses through default risk exposure and the expected credit loss rate throughout the duration.

For accounts receivable divided into portfolios, the Company refers to historical credit loss experience, combined with current conditions and predictions of future economic conditions, prepares a comparison table between the aging of accounts receivable and the expected credit loss rate for the entire duration, and calculates expected credit losses. The aging of accounts receivable is calculated from the date of confirmation.

Other receivables

The company divides other receivables into several combinations based on credit risk characteristics, and calculates expected credit losses on the basis of the combinations. The basis for determining the combinations is as follows:

Other receivables portfolio 1: Related parties within the scope of consolidation

Other receivables portfolio 2: other receivables

For other receivables classified into portfolios, the Company calculates expected credit losses through default risk exposure and expected credit loss rate within the next 12 months or throughout the duration. For other receivables grouped by aging, the aging is calculated from the date of confirmation. Debt investment, other debt investment

For debt investments and other debt investments, the Company calculates expected credit losses based on the nature of the investment, various types of counterparties and risk exposures, and through the default risk exposure and the expected credit loss rate within the next 12 months or throughout the duration. Assessment of significant increase in credit risk

79/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The Company compares the risk of default of a financial instrument on the balance sheet date with the risk of default on the initial recognition date to determine the relative change in the default risk of the financial instrument during its expected duration to assess whether the credit risk of the financial instrument has increased significantly since initial recognition.

When determining whether credit risk has increased significantly since initial recognition, the Company considers reasonable and supportable information, including forward-looking information, that is available without unnecessary additional cost or effort. Information considered by the Company includes:

The debtor fails to pay the principal and interest on the due date of the contract;

an actual or expected significant deterioration in the external or internal credit rating (if any) of the financial instrument;

The actual or expected serious deterioration in the debtor’s operating results;

Existing or expected changes in the technological, market, economic or legal environment will have a significant adverse impact on the debtor's ability to repay the company.

Depending on the nature of the financial instrument, the Company evaluates whether the credit risk has increased significantly on the basis of a single financial instrument or a combination of financial instruments. When evaluating based on a portfolio of financial instruments, the Company may classify financial instruments based on common credit risk characteristics, such as overdue information and credit risk ratings.

If the debtor's repayment ability deteriorates significantly, the Company determines that the credit risk of the financial instrument has increased significantly.

Credit-impaired financial assets

The Company assesses whether credit impairment has occurred on financial assets measured at amortized cost and debt investments measured at fair value through other comprehensive income on the balance sheet date. When one or more events that have an adverse impact on the expected future cash flows of a financial asset occur, the financial asset becomes a credit-impaired financial asset. Evidence that a financial asset has been credit-impaired includes the following observable information:

The issuer or debtor encounters significant financial difficulties;

The debtor breaches the contract, such as default or overdue payment of interest or principal;

The Company grants the debtor concessions that the debtor would not have made under any other circumstances due to economic or contractual considerations related to the debtor's financial difficulty;

the likelihood that the debtor will go bankrupt or undergo other financial reorganization;

Financial difficulties of the issuer or debtor result in the disappearance of an active market for the financial asset.

Presentation of expected credit loss provisions

In order to reflect changes in the credit risk of financial instruments since initial recognition, the company remeasures expected credit losses on each balance sheet date, and the resulting increase or reversal of loss provisions shall be included in the current profit and loss as impairment losses or gains. For financial assets measured at amortized cost, the loss provision is deducted from the book value of the financial asset listed in the balance sheet; for debt investments measured at fair value with changes included in other comprehensive income, the company recognizes its loss provision in other comprehensive income and does not deduct the book value of the financial asset.

Write off

If the company no longer reasonably expects that the contractual cash flows of a financial asset can be fully or partially recovered, it will directly write down the book balance of the financial asset. Such a write-down constitutes the derecognition of the relevant financial asset. This situation typically occurs when the Company determines that the debtor does not have the assets or sources of income to generate sufficient cash flow to repay the amount that will be written down. However, in accordance with the Company's procedures for recovering due amounts, financial assets that are written down may still be affected by execution activities.

If a financial asset that has been written down is later recovered, the reversal of the impairment loss will be included in the profit and loss of the current period of recovery.

(7) Transfer of financial assets

80/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The transfer of financial assets refers to the transfer or delivery of financial assets to another party (the transfer-in party) other than the issuer of the financial assets. If the Company has transferred substantially all risks and rewards of ownership of a financial asset to the transferee, the financial asset shall be derecognized; if the Company has retained substantially all risks and rewards of ownership of the financial asset, the financial asset shall not be derecognised.

If the company neither transfers nor retains substantially all the risks and rewards of ownership of a financial asset, the following situations will be dealt with: if it gives up control of the financial asset, it will terminate the recognition of the financial asset and recognize the resulting assets and liabilities; if it does not give up control of the financial asset, the relevant financial assets will be recognized according to the extent of its continued involvement in the transferred financial assets, and the relevant liabilities will be recognized accordingly.

(8) Offset of financial assets and financial liabilities

When the company has the legal right to offset the recognized financial assets and financial liabilities, and the legal right is currently enforceable, and the company plans to settle on a net basis or realize the financial assets and pay off the financial liabilities at the same time, the financial assets and financial liabilities will be listed in the balance sheet at the amount after offsetting each other. Otherwise, financial assets and financial liabilities are presented separately in the balance sheet and are not offset against each other.

12. Notes receivable

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on combinations of credit risk characteristics

√Applicable □Not applicable

For notes receivable, regardless of whether there is a significant financing component, the Company always measures its loss provisions at an amount equivalent to the expected credit losses during the entire duration.

When a single financial asset cannot assess expected credit losses at a reasonable cost, the company divides notes receivable and accounts receivable into combinations based on credit risk characteristics, and calculates expected credit losses on the basis of the combination. The basis for determining the combination is as follows:

Notes Receivable Portfolio 1: Bank Acceptance Bill

Notes Receivable Portfolio 2: Commercial Acceptance Bill

For notes receivable divided into portfolios, the Company refers to historical credit loss experience, combined with current conditions and predictions of future economic conditions, prepares a comparison table between the aging/overdue days of notes receivable and the expected credit loss rate for the entire duration, and calculates expected credit losses.

Account aging calculation method based on aging confirmation credit risk characteristics combination

□Applicable √Not applicable

Judgment criteria for individual provision of bad debt provisions based on individual provision

□Applicable √Not applicable

13. Accounts receivable

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on combinations of credit risk characteristics

√Applicable □Not applicable

For accounts receivable, regardless of whether there is a significant financing component, the Company always measures its loss provisions at an amount equivalent to the expected credit losses during the entire duration.

When a single financial asset cannot assess expected credit losses at a reasonable cost, the company divides notes receivable and accounts receivable into combinations based on credit risk characteristics, and calculates expected credit losses on the basis of the combination. The basis for determining the combination is as follows:

Accounts receivable portfolio 1: foreign customers

Accounts Receivable Portfolio 2: Domestic Customers

81/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Accounts receivable portfolio 3: Related parties within the scope of consolidation

For accounts receivable divided into portfolios, the Company refers to historical credit loss experience, combined with current conditions and predictions of future economic conditions, prepares a comparison table between the aging/overdue days of accounts receivable and the expected credit loss rate for the entire duration, and calculates expected credit losses.

Account aging calculation method based on aging confirmation credit risk characteristic combination □ Applicable √ Not applicable

Judgment criteria for single provision according to the determination of individual bad debt provision □ Applicable √ Not applicable

14. Receivables Financing

□Applicable √Not applicable

15. Other receivables

√Applicable □Not applicable

Combination categories and determination basis for bad debt provisions based on credit risk characteristics √ Applicable □ Not applicable

The company divides other receivables into several combinations based on credit risk characteristics, and calculates expected credit losses on the basis of the combinations. The basis for determining the combinations is as follows:

Other receivables portfolio 1: Related parties within the scope of consolidation

Other receivables portfolio 2: other receivables

For other receivables classified into portfolios, the Company calculates expected credit losses through default risk exposure and expected credit loss rate within the next 12 months or throughout the duration.

Account aging calculation method based on aging confirmation credit risk characteristic combination □ Applicable √ Not applicable

Judgment criteria for individual provision of bad debt provisions based on individual provision

□Applicable √Not applicable

16. Inventory

√Applicable □Not applicable

Inventory categories, issue pricing methods, inventory systems, amortization methods for low-value consumables and packaging √ Applicable □ Not applicable

(1) Classification of inventory

The company's inventory is divided into raw materials, semi-finished products, inventory goods, shipped goods, commissioned processing materials, low-value consumables, etc. (2) Valuation method for issued inventory

The Company's inventories are valued at actual cost when acquired. Raw materials, inventory, etc. are priced using the weighted average method when shipped. (3) Inventory inventory system

The company's inventory inventory system adopts the perpetual inventory system.

(4) Amortization method for low-value consumables and packaging materials

82/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The Company adopts the one-time write-off method for amortization of low-value consumables when they are used.

Recognition standards and accrual methods for inventory depreciation provisions

√Applicable □Not applicable

On the balance sheet date, inventories are measured at the lower of cost and net realizable value. When the net realizable value is lower than the cost, a provision for inventory depreciation is made.

Net realizable value is the estimated selling price of the inventory minus the estimated costs to be incurred upon completion, estimated selling expenses and related taxes. When determining the net realizable value of inventories, it is based on the conclusive evidence obtained and the purpose of holding the inventories and the impact of events after the balance sheet date are also considered.

The Company usually accrues inventory depreciation provisions based on individual inventory items. For inventories with large quantities and low unit prices, inventory depreciation provisions are made according to the inventory category.

On the balance sheet date, if the factors that previously caused the inventory value to be written down have disappeared, the inventory depreciation provision shall be reversed within the amount originally accrued.

The combination categories and basis for determining inventory depreciation reserves according to the combination, and the basis for determining the net realizable value of different types of inventories □ Applicable √ Not applicable

The calculation method and basis for determining the net realizable value of each warehouse age combination based on the inventory age confirmation

□Applicable √Not applicable

17. Contract assets

□Applicable √Not applicable

18. Non-current assets or disposal groups held for sale

□Applicable √Not applicable

Recognition standards and accounting treatment methods for non-current assets or disposal groups classified as held for sale

□Applicable √Not applicable

Determination standards and presentation methods for discontinued operations

□Applicable √Not applicable

19. Long-term equity investment

√Applicable □Not applicable

Long-term equity investments include equity investments in subsidiaries, joint ventures and associates. If the company can exert significant influence on the invested unit, it is an associate of the company.

(1) Determination of initial investment cost

Long-term equity investments resulting from business combinations: For long-term equity investments obtained from business combinations under common control, the share of the book value of the owner's equity of the merged party in the final controlling party's consolidated financial statements on the date of merger is regarded as the investment cost; for long-term equity investments obtained from business combinations not under common control, the investment cost of long-term equity investments is based on the merger cost.

For long-term equity investments obtained by other means: for long-term equity investments obtained by paying cash, the actual purchase price paid will be used as the initial investment cost; for long-term equity investments obtained by issuing equity securities, the fair value of the equity securities issued will be used as the initial investment cost.

(2) Subsequent measurement and profit and loss recognition methods

83/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Investments in subsidiaries are accounted for using the cost method, unless the investment qualifies as held for sale; investments in associates and joint ventures are accounted for using the equity method.

For long-term equity investments accounted for using the cost method, in addition to the actual price paid when acquiring the investment or the cash dividends or profits that have been declared but not yet distributed included in the consideration, the cash dividends or profits declared to be distributed by the investee shall be recognized as investment income and included in the current profit and loss.

For long-term equity investments accounted for using the equity method, if the initial investment cost is greater than the fair value share of the investee's identifiable net assets at the time of investment, the investment cost of the long-term equity investment will not be adjusted; if the initial investment cost is less than the fair value share of the investee's identifiable net assets at the time of investment, the book value of the long-term equity investment will be adjusted, and the difference will be included in the current profit and loss of the investment. When accounting using the equity method, investment income and other comprehensive income are recognized respectively according to the share of net profits and losses and other comprehensive income realized by the investee that should be enjoyed or shared, and the book value of long-term equity investments is adjusted at the same time; according to the profit or cash declared by the investee to be distributed The portion to be enjoyed in the calculation of dividends will be reduced accordingly and the book value of the long-term equity investment will be reduced accordingly; other changes in the owner's equity of the investee other than net profits and losses, other comprehensive income and profit distribution, the book value of the long-term equity investment will be adjusted and included in the capital reserve (other capital reserve). When confirming the share of the investee's net profits and losses, it is based on the fair value of the investee's identifiable assets when the investment is obtained, and in accordance with the company's accounting policies and accounting periods, the net profit of the investee is adjusted and recognized.

If the investee is able to exert significant influence or implement joint control due to additional investment or other reasons but does not constitute control, on the conversion date, the sum of the fair value of the original equity plus the new investment cost will be used as the initial investment cost to be accounted for under the equity method. If the original equity is classified as a non-trading equity instrument investment measured at fair value and its changes are included in other comprehensive income, the related cumulative fair value changes originally included in other comprehensive income will be transferred to retained earnings when it is accounted for under the equity method.

If the joint control or significant influence on the invested unit is lost due to the disposal of part of the equity investment or other reasons, the remaining equity after disposal will be accounted for in accordance with the "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" on the date of loss of joint control or significant influence, and the difference between the fair value and the book value shall be included in the current profit and loss. Other comprehensive income recognized due to the equity method accounting for the original equity investment will be accounted for on the same basis as the investee's direct disposal of relevant assets or liabilities when the equity method accounting is terminated; other changes in owner's equity related to the original equity investment will be transferred to the current profit and loss.

If control of the invested unit is lost due to the disposal of part of the equity investment or other reasons, and the remaining equity after disposal can jointly control or exert significant influence on the invested unit, it shall be accounted for according to the equity method, and the remaining equity shall be deemed to have been accounted for using the equity method since the time of acquisition and adjusted; after disposal If the remaining equity cannot jointly control or exert significant influence on the invested unit, accounting treatment shall be carried out in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments", and the difference between its fair value and book value on the date of loss of control shall be included in the current profit and loss.

If the company's shareholding ratio decreases due to capital increase by other investors and thus loses control but can exercise joint control or exert significant influence on the investee, the company's share of the investee's net assets increased due to the capital increase and share expansion shall be confirmed based on the new shareholding ratio, and the difference between the original book value of the long-term equity investment corresponding to the decrease in shareholding ratio that should be carried forward shall be included in the current profit and loss; then, according to the new shareholding ratio, it will be deemed to have been adjusted using the equity method since the investment was obtained.

Unrealized gains and losses from internal transactions between the Company and its associates and joint ventures are calculated based on the shareholding ratio and are attributable to the Company, and investment gains and losses are recognized on an offsetting basis. However, if the unrealized internal transaction losses between the company and the invested unit are impairment losses on the transferred assets, they will not be offset.

(3) Basis for determining joint control and significant influence on the invested unit

Joint control refers to the shared control over an arrangement in accordance with relevant agreements, and the relevant activities of the arrangement must be decided only with the unanimous consent of the parties sharing control rights. When judging whether there is joint control, first judge whether the arrangement is collectively controlled by all participants or a combination of participants, and secondly whether decisions on activities related to the arrangement must be unanimously agreed upon by the participants who collectively control the arrangement. An arrangement is considered to be collectively controlled by all parties or a group of parties if all parties or a group of parties must act in concert to determine the relevant activities of an arrangement; if there is a combination of two or more parties

84/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Being able to collectively control an arrangement does not constitute joint control. When determining whether joint control exists, the protective rights enjoyed are not taken into account.

Significant influence means that the investor has the power to participate in decision-making on the financial and operating policies of the invested unit, but it is not able to control or jointly control the formulation of these policies with other parties. When determining whether it can exert significant influence on the invested unit, the investor's direct or indirect holding of voting shares of the invested unit and the impact of the current executable potential voting rights held by the investor and other parties are assumed to be converted into equity in the invested unit, including the impact of current convertible warrants, stock options and convertible corporate bonds issued by the invested unit.

When the company directly or indirectly through subsidiaries owns more than 20% (including 20%) but less than 50% of the voting shares of the invested unit, it is generally considered to have a significant impact on the invested unit. Unless there is clear evidence that it cannot participate in the production and operation decisions of the invested unit under such circumstances, it will not have a significant impact; the company owns the invested unit When holding less than 20% (exclusive) of the voting shares, it is generally not considered to have a significant impact on the invested unit, unless there is clear evidence that under such circumstances, it can participate in the production and operation decisions of the invested unit and have a significant impact.

(4) Equity investments held for sale

For remaining equity investments that are not classified as assets held for sale, the equity method is used for accounting treatment.

If an equity investment in an associate or joint venture that has been classified as held for sale no longer meets the classification conditions for assets held for sale, it will be retrospectively adjusted using the equity method from the date it is classified as an asset held for sale.

(5) Impairment testing method and impairment provision accrual method

For investments in subsidiaries, associates and joint ventures, see "27. Impairment of long-term assets" for the method of calculating asset impairment.

20. Investment real estate

(1) If the cost measurement model is adopted

Depreciation or amortization method

Investment property is property held to earn rentals or for capital appreciation, or both. The company's investment real estate includes leased land use rights, land use rights held and prepared to be transferred after appreciation, and leased buildings.

The Company's investment real estate is initially measured based on the cost when acquired, and depreciation or amortization is provided periodically in accordance with the relevant regulations on fixed assets or intangible assets.

For investment real estate that adopts the cost model for subsequent measurement, please refer to "27. Impairment of long-term assets" for the method of accruing asset impairment. The difference between the disposal income from the sale, transfer, scrapping or damage of investment real estate after deducting its book value and relevant taxes is included in the current profit and loss.

21. Fixed assets

(1) Confirmation conditions

√Applicable □Not applicable

The company's fixed assets refer to tangible assets held for the production of goods, provision of labor services, leasing or operation and management, and with a service life of more than one accounting year.

A fixed asset can only be recognized when the economic benefits related to the fixed asset are likely to flow into the enterprise and the cost of the fixed asset can be measured reliably.

The company's fixed assets are initially measured based on the actual cost when acquired.

85/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Subsequent expenditures related to fixed assets are included in the cost of fixed assets when the economic benefits related to them are likely to flow into the company and their costs can be measured reliably. Daily repair costs of fixed assets that do not meet the conditions for subsequent expenditures for capitalization of fixed assets are included in the current profit and loss or included in the cost of related assets according to the beneficiary objects when incurred. For the replaced part, its book value is derecognized.

(2) Depreciation method

√Applicable □Not applicable

Category Depreciation method Depreciation period (years) Residual value rate Annual depreciation rate Houses and buildings Year-averaged method 40.00 5.00 2.38

Machinery and equipment Average age method 5.00 5.00 19.00

Transportation equipment average age method 3.00 5.00 31.67

Office equipment and other years average method 5.00 5.00 19.00

The Company uses the straight-line method to calculate depreciation. Depreciation begins when a fixed asset reaches its intended usable condition, and depreciation stops when it is derecognized or classified as a non-current asset held for sale. Without considering impairment provisions, by fixed asset category, estimated useful life and estimated residual value. Among them, for fixed assets for which impairment provisions have been made, the depreciation rate should also be calculated and determined by deducting the accumulated amount of fixed asset impairment provisions.

For the impairment test method of fixed assets and the method of accruing asset impairment, please refer to "27. Impairment of long-term assets".

At the end of each year, the Company reviews the useful life, estimated net residual value and depreciation method of fixed assets. If there is a difference between the estimated useful life and the original estimate, the useful life of the fixed assets will be adjusted; if there is a difference between the expected net residual value and the original estimate, the estimated net residual value will be adjusted.

When a fixed asset is disposed of or no economic benefits are expected to be generated through use or disposal, the fixed asset is derecognised. The amount of disposal income from the sale, transfer, scrapping or damage of fixed assets after deducting their book value and related taxes is included in the current profit and loss.

22. Projects under construction

√Applicable □Not applicable

The cost of the company's construction-in-progress is determined based on actual project expenditures, including various necessary project expenditures incurred during the construction period, borrowing costs that should be capitalized before the project reaches its intended usable state, and other related expenses.

Construction in progress is transferred to fixed assets when it reaches the intended usable state.

For the method of accruing asset impairment for projects under construction, see "27. Impairment of long-term assets".

23. Borrowing costs

□Applicable √Not applicable

24. Biological assets

□Applicable √Not applicable

25. Oil and gas assets

□Applicable √Not applicable

26. Intangible assets

(1) Useful life and its basis for determination, estimation, amortization method or review procedure

√Applicable □Not applicable

86/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The company's intangible assets include land use rights, etc.

Intangible assets are initially measured based on cost, and their service life is analyzed and judged when the intangible assets are acquired. If the service life is limited, from the time the intangible asset becomes available for use, an amortization method that can reflect the expected realization method of the economic benefits related to the asset will be used and amortized over the expected service life; if the expected realization method cannot be reliably determined, the straight-line method will be used for amortization; intangible assets with indefinite service life will not be amortized.

The amortization method of intangible assets with limited useful life is as follows:

Category Useful life Amortization method Remarks

Land use rights 43.75 years, 50 years Straight-line method -

At the end of each year, the company reviews the useful life and amortization method of intangible assets with limited service life. If it is different from the previous estimate, the original estimate is adjusted and treated as a change in accounting estimate.

If it is expected that an intangible asset will no longer bring future economic benefits to the enterprise on the balance sheet date, all the book value of the intangible asset will be transferred to the current profit and loss.

For the method of accruing asset impairment for intangible assets, see “27. Impairment of long-term assets”.

(2) Scope of aggregation of R&D expenditures and related accounting treatment methods

√Applicable □Not applicable

The company's R&D expenditures are expenditures directly related to the company's R&D activities, including employee compensation, equity incentive expenses, product testing expenses, depreciation and amortization expenses, material expenses and others. The wages of R&D personnel are included in R&D expenditures based on project working hours. Equipment, production lines, and sites shared between R&D activities and other production and operation activities are included in R&D expenses according to the proportion of working hours and the proportion of area.

The Company divides the expenditures on internal research and development projects into expenditures in the research phase and expenditures in the development phase.

Expenditures in the research stage are included in the current profits and losses when incurred.

Expenditures in the development stage can only be capitalized if they meet the following conditions: it is technically feasible to complete the intangible asset so that it can be used or sold; there is the intention to complete the intangible asset and use or sell it; the intangible asset generates economic benefits in a manner that can prove the use of the intangible asset to produce products There is a market or there is a market for the intangible asset itself, and if the intangible asset will be used internally, its usefulness can be proven; there is sufficient technical, financial and other resource support to complete the development of the intangible asset, and the ability to use or sell the intangible asset; the expenditures attributable to the development stage of the intangible asset can be measured reliably. Development expenditures that do not meet the above conditions are included in the current profit and loss.

The company's research and development projects will enter the development stage after meeting the above conditions and passing technical feasibility and economic feasibility studies to form a project.

Capitalized expenditures in the development phase are listed as development expenditures on the balance sheet and are converted into intangible assets from the date the project reaches its intended use.

27. Impairment of long-term assets

√Applicable □Not applicable

The asset impairment of long-term equity investments in subsidiaries, investment real estate, fixed assets, construction in progress, right-of-use assets, intangible assets, goodwill, etc. (except inventories, deferred income tax assets, and financial assets) that are subsequently measured using the cost model is determined according to the following method:

On the balance sheet date, it is judged whether there are any signs that the asset may be impaired. If there are signs of impairment, the company will estimate its recoverable amount and conduct an impairment test. Goodwill formed due to business mergers, intangible assets with indefinite useful lives and intangible assets that have not yet reached their intended use are subject to impairment testing every year regardless of whether there are signs of impairment.

87/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The recoverable amount is determined based on the higher of the asset's fair value less disposal costs and the present value of the asset's expected future cash flows. The Company estimates the recoverable amount on the basis of a single asset; if it is difficult to estimate the recoverable amount of an individual asset, the recoverable amount of the asset group to which the asset belongs is determined based on the asset group. The identification of an asset group is based on whether the main cash inflow generated by the asset group is independent of the cash inflows of other assets or asset groups.

When the recoverable amount of an asset or asset group is lower than its book value, the company will write down its book value to the recoverable amount, and the amount of the write-down will be included in the current profit and loss, and the corresponding asset impairment provision will be made.

As far as the impairment test of goodwill is concerned, the book value of goodwill formed due to a business combination shall be allocated to the relevant asset groups in a reasonable manner from the date of purchase; if it is difficult to allocate it to the relevant asset groups, it shall be allocated to the relevant asset group combinations. The relevant asset group or asset group combination is an asset group or asset group combination that can benefit from the synergy effects of the business combination, and is no larger than the reporting segment determined by the company.

During impairment testing, if there are signs of impairment in an asset group or combination of asset groups related to goodwill, first conduct an impairment test on the asset group or combination of asset groups that does not contain goodwill, calculate the recoverable amount, and recognize the corresponding impairment loss. Then conduct an impairment test on the asset group or asset group combination containing goodwill, and compare its book value with the recoverable amount. If the recoverable amount is lower than the book value, the impairment loss of goodwill is recognized.

Once the asset impairment loss is recognized, it will not be reversed in subsequent accounting periods.

28. Long-term deferred expenses

√Applicable □Not applicable

The long-term deferred expenses incurred by the company are measured at actual costs and amortized evenly over the expected benefit period. For long-term deferred expense items that cannot benefit future accounting periods, their amortized value shall be fully included in the current profit and loss.

29. Contract liabilities

√Applicable □Not applicable

The Company presents contract assets or contract liabilities on the balance sheet based on the relationship between performance services and customer payments. The Company's obligations received or receivable from customers to transfer goods or provide services to customers are listed as contract liabilities. Contract assets and contract liabilities under the same contract are presented on a net basis.

30. Employee compensation

(1) Accounting treatment of short-term compensation

√Applicable □Not applicable

During the accounting period when employees provide services, the company recognizes the actual employee wages, bonuses, social insurance premiums such as medical insurance premiums, work-related injury insurance premiums, maternity insurance premiums, and housing provident funds paid for employees according to prescribed standards and proportions as liabilities, and includes them in the current profit and loss or related asset costs.

(2) Accounting treatment of post-employment benefits

√Applicable □Not applicable

Post-employment benefit plans include defined contribution plans and defined benefit plans. Among them, a defined contribution plan refers to a post-employment benefit plan in which the enterprise no longer bears further payment obligations after paying a fixed fee to an independent fund; a defined benefit plan refers to a post-employment benefit plan other than a defined contribution plan.

Set up a savings plan

88/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Defined contribution plans include basic pension insurance, unemployment insurance, etc.

During the accounting period when employees provide services, the deposit amount payable calculated according to the defined contribution plan is recognized as a liability and included in the current profit and loss or related asset costs.

defined benefit plan

For defined benefit plans, an actuarial valuation is performed by an independent actuary on the annual balance sheet date to determine the cost of providing benefits using the expected accumulated benefit unit method. The employee compensation costs caused by the company's defined benefit plan include the following components:

① Service costs include current service costs, past service costs and settlement gains or losses. Among them, the current service cost refers to the increase in the present value of the defined benefit plan obligations caused by the services provided by employees in the current period; the past service cost refers to the increase or decrease in the present value of the defined benefit plan obligations related to employee services in previous periods caused by the modification of the defined benefit plan.

② The net interest on the net liabilities or net assets of the defined benefit plan includes the interest income on the plan assets, the interest expense on the obligations of the defined benefit plan, and the interest affected by the asset ceiling.

③ Changes caused by re-measurement of net liabilities or net assets of defined benefit plans.

Unless other accounting standards require or allow employee benefit costs to be included in asset costs, the company will include the above items ① and ② in the current profit and loss; item ③ will be included in other comprehensive income and will not be transferred back to profit and loss in subsequent accounting periods. When the original defined benefit plan is terminated, all parts originally included in other comprehensive income will be carried forward to undistributed profits within the scope of equity.

(3) Accounting treatment of dismissal benefits

√Applicable □Not applicable

If the company provides dismissal benefits to employees, the employee compensation liabilities arising from the dismissal benefits will be recognized and included in the current profit and loss at the earliest of the following two situations: when the company cannot unilaterally withdraw the dismissal benefits provided due to the termination of labor relations plan or layoff proposal; when the company recognizes the costs or expenses related to the restructuring involving the payment of dismissal benefits.

If an internal retirement plan is implemented for employees, the economic compensation before the official retirement date shall be regarded as dismissal benefits. From the date when the employee stops providing services to the normal retirement date, the wages and social insurance premiums to be paid to the employees who retire early shall be included in the current profit and loss in one go. Financial compensation after the official retirement date (such as normal pension and pension) will be treated as post-employment benefits.

(4) Accounting treatment methods for other long-term employee benefits

√Applicable □Not applicable

Other long-term employee benefits provided by the company to employees that meet the conditions of a defined contribution plan shall be handled in accordance with the above-mentioned relevant regulations on defined contribution plans. If it is in compliance with a defined benefit plan, it will be handled in accordance with the above-mentioned relevant provisions on defined benefit plans, but the "changes resulting from the remeasurement of the net liabilities or net assets of the defined benefit plan" in the relevant employee compensation costs will be included in the current profit and loss or related asset costs.

31. Estimated liabilities

□Applicable √Not applicable

32. Share-based payment

√Applicable □Not applicable

(1) Types of share-based payment

The Company's share-based payment is divided into equity-settled share-based payment and cash-settled share-based payment.

(2) Method for determining the fair value of equity instruments

89/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The Company determines the fair value of options and other equity instruments granted in active markets based on quoted prices in active markets. For equity instruments such as options granted for which there is no active market, the fair value is determined using an option pricing model. The selected option pricing model considers the following factors: A. The exercise price of the option; B. The validity period of the option; C. The current price of the underlying stock; D. The expected volatility of the stock price; E. The expected dividend of the stock; F. The risk-free interest rate during the validity period of the option.

(3) Basis for confirming the best estimate of exercisable equity instruments

On each balance sheet date during the waiting period, the Company makes its best estimate based on the latest changes in the number of vested employees and other subsequent information, and revise the number of equity instruments expected to be vested. On the vesting date, the number of equity instruments ultimately expected to be vested should be consistent with the actual number of vested equity instruments.

(4) Accounting treatments related to the implementation, modification, and termination of share-based payment plans

Equity-settled share-based payments are measured at the fair value of the equity instruments granted to employees. If the rights become exercisable immediately after grant, the fair value of the equity instrument on the grant date will be included in the relevant costs or expenses, and the capital reserve will be increased accordingly. If the vesting cannot be vested until the services within the waiting period are completed or the specified performance conditions are met, on each balance sheet date during the waiting period, based on the best estimate of the number of vested equity instruments and the fair value of the equity instrument on the grant date, the services obtained in the current period will be included in the relevant costs or expenses and capital reserves. No adjustments will be made to the recognized related costs or expenses and the total owner's equity after the vesting date.

Cash-settled share-based payments are measured based on the fair value of the liability calculated and determined based on shares or other equity instruments assumed by the company. If the rights become exercisable immediately after grant, the fair value of the liability assumed by the Company on the date of grant will be included in the relevant costs or expenses, and the liability will be increased accordingly. For cash-settled share-based payments that are exercisable after completing services during the waiting period or meeting specified performance conditions, on each balance sheet date during the waiting period, based on the best estimate of the vesting situation and the fair value of the liability borne by the company, the services obtained in the current period will be included in costs or expenses and corresponding liabilities. On each balance sheet date and settlement date before the settlement of relevant liabilities, the fair value of the liability is remeasured, and its changes are included in the current profit and loss.

When the company modifies the share-based payment plan, if the modification increases the fair value of the equity instruments granted, the increase in services obtained shall be recognized accordingly according to the increase in the fair value of the equity instruments; if the modification increases the number of equity instruments granted, the fair value of the increased equity instruments shall be recognized accordingly as an increase in services obtained. The increase in the fair value of equity instruments refers to the difference between the fair values ​​of the equity instruments before and after the modification on the modification date. If the modification reduces the total fair value of share-based payment or the terms and conditions of the share-based payment plan are modified in other ways that are unfavorable to employees, the accounting treatment for the services obtained will continue to be performed as if the change has never occurred, unless the company cancels some or all of the equity instruments that have been granted.

During the waiting period, if the granted equity instruments are canceled (except for those canceled due to failure to meet non-market conditions for vesting), the company will treat the cancellation of the granted equity instruments as accelerated exercise, and the amount that should be recognized during the remaining waiting period will be immediately included in the current profit and loss, and the capital reserve will be recognized at the same time. If employees or other parties can choose to meet the non-vesting conditions but fail to do so within the waiting period, the company will treat it as the cancellation of the equity instruments granted.

(5) Restricted stocks

In the equity incentive plan, the company grants restricted stocks to the incentive recipients, who first subscribe for the shares. If the unlocking conditions specified in the equity incentive plan are not subsequently met, the company will repurchase the shares at a pre-agreed price. If the restricted stocks issued to employees have completed registration and other capital increase procedures in accordance with relevant regulations, on the date of grant, the company will confirm the share capital and capital reserve based on the subscription payments received from employees; at the same time, the company will confirm treasury shares and other payables for repurchase obligations.

33. Preferred shares, perpetual bonds and other financial instruments

□Applicable √Not applicable

34. Income

(1) Disclose the accounting policies adopted for revenue recognition and measurement according to business type

√Applicable □Not applicable

90/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(1) General principles

The company fulfills its performance obligations in the contract, that is, when the customer obtains control of the relevant goods or services, revenue is recognized. If the contract contains two or more performance obligations, the Company will allocate the transaction price to each individual performance obligation based on the relative proportion of the stand-alone selling price of the goods or services promised by each individual performance obligation on the contract commencement date, and measure revenue based on the transaction price allocated to each individual performance obligation.

When one of the following conditions is met, the performance obligation is performed within a certain period of time; otherwise, the performance obligation is performed at a certain point in time:

① When the company performs the contract, the customer obtains and consumes the economic benefits brought by the company's performance of the contract.

②Customers can control the products under construction during the company's performance of the contract.

③The goods produced by the company during the performance of the contract have irreplaceable uses, and the company has the right to collect payment for the cumulative performance part that has been completed so far during the entire contract period.

For performance obligations performed within a certain period of time, the Company recognizes revenue based on the performance progress within that period of time. When the progress of contract performance cannot be reasonably determined, if the costs incurred by the company are expected to be compensated, revenue will be recognized based on the amount of costs incurred until the progress of contract performance can be reasonably determined.

For performance obligations fulfilled at a certain point in time, the Company recognizes revenue at the point when the customer obtains control of the relevant goods or services. When judging whether the customer has obtained control of the goods or services, the company will consider the following signs:

① The company has the current right to receive payment for the goods or services, that is, the customer has current payment obligations for the goods.

②The company has transferred the legal ownership of the product to the customer, which means that the customer already has the legal ownership of the product.

③The company has transferred the physical goods of the goods to the customer, that is, the customer has physical possession of the goods.

④ The company has transferred the main risks and rewards of ownership of the commodity to the customer, that is, the customer has obtained the main risks and rewards of ownership of the commodity.

⑤The customer has accepted the goods or services.

⑥Other indications that the customer has obtained control of the product.

(2) Similar businesses using different business models involve different revenue recognition methods and measurement methods

√Applicable □Not applicable

The specific method for recognizing revenue from the company's production and sales of reagents and other products is as follows:

Domestic sales: Products are delivered to customers as stipulated in the contract and are confirmed after signing for the relevant products. Relevant economic benefits are likely to flow in. The main risks and rewards of product ownership have been transferred. The amount of product payment has been determined. The payment has been received or is expected to be recovered. The legal ownership of the products has been transferred to the customer.

Overseas sales: The product has been declared to customs as stipulated in the contract and has been cleared. Relevant economic benefits are likely to flow in. The main risks and rewards of commodity ownership have been transferred. The amount of payment received from product export has been determined. The payment has been received or is expected to be recovered.

35. Contract costs

√Applicable □Not applicable

Contract costs include incremental costs incurred to obtain the contract and contract performance costs.

91/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The incremental costs incurred to obtain the contract refer to costs that the company would not have incurred if it had not obtained the contract (such as sales commissions, etc.). If the cost is expected to be recovered, the company will recognize it as the contract acquisition cost and as an asset. Other expenses incurred by the Company to obtain the contract, except for the incremental costs expected to be recovered, are included in the current profits and losses when incurred.

If the costs incurred to fulfill the contract do not fall within the scope of other accounting standards for enterprises such as inventories and meet the following conditions, the company will recognize them as contract performance costs as an asset:

① The cost is directly related to a current or expected contract, including direct labor, direct materials, manufacturing overhead (or similar expenses), costs clearly borne by the customer, and other costs incurred solely because of the contract;

② This cost increases the company’s resources for fulfilling its performance obligations in the future;

③The cost is expected to be recovered.

Assets recognized as contract acquisition costs and assets recognized as contract performance costs (hereinafter referred to as "assets related to contract costs") are amortized on the same basis as the revenue recognition of goods or services related to the assets and included in the current profit and loss.

When the book value of assets related to contract costs is higher than the difference between the following two items, the company makes impairment provisions for the excess and recognizes it as asset impairment losses:

① The remaining consideration that the company expects to obtain from the transfer of goods or services related to the asset;

② The estimated cost that will be incurred to transfer the relevant goods or services.

36. Government subsidies

√Applicable □Not applicable

Government subsidies are recognized when the conditions attached to the government subsidies are met and can be received.

Government subsidies for monetary assets are measured based on the amount received or receivable. Government subsidies for non-monetary assets are measured at fair value; if the fair value cannot be obtained reliably, they are measured at a nominal amount of 1 yuan.

Asset-related government subsidies refer to government subsidies obtained by the company and used to purchase, construct or otherwise form long-term assets; in addition, they are government subsidies related to income.

For government documents that do not clearly stipulate the subsidy objects and can form long-term assets, the part of the government subsidy corresponding to the asset value shall be regarded as the government subsidy related to the assets, and the remaining part shall be regarded as the government subsidy related to the income; if it is difficult to distinguish, the entire government subsidy shall be regarded as the government subsidy related to the income.

Government subsidies related to assets are recognized as deferred income and are included in profits and losses in installments according to a reasonable and systematic method during the use period of the relevant assets. If government subsidies related to income are used to compensate for relevant costs or losses that have already occurred, they will be included in the current profits and losses; if they are used to compensate for relevant costs or losses in subsequent periods, they will be included in deferred income and will be included in the current profits and losses during the period when the relevant costs or losses are recognized. Government subsidies measured according to the nominal amount are directly included in the current profit and loss. The company handles the same or similar government subsidy business in a consistent manner.

Government subsidies related to daily activities shall be included in other income according to the economic business essence. Government subsidies unrelated to daily activities are included in non-operating income.

When a confirmed government subsidy needs to be returned, if the book value of the relevant assets is offset at the time of initial recognition, the book value of the assets is adjusted; if there is a balance of relevant deferred income, the book balance of the relevant deferred income is offset, and the excess is included in the current profit and loss; in other cases, it is directly included in the current profit and loss.

37. Deferred income tax assets/deferred income tax liabilities

√Applicable □Not applicable

92/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Income tax includes current income tax and deferred income tax. Except for adjustments to goodwill arising from business combinations, or deferred income taxes related to transactions or events directly included in owners' equity, which are included in owners' equity, they are all included in current profits and losses as income tax expenses.

The company uses the balance sheet debt method to recognize deferred income tax based on the temporary differences between the book values ​​of assets and liabilities on the balance sheet date and their tax basis.

Each taxable temporary difference is recognized as a related deferred income tax liability, unless the taxable temporary difference is generated in the following transactions:

(1) Initial recognition of goodwill, or the initial recognition of assets or liabilities arising from a transaction with the following characteristics: the transaction is not a business combination, and the transaction affects neither accounting profits nor taxable income when the transaction occurs (except for individual transactions where the initial recognition of assets and liabilities results in equal amounts of taxable temporary differences and deductible temporary differences);

(2) For taxable temporary differences related to investments in subsidiaries, joint ventures and associates, the reversal time of the temporary differences can be controlled and the temporary differences are likely not to be reversed in the foreseeable future.

For deductible temporary differences, deductible losses and tax credits that can be carried forward to future years, the company recognizes the resulting deferred income tax assets to the extent that it is likely to obtain future taxable income that can be used to offset the deductible temporary differences, deductible losses and tax credits, unless the deductible temporary differences are generated in the following transactions:

(1) The transaction is not a business combination, and when the transaction occurs, it affects neither accounting profits nor taxable income (except for individual transactions in which the initial recognition of assets and liabilities results in equal amounts of taxable temporary differences and deductible temporary differences);

(2) For deductible temporary differences related to investments in subsidiaries, joint ventures and associates, corresponding deferred income tax assets are recognized if the following conditions are met: the temporary differences are likely to be reversed in the foreseeable future, and it is likely to be taxable income that can be used to offset the deductible temporary differences in the future.

On the balance sheet date, the Company's deferred income tax assets and deferred income tax liabilities are measured at the applicable tax rate during the period when the asset is expected to be recovered or the liability is settled, and the income tax impact of the expected method of recovering the asset or settling the liability on the balance sheet date is reflected.

On the balance sheet date, the Company reviews the book value of deferred income tax assets. If it is probable that sufficient taxable income will not be available in future periods to offset the benefits of deferred tax assets, the carrying amount of the deferred tax assets will be reduced. The amount of the write-down is reversed when it is probable that sufficient taxable income will be obtained.

On the balance sheet date, deferred income tax assets and deferred income tax liabilities are presented as the net amount after offsetting when the following conditions are met at the same time:

(1) The tax payer within the company has the legal right to settle current income tax assets and current income tax liabilities on a net basis;

(2) Deferred income tax assets and deferred income tax liabilities are related to income taxes levied by the same tax collection and administration department on the same taxpayer within the company.

38. Leasing

√Applicable □Not applicable

As a lessee, the judgment basis and accounting treatment method for simplified treatment of short-term leases and low-value asset leases

√Applicable □Not applicable

Identification of leases

On the contract commencement date, the Company, as a lessee or lessor, evaluates whether the customer in the contract has the right to obtain substantially all of the economic benefits generated from the use of the identified assets during the use period, and has the right to direct the use of the identified assets during the use period. If a party in a contract transfers the right to control the use of one or more identified assets within a certain period in exchange for consideration, the Company determines that the contract is a lease or contains a lease.

93/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The company as lessee

On the start date of the lease period, the Company recognizes right-of-use assets and lease liabilities for all leases, except short-term leases and low-value asset leases that are simplified.

(1) Recognition conditions for right-of-use assets

Right-of-use assets refer to the company's rights as a lessee to use the leased assets during the lease term.

On the commencement date of the lease term, the right-of-use asset is initially measured at cost. This cost includes: the initial measurement amount of the lease liability; the lease payment amount paid on or before the start date of the lease term, and if there is a lease incentive, the amount related to the lease incentive that has been enjoyed will be deducted; the initial direct costs incurred by the company as a lessee; the costs that the company as a lessee is expected to incur to dismantle and remove the leased assets, restore the site where the leased assets are located, or restore the leased assets to the state agreed upon in the lease terms. As a lessee, the company recognizes and measures costs such as dismantling and restoration in accordance with the "Accounting Standards for Business Enterprises No. 13 - Contingencies". Adjustments are made subsequently for any subsequent remeasurement of the lease liability.

(2) Depreciation method of right-of-use assets

The Company uses the straight-line method to calculate depreciation. If the Company, as the lessee, can reasonably determine that it will obtain ownership of the leased asset at the expiration of the lease term, depreciation will be accrued over the remaining useful life of the leased asset. If it is not reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, depreciation will be accrued during the shorter of the lease term and the remaining useful life of the leased asset.

(3) Please refer to “27. Impairment of long-term assets” for the impairment testing method and impairment provision method of right-of-use assets.

Lease liabilities are initially measured based on the present value of the unpaid lease payments at the beginning of the lease term using the interest rate implicit in the lease. If the interest rate implicit in the lease cannot be determined, the incremental borrowing rate is used as the discount rate. Lease payments include: fixed payments and substantive fixed payments, if there are lease incentives, less the amount related to the lease incentives; variable lease payments that depend on an index or ratio; the exercise price of the purchase option, provided that the lessee is reasonably certain that the option will be exercised; the amount required to exercise the option to terminate the lease, provided that the lease term reflects that the lessee will exercise the option to terminate the lease; and the amount expected to be paid based on the residual value of the guarantee provided by the lessee. Subsequently, the interest expense of the lease liability for each period during the lease term is calculated based on the fixed periodic interest rate and included in the current profit and loss. Variable lease payments that are not included in the measurement of lease liabilities are included in the current profit and loss when actually incurred.

short term rental

A short-term lease refers to a lease with a lease term of no more than 12 months on the start date of the lease period, except for leases that include a purchase option. The company will include the lease payments of short-term leases into the relevant asset costs or current profits and losses on a straight-line basis during each period of the lease term.

For short-term leases, the Company selects projects that meet the short-term lease conditions among the following asset types according to the type of leased assets and adopts the above simplified treatment method.

Low value asset leasing

Low-value asset leases refer to leases where the value of a single leased asset is less than 40,000 yuan when it is a brand-new asset.

The company will include the lease payments for low-value asset leases into the relevant asset costs or current profits and losses on a straight-line basis during each period of the lease term.

For low-value asset leases, the Company chooses to adopt the above simplified treatment method based on the specific circumstances of each lease.

Lease changes

If a lease changes and the following conditions are met at the same time, the company will account for the lease change as a separate lease: ① The lease change expands the scope of the lease by adding the right to use one or more leased assets; ② The increased consideration is equivalent to the amount of the individual price of the expanded part of the lease scope adjusted according to the conditions of the contract.

94/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

If the lease change is not accounted for as a separate lease, on the effective date of the lease change, the company re-allocates the consideration of the contract after the change, re-determines the lease term, and re-measures the lease liability based on the present value of the lease payment after the change and the revised discount rate.

If a change in the lease results in a reduction in the scope of the lease or a shortening of the lease period, the company will reduce the book value of the right-of-use assets accordingly, and include the related gains or losses from the partial or complete termination of the lease into the current profits and losses.

If other lease changes result in the remeasurement of lease liabilities, the company will adjust the book value of the right-of-use assets accordingly.

Lease classification standards and accounting treatment methods as a lessor

√Applicable □Not applicable

The company acts as lessor

When the Company acts as a lessor, leases that substantially transfer all risks and rewards related to asset ownership are recognized as finance leases, and leases other than finance leases are recognized as operating leases.

finance lease

In financial leases, on the date of the start of the lease period, the company uses the net investment in the lease as the entry value of the financial lease receivable. The net investment in the lease is the sum of the unguaranteed residual value and the present value of the lease receivables that have not been received on the date of the start of the lease period, discounted at the interest rate implicit in the lease. As the lessor, the Company calculates and recognizes interest income for each period during the lease term based on fixed periodic interest rates. Variable lease payments obtained by the Company as a lessor that are not included in the measurement of the net lease investment are included in the current profit and loss when actually incurred.

The derecognition and impairment of finance lease receivables shall be accounted for in accordance with the provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" and "Accounting Standards for Business Enterprises No. 23 - Transfer of Financial Assets".

operating lease

For rents in operating leases, the company recognizes current profits and losses according to the straight-line method in each period during the lease term. The initial direct expenses incurred in connection with the operating lease shall be capitalized, amortized during the lease period on the same basis as the rental income recognition, and included in the current profit and loss in installments. Variable lease payments related to operating leases that are not included in the lease receipts are included in the current profit and loss when they actually occur.

Lease changes

If an operating lease changes, the Company will account for it as a new lease from the effective date of the change, and the amount of lease receipts received in advance or receivable related to the lease before the change is regarded as the amount of receipts from the new lease.

If a financial lease changes and the following conditions are met at the same time, the company will account for the change as a separate lease: ① The change expands the scope of the lease by increasing the use rights of one or more leased assets; ② The increased consideration is equivalent to the amount of the individual price of the expanded part of the lease scope adjusted according to the conditions of the contract.

If a financial lease is changed and is not accounted for as a separate lease, the company will treat the changed lease under the following circumstances: ① If the change takes effect on the lease commencement date, the lease will be classified as an operating lease, the company will account for it as a new lease from the effective date of the lease change, and The net lease investment before the effective date of the lease change is used as the book value of the leased asset; ② If the change takes effect on the lease start date, the lease will be classified as a finance lease, and the company will conduct accounting treatment in accordance with the provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" regarding modification or renegotiation of contracts.

39. Other important accounting policies and accounting estimates

√Applicable □Not applicable

95/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The Company continuously evaluates the important accounting estimates and key assumptions adopted based on historical experience and other factors, including reasonable expectations for future events. The important accounting estimates and key assumptions that are likely to cause a significant adjustment in the book value of assets and liabilities in the next fiscal year are listed below:

Classification of financial assets

The Company's significant judgments involved in determining the classification of financial assets include analysis of business models and contractual cash flow characteristics.

The Company determines the business model for managing financial assets at the level of financial asset portfolios. Factors considered include the way to evaluate and report the performance of financial assets to key management personnel, the risks that affect the performance of financial assets and their management methods, and the way in which relevant business managers are remunerated.

When the company evaluates whether the contractual cash flows of financial assets are consistent with basic lending arrangements, the company makes the following main judgments: whether the time distribution or amount of the principal may change during the duration due to early repayment and other reasons; whether interest only includes the time value of money, credit risk, other basic lending risks and consideration for costs and profits. For example, whether the amount of early repayment only reflects the unpaid principal and interest based on the unpaid principal, as well as reasonable compensation paid for early termination of the contract.

Measurement of expected credit losses on accounts receivable

The Company calculates the expected credit losses of accounts receivable through the default risk exposure of accounts receivable and the expected credit loss rate, and determines the expected credit loss rate based on the probability of default and the loss given default rate. When determining the expected credit loss rate, the company uses internal historical credit loss experience and other data, and adjusts historical data based on current conditions and forward-looking information. When considering forward-looking information, the Company uses indicators including the risk of economic downturn, external market environment, technological environment and changes in customer conditions. The Company regularly monitors and reviews assumptions related to the calculation of expected credit losses.

Goodwill impairment

The Company assesses whether goodwill is impaired at least annually. This requires an estimate of the value in use of the asset group to which goodwill is assigned. When estimating value in use, the company needs to estimate future cash flows from the asset group and select an appropriate discount rate to calculate the present value of future cash flows.

Deferred tax assets

Deferred tax assets should be recognized for all unused tax losses to the extent that it is probable that sufficient taxable profits will be available against which the losses can be utilised. This requires management to use a lot of judgment to estimate the timing and amount of future taxable profits, combined with tax planning strategies, to determine the amount of deferred income tax assets that should be recognized.

40. Changes in important accounting policies and accounting estimates

(1) Changes in important accounting policies

□Applicable √Not applicable

(2) Changes in important accounting estimates

□Applicable √Not applicable

(3) The first implementation of new accounting standards or standard interpretations starting in 2026 will involve adjustments to the financial statements at the beginning of the year of first implementation.

□Applicable √Not applicable

41. Others

□Applicable √Not applicable

96/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

6. Taxes

1. Main tax types and tax rates

Main tax types and tax rates

√Applicable □Not applicable

Type of tax Tax calculation basis Tax rate

Taxable value-added amount (taxable amount is taxable sales multiplied by applicable tax

VAT 5, 6, 9, 13

Calculated as the balance after deducting the deductible input tax allowed for the current period)

Urban maintenance and construction tax Actual amount of turnover tax paid 7

Education fee surcharge Actual turnover tax paid 3

Local education surcharge Actual turnover tax paid 2

If there are taxpayers with different corporate income tax rates, a description of the disclosure

√Applicable □Not applicable

Name of taxpayer Income tax rate (%) Hangzhou Aotai Biotechnology Co., Ltd. 15 Hangzhou Aorui Biomedical Technology Co., Ltd. 20 Hangzhou Tongzhou Biotechnology Co., Ltd. 15 Hangzhou Aokai Biotechnology Co., Ltd. 25 Hangzhou Saiye Technology Co., Ltd. 20 Haining Tianyu Biotechnology Co., Ltd. 20 Zhejiang Yingxin Medical Technology Co., Ltd. 20 Zhejiang Yinghai Medical Supplies Co., Ltd. 25 Fanling Biotechnology (Hangzhou) Co., Ltd. 25 Fantian Biotechnology Co., Ltd. 16.50 Hangzhou Aceso Supply Chain Co., Ltd. 20 Citest Diagnostics Inc. Federal: 15 Local: 2.5-11 Aceso Laboratories Inc. Federal: 21 States: 8.84 Rapid Labs Limited 19 ABOUND DIAGNOSTICS INC Federal: 21 States: 8.84 RapidLabs HongKong Limited 16.50 AUSTRALIA ALLTEST BIOTECH PTY LTD No operation, not applicable ACESO DIAGNOSTICS PTY LTD No operation, not applicable VIDAQUICK BIOTECH S.L. No operation, not applicable Aceso consulting, importation and distribution of health’s 15 products LTD.

ALLTEST UK LIMITED has no operations and is not applicable. Note: Fantian Biotechnology and RapidLabs HK are subject to the Hong Kong income tax rate; CitestDiag is subject to the Canadian income tax rate; AcesoLabs and ABOUNDDiag are subject to the US income tax rate; RapidLabs is subject to the British income tax rate.

2. Tax incentives

√Applicable □Not applicable

Note 1: The company was re-certified as a national high-tech enterprise on December 19, 2025. The certificate number is: GR202533008143, and the certification is valid for three years. According to the provisions of the "Notice of the State Administration of Taxation on Issues Concerning the Implementation of Income Tax Preferential Policies for High-tech Enterprises" (Guo Shuihan (2009) No. 203) and the "Announcement of the State Administration of Taxation on Issues Concerning the Implementation of Preferential Income Tax Policies for High-tech Enterprises" (State Administration of Taxation Announcement No. 24, 2017), corporate income tax will be calculated and paid at a preferential tax rate of 15% in 2026.

97/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Note 2: The company’s subsidiary Hangzhou Tongzhou Biotechnology Co., Ltd. passed the high-tech enterprise certification on December 6, 2024. The certificate number is: GR202433008801, and the certification is valid for three years. According to the provisions of the "Notice of the State Administration of Taxation on Issues Concerning the Implementation of Income Tax Preferential Policies for High-tech Enterprises" (Guo Shuihan [2009] No. 203) and the "Announcement of the State Administration of Taxation on Issues Concerning the Implementation of Preferential Income Tax Policies for High-tech Enterprises" (State Administration of Taxation Announcement No. 24, 2017), the company will pay a reduced corporate income tax rate of 15% in 2026.

Note 3: According to the "Announcement on Relevant Tax Policies to Further Support the Development of Small and Micro Enterprises and Individual Industrial and Commercial Households" (Ministry of Finance and State Administration of Taxation Announcement No. 12 of 2023): Small and micro enterprises are subject to a 25% reduction in taxable income calculation and a corporate income tax policy of 20%, which will continue until December 31, 2027.

3. Others

□Applicable √Not applicable

7. Notes on Consolidated Financial Statement Items

1. Monetary funds

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Cash on hand 7,424.88 8,071.02 Bank deposits 1,847,406,190.32 1,066,821,268.80 Other monetary funds 150,691.15 150,667.09 Accrued interest on deposits 403,568.78 286,068.78 Total 1,847,967,875.13 1,067,266,075.69

Including: Total amount deposited abroad 70,989,991.28 46,949,276.96Other instructions

(1) At the end of the reporting period, other monetary funds of RMB 150,691.15 were the balance of the company's third-party payment platform account. The accrued interest on deposits of RMB 403,568.78 is the bank deposit interest accrued based on the actual interest rate method but has not yet reached the interest payment period.

(2) At the end of the reporting period, except for the non-redeemable 6-month time deposit of RMB 6,810,900.00 in bank deposits, the Company has no other mortgages, pledges or freezes, or funds deposited abroad with restrictions on repatriation of funds.

2. Trading financial assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Reason and basis for designation Measured at fair value with changes included in the current period

276,186,261.64 1,324,890,081.11/Profit and loss financial assets

Among them:

Bank financial products 226,152,700.00 992,711,861.93 / Structured deposits 50,033,561.64 332,178,219.18 /

Total 276,186,261.64 1,324,890,081.11 /

Other notes:

□Applicable √Not applicable

3. Derivative financial assets

□Applicable √Not applicable

98/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

4. Notes receivable

(1) Classified presentation of notes receivable

□Applicable √Not applicable

(2) The company’s pledged notes receivable at the end of the period □ Applicable √ Not applicable

(3) Notes receivable that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date □ Applicable √ Not applicable

(4) Classified disclosure according to bad debt accrual method □Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model □ Applicable √ Not applicable

The basis for dividing each stage and the proportion of provision for bad debts are not available

Explanation of significant changes in the book balance of accounts receivable that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

(5) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(6) Notes receivable actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of bills receivable: □ Applicable √ Not applicable

Instructions for writing off notes receivable:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

99/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

5. Accounts receivable

(1) Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Aging Book balance at the end of the period Book balance at the beginning of the period Within 1 year (including 1 year) 132,881,327.13 153,467,919.57 1 to 2 years 20,868,899.22 12,989,532.12 2 to 3 years 10,180,900.48 12,311,538.70 More than 3 years 7,297,377.08 3,871,009.25

Total 171,228,503.91 182,639,999.64

(2) Classified disclosure based on bad debt accrual method

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Ratio Provision Book Ratio Provision Carrying amount Example Amount Ratio Value Amount Example Amount Ratio Value

(%) (%) (%) (%)

Provision for bad debts on an individual basis

1,137,006.20 0.66 1,137,006.20 100.00 - 1,173,382.25 0.64 1,173,382.25 100.00 -Preparation

Among them:

Foreign customers 1,137,006.20 0.66 1,137,006.20 100.00 - 1,173,382.25 0.64 1,173,382.25 100.00 - Domestic customers - - - - - - - - - - Bad debts are accrued on a group basis

170,091,497.71 99.34 24,974,236.24 14.68 145,117,261.47 181,466,617.39 99.36 22,418,792.23 12.35 159,047,825.16Preparation

Among them:

Foreign customers 152,859,400.40 89.27 22,977,784.31 15.03 129,881,616.09 167,026,102.19 91.45 21,586,527.30 12.92 145,439,574.89 Domestic customers 17,232,097.31 10.06 1,996,451.93 11.59 15,235,645.38 14,440,515.20 7.91 832,264.93 5.76 13,608,250.27

Total 171,228,503.91 / 26,111,242.44 / 145,117,261.47 182,639,999.64 / 23,592,174.48 / 159,047,825.16

Provision for bad debts is made individually:

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion of provision (%) Reason for provision Other non-important individual accounts receivable 1,137,006.20 1,137,006.20 100.00 Estimated to be irrecoverable

Total 1,137,006.20 1,137,006.20 100.00 /Explanation of provision for bad debts on an individual basis:

□Applicable √Not applicable

Provision for bad debts by group:

√Applicable □Not applicable

Combined accrual items: foreign customers

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion of provision (%) Within 1 year 124,227,224.75 5,192,698.07 4.18 1 to 2 years 12,719,425.90 4,540,835.07 35.70 2 to 3 years 8,661,144.43 5,992,645.85 69.19 More than 3 years 7,251,605.32 7,251,605.32 100.00

Total 152,859,400.40 22,977,784.31 15.03 Instructions on the provision of bad debt provisions by group:

□Applicable √Not applicable

100/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Combined accrual items: domestic customers

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion of provision (%) Within 1 year 7,517,096.18 375,854.81 5.00 1 to 2 years 8,149,473.32 814,947.33 10.00 2 to 3 years 1,519,756.05 759,878.03 50.00 More than 3 years 45,771.76 45,771.76 100.00

Total 17,232,097.31 1,996,451.93 11.59 Instructions on the provision of bad debt provisions by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

Not applicable

Explanation of significant changes in the book balance of accounts receivable that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

(3) Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Opening balance Recovery or write-off or approval Other changes Ending balance accrual

Turn back pin

Provision for bad debts 23,592,174.48 2,536,471.47 17,403.51 26,111,242.44

Total 23,592,174.48 2,536,471.47 17,403.51 26,111,242.44

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable √Not applicable

(4) Accounts receivable actually written off in the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Write-off Amount

Accounts receivable actually written off 17,403.51

Among them, the important write-off of accounts receivable

□Applicable √Not applicable

Instructions for writing off accounts receivable:

□Applicable √Not applicable

(5) Accounts receivable and contract assets of the top five ending balances by debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB

101/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Accounts Receivable Accounts Receivable and Contract Assets

Contract assets Bad debt provision Ending unit name Ending balance of accounts receivable Ending balance of the same assets Ending balance plus ending balance Balance amount Count ratio

(%) Customer one 18,928,330.34 - 18,928,330.34 11.05 6,498,533.65 Customer two 12,750,459.36 - 12,750,459.36 7.45 2,710,903.37 Customer three 8,230,756.27 - 8,230,756.27 4.81 344,045.61Customer four 4,743,795.05 - 4,743,795.05 2.77 198,290.63Customer five 4,685,183.07 - 4,685,183.07 2.74 785,447.77

Total 49,338,524.09 - 49,338,524.09 28.82 10,537,221.03Other instructions

None

Other notes:

□Applicable √Not applicable

6. Contract assets

(1) Contract assets

□Applicable √Not applicable

(2) Amount and reasons for significant changes in book value during the reporting period

□Applicable √Not applicable

(3) Classified disclosure based on bad debt accrual method

□Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

Not applicable

Explanation of significant changes in the book balance of contract assets that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

(4) Bad debt provisions for contract assets in the current period

□Applicable √Not applicable

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

102/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-annual Report □ Applicable √ Not applicable

Other notes:

None

(5) Contract assets actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of contract assets □ Applicable √ Not applicable

Instructions for write-off of contract assets:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

7. Accounts receivable financing

(1) Classified presentation of financing receivables

□Applicable √Not applicable

(2) Financing of the company’s pledged receivables at the end of the period □ Applicable √ Not applicable

(3) Financing of receivables that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date □ Applicable √ Not applicable

(4) Classified disclosure according to bad debt accrual method □Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Explanation on the provision of bad debt provisions by individual items: □ Applicable √ Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model □ Applicable √ Not applicable

The basis for dividing each stage and the proportion of provision for bad debts are not available

Explanation of significant changes in the book balance of accounts receivable financing that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

103/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(5) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable √Not applicable

Other notes:

None

(6) Financing of receivables actually written off in the current period

□Applicable √Not applicable

Important financing write-offs of receivables

□Applicable √Not applicable

Write-off instructions:

□Applicable √Not applicable

(7) Increases and decreases in receivables financing and changes in fair value during the current period:

□Applicable √Not applicable

(8) Other instructions:

□Applicable √Not applicable

8. Advance payments

(1) Prepayments are presented based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance Aging

Amount Proportion (%) Amount Proportion (%) Within 1 year 10,670,739.15 81.66 10,546,431.15 74.63 1 to 2 years 1,094,254.00 8.37 1,279,628.11 9.06 2 to 3 years 1,245,561.23 9.53 179,144.11 1.27 More than 3 years 56,000.00 0.43 2,124,608.75 15.04

Total 13,066,554.38 100 14,129,812.12 100.00 Explanation of reasons why prepayments with an aging of more than 1 year and significant amounts were not settled in a timely manner:

None

(2) Prepayments of the top five closing balances by prepayment objects

√Applicable □Not applicable

Unit: Yuan Currency: RMB accounts for the total closing balance of prepayments Name of the unit Closing balance

Proportion (%) First place 3,989,008.78 30.53 Second place 1,719,903.00 13.16 Third place 790,200.00 6.05 Fourth place 521,414.91 3.99 Fifth place 480,886.43 3.68

104/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Total 7,501,413.12 57.41Other instructions:

None

Other instructions

□Applicable √Not applicable

9. Other receivables

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Other receivables 8,684,803.56 5,979,081.69

Total 8,684,803.56 5,979,081.69Other instructions:

□Applicable √Not applicable

interest receivable

(1) Classification of interest receivable

□Applicable √Not applicable

(2) Important overdue interest

□Applicable √Not applicable

(3) Classified disclosure according to bad debt accrual method □Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Explanation on the provision of bad debt provisions by individual items: □ Applicable √ Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model □ Applicable √ Not applicable

(4) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

105/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(5) Interest receivable actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of interest receivable □ Applicable √ Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Dividends receivable

(1) Dividends receivable

□Applicable √Not applicable

(2) Important dividends receivable aged more than 1 year □ Applicable √ Not applicable

(3) Classified disclosure according to bad debt accrual method □Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Explanation on the provision of bad debt provisions by individual items: □ Applicable √ Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model □ Applicable √ Not applicable

(4) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(5) Dividends receivable actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of dividends receivable □ Applicable √ Not applicable

Write-off instructions:

106/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Other receivables

(1) Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Aging Book balance at the end of the period Book balance at the beginning of the period Within 1 year (including 1 year) 5,679,378.89 4,210,152.08 1 to 2 years 2,887,362.61 917,933.10 2 to 3 years 3,000.00 788,382.59 More than 3 years 572,157.00 424,720.00

Total 9,141,898.50 6,341,187.77

(2) Classification by nature of payment

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Nature of payment Book balance at the end of the period Book balance at the beginning of the period Security deposit and deposit 2,370,747.68 2,694,735.03 Rent and collection 5,618,630.26 3,114,937.45 Others 1,152,520.56 531,515.29

Total 9,141,898.50 6,341,187.77

(3) Bad debt provision accrual

√Applicable □Not applicable

Unit: Yuan Currency: RMB Phase 1 Phase 2 Phase 3

Lifetime expectations Lifetime expectations

Provision for bad debts Expected total credit losses in the next 12 months (not incurred Credit losses (incurred

credit loss

credit impairment) credit impairment)

Balance on January 1, 2026 362,106.08 362,106.08 Balance on January 1, 2026 at

362,106.08 362,106.08This issue

--Transfer to the second stage

--Transfer to the third stage

--Return to the second stage

--Return to the first stage

Provision in this period 94,988.86 94,988.86 Transferred in this period

Sales in this period

Write-off in this period

Other changes

Balance on June 30, 2026 457,094.94 457,094.94

Basis for division of each stage and provision ratio for bad debts

None

107/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Explanation of significant changes in the book balance of other receivables that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

The amount of bad debt provision for the current period and the basis for assessing whether the credit risk of financial instruments has increased significantly:

□Applicable √Not applicable

(4) Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Opening balance Recovery or write-off or other Ending balance accrual

Reversal of write-off changes

Provision for bad debts of other receivables 362,106.08 94,988.86 - - - 457,094.94

Total 362,106.08 94,988.86 - - - 457,094.94 Among them, the amount of bad debt provision for the current period that is reversed or recovered is important:

□Applicable √Not applicable

Other instructions

None

(5) Other receivables actually written off in the current period

□Applicable √Not applicable

Important write-offs of other receivables:

□Applicable √Not applicable

Instructions for writing off other receivables:

□Applicable √Not applicable

(6) Other receivables with top five closing balances based on debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB in other receivable periods

Name of bad debt provision unit Closing balance Total closing balance Nature of payment Aging

Ending balance ratio (%)

Within 1 year,

First place 3,845,689.58 42.07 Rent and collection 192,284.48

1-2 years

Second place 1,300,000.00 14.22 Security deposit and deposit within 1 year 65,000.00 Third place 1,053,300.08 11.52 Rent and collection within 1 year 52,665.00 Fourth place 719,692.00 7.87 Security deposit and deposit 1-2 years 35,984.60

Within 1 year,

Fifth place 574,061.90 6.28 Rent and collection 28,703.10

1-2 years

Total 7,492,743.56 81.96 / / 374,637.18

(7) Presented in other receivables due to centralized management of funds

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

108/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

10. Inventory

(1) Inventory classification

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Provision for inventory decline Provision for inventory decline

Project

Book balance/Contract performance costs Book value Book balance/Contract performance costs Book value

This impairment provision This impairment provision

Raw materials 149,027,487.19 24,994,344.28 124,033,142.91 135,163,474.16 25,192,725.88 109,970,748.28 Semi-finished products 28,225,028.76 3,576,035.89 24,648,992.87 27,512,152.40 5,316,826.95 22,195,325.45 Goods in stock 33,620,926.89 2,710,589.60 30,910,337.29 33,674,386.50 2,504,352.61 31,170,033.89 Products shipped 10,426,540.66 - 10,426,540.66 10,782,465.73 - 10,782,465.73 Commissioned products

623,483.83 - 623,483.83 702,853.39 - 702,853.39 capital

Low-value consumables 1,851,536.26 - 1,851,536.26 1,867,880.10 - 1,867,880.10

Total 223,775,003.59 31,280,969.77 192,494,033.82 209,703,212.28 33,013,905.44 176,689,306.84

(2) Data resources confirmed as inventory

□Applicable √Not applicable

(3) Provision for inventory depreciation and provision for impairment of contract performance costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase amount in this period Decrease amount in this period

Item Opening balance Ending balance Provision Others Reversal or write-off Others

Raw materials 25,192,725.88 1,995,583.99 2,193,965.59 24,994,344.28 Semi-finished products 5,316,826.95 69,764.72 1,810,555.78 3,576,035.89 Inventory goods 2,504,352.61 889,153.61 682,916.62 2,710,589.60

Total 33,013,905.44 2,954,502.32 4,687,437.99 31,280,969.77

Reasons for the reversal or write-off of inventory depreciation provisions in the current period

√Applicable □Not applicable

Determine the specific parameters of net realizable value/remaining consideration and costs to be incurred. Reversal or write-off in the current period

Project

Physical basis Reasons for inventory depreciation provisions

The estimated selling price minus the estimated costs to be incurred upon completion, the estimated price impact factors have disappeared, or the raw materials have been received

The amount after sales expenses and related taxes and fees Scraping

The estimated selling price minus the estimated costs to be incurred upon completion, the estimated factors that may have affected the price have disappeared, have been used, or are semi-finished products.

The amount after sales expenses and related taxes and fees Scraping

Estimated selling price minus estimated selling expenses and related taxes. The factors affecting the price have disappeared, have been sold, or are in stock.

amount scrapped

Provision for inventory decline in value on a group basis

□Applicable √Not applicable

Standards for accruing inventory depreciation provisions on a group basis

□Applicable √Not applicable

(4) The capitalized amount of borrowing costs included in the closing balance of inventories and its calculation standards and basis

□Applicable √Not applicable

109/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(5) Explanation of the amortization amount of contract performance costs for the current period □Applicable √Not applicable

Other notes:

□Applicable √Not applicable

11. Assets held for sale

□Applicable √Not applicable

12. Non-current assets due within one year

□Applicable √Not applicable

Debt investments due within one year

□Applicable √Not applicable

Other debt investments due within one year

□Applicable √Not applicable

Other explanations for non-current assets due within one year None

13. Other current assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Amount of input tax to be deducted 81,216,746.20 82,410,651.24 Short-term rental and property fees 246,416.84 636,677.06 Prepaid tax 2,697,958.47 710,027.51

Total 84,161,121.51 83,757,355.81

Information about compensating assets

□Applicable √Not applicable

Other notes:

None

14. Debt investment

(1) Debt investment situation

□Applicable √Not applicable

Changes in provision for impairment of debt investments during the current period

□Applicable √Not applicable

(2) Important debt investments at the end of the period

□Applicable √Not applicable

110/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(3) Provision for impairment losses

□Applicable √Not applicable

Basis for division of each stage and proportion of impairment provision: None

Explanation of significant changes in the book balance of debt investments that have experienced changes in loss provisions in the current period: □ Applicable √ Not applicable

The amount of impairment provision for the current period and the basis for assessing whether the credit risk of financial instruments has significantly increased: □ Applicable √ Not applicable

(4) Actual write-off debt investments in the current period □ Applicable √ Not applicable

Among them, the write-off of important debt investments □Applicable √Not applicable

Instructions for writing off debt investments:

□Applicable √Not applicable

Other notes:

None

15. Other debt investments

(1) Other debt investments

□Applicable √Not applicable

Changes in impairment provisions for other debt investments during the period □ Applicable √ Not applicable

(2) Other important debt investments at the end of the period

□Applicable √Not applicable

(3) Provision for impairment losses

□Applicable √Not applicable

(4) Other debt investments actually written off in the current period □ Applicable √ Not applicable

Among them, the write-off situation of other important debt investments □Applicable √Not applicable

Instructions for writing off other debt investments:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

111/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

16. Long-term receivables

(1) Long-term receivables

□Applicable √Not applicable

(2) Classified disclosure according to bad debt accrual method □ Applicable √ Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Explanation on the provision of bad debt provisions by individual items: □ Applicable √ Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model □ Applicable √ Not applicable

(3) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(4) Long-term receivables actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of long-term receivables □ Applicable √ Not applicable

Instructions for writing off long-term receivables:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

112/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

17. Long-term equity investment

(1) Long-term equity investment

√Applicable □Not applicable

Unit: Yuan Currency: RMB Impairment Changes in current period

Beginning of the period Preparation for invested entities at the end of the period Other comprehensive declarations and releases under the equity method Impairment provision balance (book value Decrease in investment Other rights Impairment provision balance (book position Additional investment at the beginning of the period Confirmed investment income Cash dividend Other closing balance value) Provision value for changes in assets)

Balance Capital Gains and Loss Adjustment or Profit

1. Joint ventures

None

Subtotal - - -

2. Joint ventures

Weisbo Medical 21,224,269.55 -155,961.21 21,068,308.34 Chaowu Yunxin 19,293,101.37 -73,925.00 19,219,176.37 Qitianxia Digital Technology 38,156,541.98 - 38,156,541.98 Future Freshmen Health 20,054,330.83 -97,560.00 19,956,770.83 Subtotal 98,728,243.73 - -327,446.21 - - - - - 98,400,797.52

Total 98,728,243.73 - -327,446.21 - - - - - 98,400,797.52

(2) Impairment testing of long-term equity investments

□Applicable √Not applicable

Other instructions

None

18. Investment in other equity instruments

(1) Investment in other equity instruments

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Beginning of the period Increases and decreases in the period End of the period The cumulative amount recognized in the current period is included in it The cumulative amount is included in it Designated as a public company

113/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Balance Balance Dividend income Other comprehensive income Other comprehensive income Fair value measurement is included in other in the current period. Loss is included in other gains in the current period, and its changes are included in additional investment. Reduction in investment. Altruistic comprehensive income. Others included in other comprehensive income.

Reasons for gains and losses

Shuguang Technology 10,000,000.00 10,000,000.00

Ruichi Biotechnology 1,500,000.00 1,500,000.00

Yile Biotech 999,981.60 999,981.60

FuXin Medical 5,347,875.00 5,347,875.00

Parmatech - 6,902,500.00 6,902,500.00

Total 17,847,856.60 24,750,356.60 /

(2) Explanation of termination of recognition in this period

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

114/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

19. Other non-current financial assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Hangzhou Qinzhi Jianyuan Venture Capital Partnership (Limited Partnership) 18,000,000.00 18,000,000.00

Total 18,000,000.00 18,000,000.00Other instructions:

None

20. Investment real estate

Investment real estate measurement model

(1) Investment real estate using cost measurement model

Unit: Yuan Currency: RMB Projects Houses and buildings Land use rights Construction in progress Total

1. Original book value

1. Opening balance 58,420,358.88 7,322,076.68 65,742,435.56 2. Increase in the current period 14,948,555.04 1,794,628.07 16,743,183.11 (1) Outsourcing 1,427,313.75 413,478.15 1,840,791.90 (2) Inventory\fixed assets\construction in progress

13,521,241.29 1,381,149.92 14,902,391.21 Transfer in

(3) Increase in business mergers

3. Reduction amount in the current period 1,945,861.32 198,763.24 2,144,624.56 (1) Disposal

(2) Other transfers 1,945,861.32 198,763.24 2,144,624.56 4. Closing balance 71,423,052.60 8,917,941.51 80,340,994.11

2. Accumulated depreciation and accumulated amortization

1. Balance at the beginning of the period 3,021,571.12 800,906.86 3,822,477.98 2. Increase in the current period 1,619,130.17 269,594.64 1,888,724.81

(1) Provision or amortization 1,619,130.17 269,594.64 1,888,724.81 3. Decrease amount in the current period 95,390.83 15,493.34 110,884.17 (1) Disposal

(2) Other transfers 95,390.83 15,493.34 110,884.17 4. Closing balance 4,545,310.46 1,055,008.16 5,600,318.62

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1) Provision

3. Reduction amount in this period

(1) Disposal

(2) Other transfer-out

4. Ending balance

4. Book value

1. Book value at the end of the period 66,877,742.14 7,862,933.35 74,740,675.49 2. Book value at the beginning of the period 55,398,787.76 6,521,169.82 61,919,957.58

(2) Investment real estate for which the title certificate has not been obtained:

□Applicable √Not applicable

115/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(3) Impairment testing of investment real estate using the cost measurement model

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

21. Fixed assets

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Fixed assets 970,728,665.42 994,456,083.70 Fixed assets liquidation -

Total 970,728,665.42 994,456,083.70Other instructions:

None

fixed assets

(1) Fixed assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB Office equipment and its

Items Houses and buildings Machinery and equipment Transportation Total

him

1. Original book value:

1. Opening balance 986,163,653.39 176,037,703.22 6,101,055.40 4,859,676.26 1,173,162,088.27 2. Increase in the current period 1,945,861.32 6,698,389.36 - 1,991,453.45 10,635,704.13 (1) Purchase 6,827,456.22 - 310,609.38 7,138,065.60 (2) Transfer of construction in progress 1,680,844.07 1,680,844.07

(3) Increase in business combination 1,945,861.32 -129,066.86 1,816,794.46 3. Decrease in current period 14,948,555.04 489,696.52 - - 15,438,251.56 (1) Disposal or scrapping 489,696.52 489,696.52

(2) Other decreases 14,948,555.04 14,948,555.04 4. Closing balance 973,160,959.67 182,246,396.06 6,101,055.40 6,851,129.71 1,168,359,540.84

2. Accumulated depreciation

1. Opening balance 37,835,626.23 71,884,512.45 4,964,162.34 3,317,740.61 118,002,041.63 2. Increase in the current period 9,422,489.72 10,509,736.38 12,143.64 168,961.40 20,113,331.14

(1) Provision 9,422,489.72 10,509,736.38 12,143.64 168,961.40 20,113,331.14 3. Decrease amount in the current period 826,807.42 361,652.87 - - 1,188,460.29 (1) Disposal or scrapping 361,652.87 361,652.87

(2) Other decreases 826,807.42 826,807.42 4. Ending balance 46,431,308.53 82,032,595.96 4,976,305.98 3,486,702.01 136,926,912.48

3. Impairment provision

1. Opening balance - 60,703,962.94 - - 60,703,962.94 2. Increase in the current period

(1) Provision

3. Reduction amount in this period

(1) Disposal or scrapping

4. Closing balance - 60,703,962.94 - - 60,703,962.94

4. Book value

1. Book value at the end of the period 926,729,651.14 39,509,837.16 1,124,749.42 3,364,427.70 970,728,665.42 2. Book value at the beginning of the period 948,328,027.16 43,449,227.83 1,136,893.06 1,541,935.65 994,456,083.70

116/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) Temporarily idle fixed assets

□Applicable √Not applicable

(3) Fixed assets leased through operating leases

□Applicable √Not applicable

(4) Fixed assets for which title certificates have not been obtained

□Applicable √Not applicable

(5) Impairment testing of fixed assets

□Applicable □Not applicable

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable √Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable √Not applicable

Reasons for the obvious inconsistency between the above information and the information used in impairment testing in previous years or external information □ Applicable √ Not applicable

Reasons for the significant inconsistency between the information used in the company's impairment testing in previous years and the actual situation of the year □ Applicable √ Not applicable

Other notes:

□Applicable √Not applicable

Fixed asset liquidation

□Applicable √Not applicable

22. Projects under construction

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Construction in progress 39,001,920.92 15,336,809.11 Engineering materials - -

Total 39,001,920.92 15,336,809.11Other instructions:

None

Construction in progress

(1) Situation of projects under construction

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Beginning balance items

Book balance Impairment provision Book value Book balance Impairment provision Book value

117/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

New factory building 37,973,252.78 37,973,252.78 10,766,069.23 - 10,766,069.23 Decoration project 1,028,668.14 1,028,668.14 4,426,111.56 - 4,426,111.56 Equipment installation - - 144,628.32 - 144,628.32 Total 39,001,920.92 39,001,920.92 15,336,809.11 - 15,336,809.11

(2) Changes in important projects under construction during the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Projects including:

Current Period Interest Current Period

Current period Cumulative Current period

Transferred capital Interest items at the beginning of the period Increase in the current period Others End of the period Investment project interest Fund budget number Fixed accumulation Capital name Balance Amount Decrease Balance accounted for in advance Progress capital source assets Accounting rate

Amount Calculation Ratio Funding

Amount Amount (%)

Example (%) Amount

Fanling biology

240,000,000 10,766,069.23 20,084,323.56 30,852,763.15 12.86 12.86 - - - Owned new factory

Total 240,000,000 10,766,069.23 20,084,323.56 30,852,763.15 / / / /

(3) Provision for impairment of projects under construction in the current period

□Applicable √Not applicable

(4) Impairment testing of projects under construction

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

Engineering supplies

□Applicable √Not applicable

23. Productive biological assets

(1) Productive biological assets using cost measurement model

□Applicable√Not applicable

(2) Impairment testing of productive biological assets using the cost measurement model

□Applicable √Not applicable

(3) Productive biological assets using fair value measurement model

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

24. Oil and gas assets

(1) Oil and gas assets

□Applicable √Not applicable

(2) Impairment testing of oil and gas assets

□Applicable √Not applicable

118/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Other notes:

None

25. Right-of-use assets

(1) Right-of-use assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Project Houses and Buildings Total

1. Original book value

1. Opening balance 9,053,063.75 9,053,063.75 2. Increase in the current period -280,654.25 -280,654.25 3. Decrease in the current period

2. Closing balance 8,772,409.50 8,772,409.50

2. Accumulated depreciation

1. Balance at the beginning of the period 1,163,955.71 1,163,955.71 2. Increase in the current period 660,859.78 660,859.78

(1) Provision 660,859.78 660,859.78 3. Decrease amount in the current period

(1)Disposal

4. Ending balance 1,824,815.49 1,824,815.49

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1)Provision

3. Reduction amount in this period

(1)Disposal

4. Ending balance

4. Book value

1. Book value at the end of the period 6,947,594.01 6,947,594.01 2. Book value at the beginning of the period 7,889,108.04 7,889,108.04

(2) Impairment testing of right-of-use assets

□Applicable √Not applicable

Other notes:

None

26. Intangible assets

(1) Intangible assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Land use rights Patent rights Non-patented technology Total

1. Original book value

1. Opening balance 146,998,313.41 146,998,313.41 2. Increase in the current period 198,763.24 198,763.24 (1) Other increases 198,763.24 198,763.24

119/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

3. Decrease amount in this period 1,794,628.07 1,794,628.07

(1) Other decreases 1,794,628.07 1,794,628.07 4. Closing balance 145,402,448.58 145,402,448.58

2. Accumulated amortization

1. Balance at the beginning of the period 10,179,467.65 10,179,467.65 2. Increase in the current period 1,485,913.20 1,485,913.20

(1) Provision 1,485,913.20 1,485,913.20 3. Decrease amount in the current period 182,288.46 182,288.46

(1) Other decreases 182,288.46 182,288.46 4. Closing balance 11,483,092.39 11,483,092.39

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1) Provision

3. Reduction amount in this period

(1)Disposal

4. Ending balance

4. Book value

1. Book value at the end of the period 133,919,356.19 133,919,356.19 2. Book value at the beginning of the period 136,818,845.76 136,818,845.76 The proportion of intangible assets formed through the company’s internal research and development at the end of the period to the balance of intangible assets is 0%

(2) Data resources recognized as intangible assets

□Applicable √Not applicable

(3) Land use rights for which property rights certificates have not been obtained

□Applicable √Not applicable

(3) Impairment testing of intangible assets

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

27. Goodwill

(1) Original book value of goodwill

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Increase in this period Decrease in this period

The name or form of the invested unit

Balance at the beginning of the period Business merger form Disposal of matters that the balance at the end of the period becomes goodwill

Made

Acquisition of Rapid Labs

14,005,013.70 - - 14,005,013.70 Limited

Total 14,005,013.70 - - 14,005,013.70

120/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) Goodwill impairment provision

√Applicable □Not applicable

Unit: Yuan Currency: RMB Name or form of invested unit Increase in this period Decrease in this period Beginning balance Ending balance

Provision and disposal of events resulting in goodwill

Acquisition of Rapid Labs

14,005,013.70 - - 14,005,013.70 Limited

Total 14,005,013.70 - - 14,005,013.70

(3) Information related to the asset group or asset group combination where the goodwill is located

□Applicable √Not applicable

Changes in asset group or asset group combination

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

(4) Specific determination method of recoverable amount

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable √Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable √Not applicable

Reasons for the obvious inconsistency between the above information and the information used in impairment testing in previous years or external information □ Applicable √ Not applicable

Reasons for the significant inconsistency between the information used in the company's impairment testing in previous years and the actual situation of the year □ Applicable √ Not applicable

(5) Performance commitments and corresponding goodwill impairment

There is a performance commitment when goodwill is formed and the reporting period or the previous period of the reporting period is within the performance commitment period □ Applicable √ Not applicable

Other instructions

□Applicable √Not applicable

28. Long-term deferred expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Beginning balance Increase in the current period Amortization amount in the current period Other decreases Ending balance Decoration project 16,490,866.54 7,067,715.95 4,320,397.18 19,238,185.31

Total 16,490,866.54 7,067,715.95 4,320,397.18 19,238,185.31Other instructions:

None

121/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

29. Deferred income tax assets/deferred income tax liabilities

(1) Deferred income tax assets without offset

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Items Deductible temporary differences Deferred income tax Deductible temporary differences Deferred income taxes

Different assets Different assets Asset impairment provision 117,520,481.94 17,428,355.55 114,201,158.54 17,136,801.38 Unrealized profits from internal transactions - - 6,600,203.54 990,030.53 Trading financial instruments, derivatives

12,145,021.00 1,821,753.15 19,809,014.00 2,971,352.10 Valuation of financial instruments

Deductible losses 17,490,444.59 3,513,910.77 13,673,825.12 2,051,073.77 Share-based payment 304,186.65 50,235.64 9,136,732.68 1,366,185.93 Deferred income 1,164,882.31 174,732.35 2,022,679.59 303,401.94 Lease liabilities 13,128,813.25 1,971,513.76 4,153,252.53 207,662.63 Total 161,753,829.74 24,960,501.22 169,596,866.00 25,026,508.28

(2) Deferred income tax liabilities without offset

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Item Taxable temporary deferred income tax Taxable temporary deferred income tax

Differences Liabilities Differences Liabilities Trading financial instruments, derivatives

21,186,261.64 3,177,939.25 18,855,581.11 2,828,337.17 Valuation of financial instruments

Right-of-use assets - - 2,975,196.13 148,759.81

Total 21,186,261.64 3,177,939.25 21,830,777.24 2,977,096.98

(3) Deferred income tax assets or liabilities presented on a net basis after offsetting

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Deferred income tax assets Deferred items after offsets Deferred income items after offsets Deferred income tax assets

Assets and liabilities are offset by each other. Taxable assets or liabilities are offset by taxable assets or liabilities.

Amount Debt balance Debt balance Deferred income tax assets 3,177,939.25 21,782,561.97 2,977,096.98 22,049,411.30 Deferred income tax liabilities 3,177,939.25 - 2,977,096.98 -

(4) Details of deferred income tax assets not recognized

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Deductible temporary differences 2,331,800.66 2,340,154.18

Deductible losses 80,992,603.73 97,437,119.48

Total 83,324,404.39 99,777,273.66

122/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(5) Deductible losses that have not been recognized as deferred income tax assets will expire in the following years

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

30. Other non-current assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Item Impairment allowance Impairment allowance

Book balance Book value Book balance Book value provision

prepaid works

11,705,845.50 - 11,705,845.50 10,658,239.89 - 10,658,239.89 and equipment payment

more than 1 year

10,470,000.00 - 10,470,000.00 10,470,000.00 - 10,470,000.00 Time deposit certificate

Total 22,175,845.50 22,175,845.50 21,128,239.89 - 21,128,239.89

Information about compensating assets

□Applicable √Not applicable

Other notes:

None

31. Assets with restricted ownership or use rights

√Applicable □Not applicable

Unit: Yuan Currency: RMB End of Period Beginning of Period

Item Book balance Book value Restricted Restricted Book balance Book value Restricted Restricted type Situation Type Situation Not possible Not monetary Redemption Redemption 6,810,900.00 6,810,900.00 Others 4,217,280.00 4,217,280.00 Others

Funds Fixed time deposits Deposits are used for guarantees guarantees guarantees guarantees others 10,470,000.00 10,470,000.00 others 10,470,000.00 10,470,000.00 others

fixed time deposit certificate

/Total 17,280,900.00 17,280,900.00 / / 14,687,280.00 14,687,280.00 /

Other notes:

None

32. Short-term borrowings

(1) Classification of short-term loans

□Applicable √Not applicable

123/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) Overdue short-term borrowings that have not been repaid

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

33. Trading financial liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Closing balance Reasons and basis for designation Foreign exchange option products 19,809,014.00 12,145,021.00 Foreign exchange option products

Total 19,809,014.00 12,145,021.00 /

Other notes:

□Applicable √Not applicable

34. Derivative financial liabilities

□Applicable √Not applicable

35. Notes payable

□Applicable √Not applicable

36. Accounts payable

(1) Presentation of accounts payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Payment for goods and labor processing 52,049,945.39 60,806,915.67 Long-term assets 26,023,190.80 53,290,512.40 Others 4,226,667.48 5,948,189.74

Total 82,299,803.67 120,045,617.81

(2) Important accounts payable that are aged more than 1 year or are overdue

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

37. Advance payments

(1) Presentation of advance receipts

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Rent and property fees 2,055,784.10 872,190.32 Total 2,055,784.10 872,190.32

124/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) Important advances from customers aged more than 1 year

□Applicable √Not applicable

(3) Amount and reasons for significant changes in book value during the reporting period

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

38. Contract liabilities

(1)Contract liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance Payment for goods 39,250,193.85 35,023,065.15

Total 39,250,193.85 35,023,065.15

(2) Important contract liabilities aged more than 1 year

□Applicable √Not applicable

(3) Amount and reasons for significant changes in book value during the reporting period

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

39. Payable to employees

(1) Presentation of employee benefits payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Short-term salary 25,194,047.15 77,293,656.39 86,920,890.81 15,566,812.73

2. Post-employment benefits-set withdrawals

873,121.10 6,078,472.73 5,954,648.36 996,945.47 plan

3. Dismissal benefits -

4. Other benefits that expire within one year

-

profit

Total 26,067,168.25 83,372,129.12 92,875,539.17 16,563,758.20

(2) Presentation of short-term remuneration

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Salaries, bonuses, allowances and

24,648,398.01 65,891,181.99 75,583,167.87 14,956,412.13 Subsidy

2. Employee welfare fees - 5,005,833.85 5,005,833.85 -

3. Social insurance premiums 523,608.62 3,709,287.18 3,639,915.22 592,980.58

125/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Including: Medical insurance premium 502,645.24 3,609,579.55 3,535,031.87 577,192.92 Work-related injury insurance premium 20,963.38 99,707.63 104,883.35 15,787.66

maternity insurance premium

4. Housing provident fund 14,832.00 2,618,430 2,622,569 10,693.00

5. Trade union funds and employee education

7,208.52 68,923.37 69,404.87 6,727.02 Funding

6. Short-term paid absences

7. Short-term profit sharing plan

Total 25,194,047.15 77,293,656.39 86,920,890.81 15,566,812.73

(3) Display of defined contribution plan

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Basic pension insurance 846,662.88 5,894,322.88 5,774,224.45 966,761.31

2. Unemployment insurance premium 26,458.22 184,149.85 180,423.91 30,184.16

3. Enterprise annuity payment -

Total 873,121.10 6,078,472.73 5,954,648.36 996,945.47

Other notes:

□Applicable √Not applicable

40. Taxes payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Corporate income tax 71,883,878.79 76,304,004.08 Real estate tax 125,203.75 3,946,099.16

Personal income tax 421,902.91 1,135,095.53

Value-added tax 167,305.97 741,848.43

Urban maintenance and construction tax 927,449.12 7,387.35

Education fee surcharge 397,478.19 3,166.01

Local education surcharge 264,985.46 2,110.67

Stamp duty 19,269.87 112,662.00

Land use tax - 803,973.50

Total 74,207,474.06 83,056,346.73Other instructions:

None

41. Other payables

(1) Project list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

Other payables 1,421,941.02 910,334.89

Total 1,421,941.02 910,334.89

126/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) Interest payable

□Applicable √Not applicable

(3) Dividends payable

□Applicable √Not applicable

(4) Other payables

Present other payables according to nature of payment

√Applicable □Not applicable

Unit: Yuan Currency: RMB items Ending balance Beginning balance Guarantee and deposit 880,305.00 - Others 541,636.02 910,334.89 Total 1,421,941.02 910,334.89

Important other payables aged more than 1 year or overdue

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

42. Liabilities held for sale

□Applicable √Not applicable

43. Non-current liabilities due within one year

√Applicable □Not applicable

Unit: Yuan Currency: RMB items Ending balance Beginning balance Lease liabilities due within one year 868,962.89 544,672.40Total 868,962.89 544,672.40Other notes:

None

44. Other current liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Closing balance Opening balance Output tax to be transferred 530,034.75 316,151.15 Total 530,034.75 316,151.15

Changes in short-term bonds payable:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

127/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

45. Long-term borrowing

(1) Classification of long-term loans

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

46. Bonds payable

(1) Bonds payable

□Applicable √Not applicable

(2) Details of bonds payable: (excluding preference shares, perpetual bonds and other financial instruments classified as financial liabilities) □ Applicable √ Not applicable

(3) Description of convertible corporate bonds

□Applicable √Not applicable

Accounting treatment and judgment basis for equity transfer

□Applicable √Not applicable

(4) Description of other financial instruments classified as financial liabilities

Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period □ Applicable √ Not applicable

Table of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period □ Applicable √ Not applicable

Explanation of the basis for classifying other financial instruments as financial liabilities

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

47. Lease liabilities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Lease liabilities 7,031,600.00 7,411,990.50 Subtotal 7,031,600.00 7,411,990.50 Less: Lease liabilities due within one year 868,962.89 544,672.40

Total 6,162,637.11 6,867,318.10Other instructions:

None

128/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

48. Long-term accounts payable

Item list

□Applicable √Not applicable

long-term payables

□Applicable √Not applicable

Special payables

□Applicable √Not applicable

49. Long-term employee benefits payable

□Applicable √Not applicable

50. Estimated liabilities

□Applicable √Not applicable

51. Deferred income

Deferred income

√Applicable □Not applicable

Unit: Yuan Currency RMB item Beginning balance Increase in the current period Decrease in the current period Ending balance Reasons for formation

Asset-related government subsidies 2,574,138.25 - 863,716.34 1,710,421.91 subsidies

Total 2,574,138.25 - 863,716.34 1,710,421.91 /

Other notes:

□Applicable √Not applicable

52. Other non-current liabilities

□Applicable √Not applicable

53. Share capital

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase or decrease due to this change (+, one) Opening balance Issuance of provident fund Ending balance bonus shares Others Subtotal

New shares Conversion

Total number of shares 79,280,855.00 - - - - - 79,280,855.00

Other notes:

None

54. Other equity instruments

(1) Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

□Applicable √Not applicable

129/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

□Applicable √Not applicable

Changes in other equity instruments during the current period, explanations of reasons for changes, and the basis for relevant accounting treatments: □ Applicable √ Not applicable

Other instructions:

□Applicable √Not applicable

55. Capital reserve

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance Capital premium (equity premium

1,669,982,786.63 - 164,284.22 1,669,818,502.41 price)

Other capital reserves 10,371,714.79 5,000,192.58 - 15,371,907.37

Total 1,680,354,501.42 5,000,192.58 164,284.22 1,685,190,409.78 Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

(1) The decrease in equity premium in the current period is mainly due to taxes and fees arising from stock repurchases.

(2) The increase in other capital reserves is mainly due to the recognition of share-based payment expenses in the current period.

56. Treasury stocks

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance Repurchase of shares 47,406,740.77 165,014,517.69 - 212,421,258.46

Total 47,406,740.77 165,014,517.69 - 212,421,258.46 Other explanations, including changes in increases and decreases in the current period and reasons for changes:

None

57. Other comprehensive income

√Applicable □Not applicable

Unit: Yuan Currency: RMB Amount incurred in the current period

Less: in the previous period Less: in the earlier period

At the beginning of the period, the income of the current period is included in other comprehensive income. Items attributable after tax. Items at the end of the period. Less: Income tax. Balance attributable after tax. Consolidated income before tax. Consolidated income is equal to minority shares. Balance expenses. Amount of the parent company. Loss transferred during the period. Transferred to shareholders during the period.

profit deposit income

1. Can’t be heavy

Classification entry and loss

Other benefits

Comprehensive income

Where: re

Measuring settings

Benefit plan

Change amount

equity method

Can't download

profit and loss

He comprehensively collects

benefit

Other rights

profit tool investment

130/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Amount incurred in this period

Less: in the previous period Less: in the earlier period

At the beginning of the period, the income of the current period is included in other comprehensive income. Items attributable after tax. Items at the end of the period. Less: Income tax. Balance attributable after tax. Consolidated income before tax. Consolidated income is equal to minority shares. Balance expenses. Amount of the parent company. Loss transferred during the period. Transferred to shareholders during the period.

profit deposit income

fair value

value change

Enterprise since

body credit style

fair value of insurance

value change

2. Divide again

Profit and loss by analogy

32,169,058.37 387,157.60 32,556,215.97 Other comprehensive

combined income

Among them: equity

transferable under law

Other comprehensive income of profit and loss 18,594.87 - 18,594.87

benefit

Other debts

equity investment company

Allowable value change

move

Financial financing

Product weight classification

Included in other

Comprehensive income

amount of

Other debts

equity investment letter

Use impairment

Prepare

cash flow

quantity hedging reserves

Prepare

foreign currency wealth

Financial statement discount 32,150,463.50 387,157.60 32,537,621.10 Calculate the difference

Other comprehensive

32,169,058.37 387,157.60 32,556,215.97 Total income

Other explanations include adjustments to the initial recognition amount of the effective portion of cash flow hedging gains and losses converted into hedged items:

None

58. Special reserves

□Applicable √Not applicable

59. Surplus reserve

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Opening balance Increase in the current period Decrease in the current period Ending balance Statutory surplus reserve 266,191,150.02 266,191,150.02 Discretionary surplus reserve - - Others - -

Total 266,191,150.02 266,191,150.02

Description of surplus reserve, including changes in increases and decreases in the current period and explanation of reasons for changes:

None

60. Undistributed profits

√Applicable □Not applicable

131/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Unit: Yuan Currency: RMB

Items Current period Last year Undistributed profits at the end of the previous period before adjustment 1,936,102,142.30 1,911,019,965.65 Total undistributed profits at the beginning of the adjustment period (Adjustment +, Decrease -) - - Undistributed profits at the beginning after adjustment 1,936,102,142.30 1,911,019,965.65 plus: net profit attributable to owners of the parent company for the current period 50,844,708.31 220,191,901.65 minus: withdrawal of statutory surplus reserve - - withdrawal of discretionary surplus reserve

Withdraw general risk reserve

Dividends payable on ordinary shares 77,016,414.00 195,109,725.00

Dividends on common shares converted into equity capital

Undistributed profits at the end of the period 1,909,930,436.61 1,936,102,142.30 Adjustment details of undistributed profits at the beginning of the period:

1. Due to the retrospective adjustment of the "Accounting Standards for Business Enterprises" and its related new regulations, the undistributed profit at the beginning of the period was affected by RMB 0.

2. Due to changes in accounting policies, the undistributed profit at the beginning of the period was affected by RMB 0.

3. Due to the correction of major accounting errors, the undistributed profit at the beginning of the period was affected by RMB 0.

4. The change in the scope of consolidation due to the same control affects the undistributed profit at the beginning of the period of 0 yuan.

5. The total impact of other adjustments on the undistributed profit at the beginning of the period is 0 yuan.

6. Operating income and operating costs

(1) Operating income and operating costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Amount for the current period Amount for the previous period

Project

Revenue Cost Revenue Cost Main business 387,545,823.81 181,491,627.07 427,835,357.31 185,245,554.12 Other business 4,599,093.87 2,462,828.28 2,014,667.44 1,680,612.07

Total 392,144,917.68 183,954,455.35 429,850,024.75 186,926,166.19

(2) Breakdown information of operating income and operating costs

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

(3) Description of performance obligations

□Applicable √Not applicable

(4) Description of allocation to remaining performance obligations

□Applicable √Not applicable

(5) Major contract changes or major transaction price adjustments

□Applicable √Not applicable

Other notes:

None

132/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

62. Taxes and surcharges

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in the current period Amount incurred in the previous period Urban maintenance and construction tax 5,609,993.64 1,783,808.06 Education surcharge 2,404,282.98 764,343.19 Local education surcharge 1,602,855.31 509,562.12 Stamp tax 127,709.62 273,311.42 Real estate tax 919,848.89 644,687.91 Land use tax 26,205.93 62,860.47

Environmental protection tax 600.00 900.00

Total 10,691,496.37 4,039,473.17Other instructions:

None

63. Sales expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Employee compensation for the previous period 15,768,325.78 16,825,909.71 Sample fee 436,197.00 652,674.42 Marketing and service fee 7,318,013.42 11,252,961.78 Exhibition fee 727,205.92 1,592,859.32 Travel and entertainment expenses 910,122.24 1,074,368.03 Office expenses 484,268.68 430,455.97 Equity incentive expenses 1,351,773.96 2,753,947.43 Others 3,568,991.56 3,853,206.55

Total 30,564,898.56 38,436,383.21Other instructions:

None

64. Management expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Amount incurred in the current period Employee compensation incurred in the previous period 16,638,895.66 14,452,639.95 Inventory scrapping 1,440,635.57 599,312.07 Intermediary agencies and service fees 2,746,209.52 3,779,700.15 Travel and entertainment expenses 1,711,157.38 4,054,147.98 Depreciation and amortization 8,770,726.69 4,129,335.21 Office expenses 4,227,015.01 3,079,764.35 Equity incentive expenses 1,108,985.52 1,991,172.84 Others 3,133,594.73 2,519,155.39

Total 39,777,220.08 34,605,227.94Other instructions:

None

133/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

65. Research and development expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in the current period Amount incurred in the previous period Employee compensation 22,778,564.68 20,537,192.02 Product testing fee 16,841,568.45 8,347,634.98 Material fee 13,362,536.81 11,163,515.38 Depreciation and amortization 2,013,679.49 1,784,160.82 Equity incentive expenses 1,832,327.46 4,409,874.32 Others 3,556,079.03 1,953,334.33

Total 60,384,755.92 48,195,711.85Other instructions:

None

66. Financial expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Amount incurred in the current period Interest expense incurred in the previous period 158,237.55 77,640.62 Less: Interest income 13,474,004.03 13,558,274.96 Exchange gains and losses 32,121,502.26 -489,862.79 Handling fees and others 854,518.72 878,112.55

Total 19,660,254.50 -13,092,384.58Other instructions:

None

67. Other income

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Classification by nature Amount incurred in the current period Amount incurred in the previous period Government subsidies 2,484,701.69 5,286,783.81 Personal tax fee refund 244,696.27 250,965.59

Total 2,729,397.96 5,537,749.40Other instructions:

None

68. Investment income

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Amount incurred in the current period Amount incurred in the previous period Long-term equity investment income calculated by equity method -327,446.21 -215,248.83 Investment income from trading financial assets during the holding period 1,184,256.32 6,299,575.28 Investment income from disposal of trading financial liabilities -6,376,392.00 -

Total -5,519,581.89 6,084,326.45

Other notes:

None

134/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

69. Net exposure hedging income

□Applicable √Not applicable

70. Income from changes in fair value

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Sources of gains from changes in fair value Amount for the current period Amount for the previous period Trading financial assets 5,681,605.16 15,103,752.70 Trading financial liabilities 7,663,993.00 720,130.00

Total 13,345,598.16 15,823,882.70Other instructions:

None

71. Income from asset disposal

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in the current period Amount incurred in the previous period Gains from disposal of right-of-use assets (losses are listed with “-”) 65,174.37 -

Total 65,174.37 -Other notes:

□Applicable √Not applicable

72. Credit impairment losses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in the current period Amount incurred in the previous period Bad debt losses on accounts receivable 2,638,662.09 -5,015,182.60 Bad debt losses on other receivables 96,607.45 18,655.16

Total 2,735,269.54 -4,996,527.44Other instructions:

None

73. Asset impairment losses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period

1. Impairment losses on contract assets - -

2. Loss on inventory depreciation and impairment loss on contract performance costs 1,006,923.80 608,005.17

3. Impairment losses on long-term equity investments - -

Total 1,006,923.80 608,005.17Other instructions:

None

74. Non-operating income

√Applicable □Not applicable

Unit: Yuan Currency: RMB Items Amount incurred in the current period Amount incurred in the previous period Included in non-recurring gains and losses for the current period

135/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The amount of total gains on disposal of non-current assets

Including: Profit from disposal of fixed assets

Gains from disposal of intangible assets

Debt restructuring gains

Gains from exchange of non-monetary assets

Donations accepted

government subsidies

Others 169,603.53 0.30 169,603.53

Total 169,603.53 0.30 169,603.53

Other notes:

□Applicable √Not applicable

75. Non-operating expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB Included in non-recurring profit and loss items for the current period Amount incurred in the current period Amount incurred in the previous period

Total amount of losses on disposal of non-current assets 16,232.60 2,712.14 16,232.60 Among them: losses on disposal of fixed assets 16,232.60 2,712.14 16,232.60

Loss on disposal of intangible assets - - - External donations 75,000.00 283,356.16 75,000.00 Others 45,706.34 187,417.17 45,706.34

Total 136,938.94 473,485.47 136,938.94Other instructions:

None

76. Income tax expenses

(1) Income tax expense schedule

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in the current period Amount incurred in the previous period Current income tax expense 3,116,966.71 23,091,649.20 Deferred income tax expense 263,796.93 -3,086,066.32

Total 3,380,763.64 20,005,582.88

(2) Adjustment process of accounting profits and income tax expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Total profits incurred in the current period 54,022,896.75 Income tax expense calculated according to statutory/applicable tax rates 9,536,219.44 Impact of different tax rates applicable to subsidiaries - Impact of adjusting income tax in previous periods - Impact of non-taxable income 31,968.43 Impact of non-deductible costs, expenses and losses 53,147.34 Impact of using deductible losses that have not been recognized as deferred income tax assets in previous periods 830,880.53

136/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The impact of deductible temporary differences or deductible losses of deferred income tax assets not recognized in the current period -638,367.41 The tax impact of the deduction of research and development fees (filled in with "-") -8,275,914.43 Others 1,439,382.40 Income tax expenses 3,380,763.64

Other notes:

□Applicable √Not applicable

77. Other comprehensive income

√Applicable □Not applicable

See notes for details

78. Cash flow statement items

(1) Cash related to operating activities

Other cash received related to operating activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Amount for the current period Current accounts and others for the previous period 10,348,948.63 1,350,079.64 Interest income 13,356,554.71 13,558,282.68 Non-operating income 3.69 0.30 Government subsidies 1,866,193.39 6,424,543.80 Guarantee deposit 353,682.00 304,000.00

Total 25,925,382.42 21,636,906.42 Description of other cash received related to operating activities:

None

Other cash paid related to operating activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Amount incurred in the current period Expenses incurred in the previous period 49,895,872.11 77,491,606.90 Non-operating expenses 120,706.34 187,417.17 Current accounts and others 5,863,295.86 1,692,328.60

Total 55,879,874.31 79,371,352.67 Description of other cash paid related to operating activities:

None

(2) Cash related to investing activities

Cash received in connection with significant investing activities

□Applicable √Not applicable

Cash payments related to significant investment activities

□Applicable √Not applicable

Other cash received related to investing activities

□Applicable √Not applicable

137/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Other cash paid related to investing activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount for the current period Amount for the previous period Payment of time deposits for investment purposes 2,766,120.00 -

Total 2,766,120.00 - Description of other cash paid related to investment activities:

None

(3) Cash related to financing activities

Other cash received related to financing activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Amount incurred in the current period Amount incurred in the previous period pledged as bank acceptance bill deposit and time deposit recovery 286,068.78 -

Total 286,068.78 - Description of other cash received related to financing activities:

None

Other cash payments related to financing activities

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Items Amount incurred in the current period Lease liability expenses paid in the previous period 533,612.95 1,342,278.99 Purchase of treasury shares 165,014,517.69 - Others 567,853.00 -

Total 166,115,983.64 1,342,278.99 Description of other cash paid related to financing activities:

None

Changes in various liabilities arising from financing activities

□Applicable √Not applicable

(4) Explanation on presenting cash flows in net amount

□Applicable √Not applicable

(5) Major activities and financial activities that do not involve current cash receipts and payments but affect the company's financial status or may affect the company's cash flow in the future.

business impact

□Applicable √Not applicable

79. Supplementary information for cash flow statement

(1) Supplementary information for cash flow statement

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Supplementary information Amount for the current period Amount for the previous period 1. Reconcile net profit to cash flow from operating activities:

Net profit 50,642,133.11 132,101,804.86

138/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Add: Asset impairment provision 1,006,923.80 608,005.17 Credit impairment loss 2,735,269.54 4,996,527.44 Depreciation of fixed assets, depreciation of oil and gas assets, depreciation of productive biological assets

21,692,512.42 14,984,686.14 old

Amortization of right-of-use assets - -

Amortization of intangible assets 1,199,606.14 695,669.45 Amortization of long-term prepaid expenses 4,358,917.47 3,381,437.94 Losses on disposal of fixed assets, intangible assets and other long-term assets (acquisition

-65,174.37 -

Please fill in the column with "-" sign)

Losses from scrapping of fixed assets (income is listed with "-") 16,232.60 2,712.14 Loss from changes in fair value (income is listed with "-") -13,345,598.16 -15,823,882.70 Financial expenses (income is listed with "-") 25,557,571.40 108,215.33 Investment losses (income is shown with "-") 5,519,581.89 -6,084,326.45 Decrease in deferred income tax assets (increases are shown with "-") 266,849.33 -3,072,716.68 Increase in deferred income tax liabilities (decreases are shown with "-") - -11,274.11 Decrease in inventory (increases are indicated by "-") -17,309,479.70 -6,893,892.49 Decrease in operating receivables (increases are indicated by "-") -6,836,002.85 -40,221,876.20 Increase in operating payables (decreases are indicated by "-") -27,554,526.20 -32,616,589.87 Others 5,000,192.58 9,199,135.78 Net cash flow from operating activities 52,885,009.00 61,353,635.75 2. Major investing and financing activities that do not involve cash receipts and payments:

debt to capital

Convertible corporate bonds due within one year

Financing leased fixed assets

3． Net changes in cash and cash equivalents:

Closing balance of cash 1,840,753,406.35 1,088,999,228.39 Less: Opening balance of cash 1,062,762,726.91 900,336,955.59 Add: Closing balance of cash equivalents

Less: Opening balance of cash equivalents

Net increase in cash and cash equivalents 777,990,679.44 188,662,272.80

(2) Net cash paid in the current period to acquire subsidiaries

□Applicable √Not applicable

(3) Net cash received from disposal of subsidiaries in the current period

□Applicable √Not applicable

(4) Composition of cash and cash equivalents

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance

1. Cash 1,840,753,406.35 1,062,762,726.91 Including: cash on hand 7,424.88 8,071.02

Bank deposits available for payment at any time 1,840,595,290.32 1,062,603,988.80

Other monetary funds available for payment at any time 150,691.15 150,667.09

2. Cash equivalents

Including: Bond investments due within three months

139/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

3. Balance of cash and cash equivalents at the end of the period 1,840,753,406.35 1,062,762,726.91

Among them: the use of the parent company or subsidiaries within the group is subject to

Restricted cash and cash equivalents

(5) Situations where the scope of use is limited but still presented as cash and cash equivalents

□Applicable √Not applicable

(6) Monetary funds other than cash and cash equivalents

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Ending balance Beginning balance Reason Deposit accrued interest 403,568.78 286,068.78 Accrued interest time deposit certificate 6,810,900.00 4,217,280.00 Time deposit certificate

Total 7,214,468.78 4,503,348.78 /

Other notes:

□Applicable √Not applicable

80. Notes on items in the statement of changes in owners’ equity

Explain the names of "other" items that were adjusted to the closing balance of the previous year and the amount of adjustment, etc.:

□Applicable √Not applicable

81. Foreign currency monetary items

(1) Foreign currency monetary items

√Applicable □Not applicable

Unit: yuan Conversion of RMB items at the end of the period Foreign currency balance at the end of the period Conversion exchange rate

Balance monetary funds

Of which: US dollars 144,499,154.71 6.8109 984,169,292.78 Euros 3,715,766.92 7.7671 28,860,733.24 British pounds 613,424.57 9.0145 5,529,715.79 Canadian dollars 15,545.44 4.7847 74,380.27 Brazilian Real 374,862.26 1.3205 495,005.61Accounts receivable

Including: USD 19,899,675.17 6.8109 135,534,697.62 EUR 544,746.33 7.7671 4,231,099.22 GBP 320,867.57 9.0145 2,892,460.71Accounts payable

Including: USD 2,543,681.74 6.8109 17,324,761.95 EUR 6,234.00 7.7671 48,420.10 GBP 289,881.12 9.0145 2,613,133.34 Other receivables

Among them: USD 120,990.13 6.8109 824,051.68 Other notes:

None

140/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) The nature of currency lack of convertibility and its financial impact, the spot exchange rate used and its estimation process, and the risks faced by the enterprise due to currency lack of convertibility

□Applicable √Not applicable

(3) Description of overseas operating entities, including for important overseas operating entities, their main overseas operating place, accounting standard currency and basis for selection should be disclosed. If the accounting standard currency changes, the reasons should also be disclosed.

√Applicable □Not applicable

Company Main place of business Accounting functional currency Accounting currency selection basis Fantian Biotech Hong Kong, China USD Main currency for business income and expenses AcesoLab United States USD Main currency for business income and expenses CitestDiag Canada USD Main currency for business income and expenses RapidLabs United Kingdom Pounds Main currency for business income and expenses ABOUNDDiag United States USD Main currency for business income and expenses RapidLabs HK Hong Kong, China US Dollar Main currency for business income and expenses Aceso Consulting Brazil Real Primary currency for business receipts and payments

(4) Lack of convertibility between the accounting functional currency of overseas operations and the enterprise’s presentation currency

□Applicable √Not applicable

82. Leasing

(1) As a lessee

√Applicable □Not applicable

Variable lease payments not included in the measurement of lease liabilities

□Applicable √Not applicable

Simplified treatment of short-term leases or lease payments for low-value assets

√Applicable □Not applicable

Unit: Yuan Currency: RMB Item Amount incurred in the current period Short-term lease expenses 1,094,732.00

Sale and leaseback transactions and basis for judgment

□Applicable √Not applicable

The total cash outflow related to leasing is 68.67 (unit: 10,000 yuan, currency: RMB)

(2) As a lessor

Operating lease as lessor

√Applicable □Not applicable

Unit: Yuan Currency: RMB Including: Variable items not included in lease receipts Lease income

Income related to lease payments House rental income 3,059,880.06 -

Total 3,059,880.06 -

Finance lease as lessor

141/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

□Applicable √Not applicable

Reconciliation of undiscounted lease receipts and net lease investment

□Applicable √Not applicable

Undiscounted lease receipts over the next five years

□Applicable √Not applicable

(3) Recognizing financial lease sales profits and losses as a manufacturer or distributor

□Applicable √Not applicable

Other instructions

None

83. Data resources

□Applicable √Not applicable

84. Others

□Applicable √Not applicable

8. R&D expenditures

1. List according to nature of expenses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in the current period Amount incurred in the previous period Employee compensation 22,778,564.68 20,537,192.02 Material expenses 13,362,536.81 8,347,634.98 Product testing expenses 16,841,568.45 11,163,515.38 Equity incentive expenses 1,832,327.46 1,784,160.82 Depreciation and amortization 2,013,679.49 4,409,874.32 Others 3,556,079.03 1,953,334.33

Total 60,384,755.92 48,195,711.85 Including: Expenditure R&D expenditure 60,384,755.92 48,195,711.85

Capitalized R&D Expenditures - -Other Notes:

None

2. Development expenditures on R&D projects that meet capitalization conditions

□Applicable √Not applicable

Significant Capitalized R&D Projects

□Applicable √Not applicable

Impairment provision for development expenditures

□Applicable √Not applicable

Other instructions

None

142/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

3. Important outsourced research projects

□Applicable √Not applicable

9. Changes in consolidation scope

1. Merger of enterprises not under common control

□Applicable √Not applicable

2. Merger of enterprises under common control

□Applicable √Not applicable

3. Reverse purchase

□Applicable √Not applicable

4. Disposal of subsidiaries

Are there any transactions or events that result in the loss of control of subsidiaries during this period?

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Is there any situation where investments in subsidiaries are disposed of step by step through multiple transactions and control is lost in the current period? Applicable √ Not applicable

Other notes:

□Applicable √Not applicable

5. Changes in the scope of consolidation due to other reasons

Explain the changes in the scope of consolidation caused by other reasons (such as the establishment of new subsidiaries, liquidation of subsidiaries, etc.) and their related situations: □ Applicable √ Not applicable

6. Others

□Applicable √Not applicable

10. Interests in other entities

1. Interests in subsidiaries

(1) Composition of enterprise groups

√Applicable □Not applicable

Unit: Yuan Currency: RMB shareholding ratio

Main business registration (%) Obtained subsidiary name Registered capital Business nature

Ground, ground, direct, indirect way

Qi Aorui Biotech under common control Hangzhou 5 million RMB Hangzhou Manufacturing 100

Business merger with Tongzhou Biotechnology Hangzhou 20 million RMB Hangzhou Manufacturing 100 Establishment

China

Fantian Biotechnology Hong Kong, China US$6.428 million Trade and investment 100 Established in Hong Kong

143/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Fanling Biotech Hangzhou USD 20 million Hangzhou Manufacturing 100 New establishment

Canada CitestDiag, a subsidiary under common control Canada 100 Canadian dollars Trade 100

Daye merged with Aokai Biotech Hangzhou 20 million RMB Hangzhou Manufacturing 100 Established Saiye Technology Hangzhou 20 million RMB Hangzhou Investment consulting 100 Established Tianyu Biotech Jiaxing 5 million RMB Jiaxing Manufacturing 100 Established

manufacturing and

AcesoLab United States $1 million United States 100 Established

trade

Yingxin Medical Jiaxing 10 million RMB Jiaxing Manufacturing 100 Establishment

manufacturing and

Yinghai Medical Jiaxing US$30 million Jiaxing 100 Establishment services

Not under common control RapidLabs UK £300 UK Trading 97

business combination

UM

ACESO PTY Australia 1 million USD Trading 100 Establishment

Leah

AUSTRALI Australian University

Australia $100 Trade 100 Set Up A ALLTEST Leah

ABOUNDDi Trade Kimono

United States 1 million US dollars United States 80 Establish ag business

RapidLabs H China

Hong Kong, China USD 10,000 Trade 100 Establishment K Hong Kong

VIDAQUIC Spanish

Spain €3000 Trade 100 Establishment of K S.L.

Aceso

Brazil BRL 570,000 Brazil Business Consulting 100 Establishment Consulting

ALLTEST

UK 1 GBP UK Trade 100 Establish UK

Supply chain management

Jiesuda Hangzhou 1 million RMB Hangzhou 100 Establishment

reason

Explanation on the difference between the proportion of shareholding in subsidiaries and the proportion of voting rights:

None

Basis for holding half or less of the voting rights but still controlling the invested unit, and holding more than half of the voting rights but not controlling the invested unit:

None

For important structured entities included in the scope of consolidation, the basis for control is:

None

Basis for determining whether a company is agent or principal:

None

Other notes:

None

(2) Important non-wholly owned subsidiaries

□Applicable √Not applicable

144/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(3) Main financial information of important non-wholly owned subsidiaries

□Applicable √Not applicable

(4) Significant restrictions on the use of enterprise group assets and settlement of enterprise group debts: □ Applicable √ Not applicable

(5) Financial support or other support provided to structured entities included in the scope of consolidated financial statements: □ Applicable √ Not applicable

Other notes:

□Applicable √Not applicable

2. Transactions in which the ownership share of the subsidiary changes and the subsidiary is still controlled □Applicable √Not applicable

3. Interests in joint ventures or associated enterprises

√Applicable □Not applicable

(1) Important joint ventures or associates

□Applicable √Not applicable

(2) Main financial information of important joint ventures

□Applicable √Not applicable

(3) Main financial information of important associates

□Applicable √Not applicable

(4) Summary financial information of unimportant joint ventures and associates □ Applicable √ Not applicable

(5) Explanation of significant restrictions on the ability of joint ventures or associates to transfer funds to the company □ Applicable √ Not applicable

(6) Excess losses incurred by joint ventures or associates

□Applicable √Not applicable

(7) Unconfirmed commitments related to investment in joint ventures

□Applicable √Not applicable

(8) Contingent liabilities related to investments in joint ventures or associates □ Applicable √ Not applicable

4. Important joint operations

□Applicable √Not applicable

5. Interests in structured entities that are not included in the scope of consolidated financial statements. Relevant instructions for structured entities that are not included in the scope of consolidated financial statements:

145/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

□Applicable √Not applicable

6. Others

□Applicable √Not applicable

11. Government subsidies

1. Government subsidies recognized according to the amount receivable at the end of the reporting period

□Applicable √Not applicable

Reasons for failure to receive the estimated amount of government subsidy at the estimated time

□Applicable √Not applicable

2. Liability items involving government subsidies

□Applicable √Not applicable

3. Government subsidies included in current profits and losses

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Type Amount for the current period Amount for the previous period related to assets 863,716.34 2,862,627.58 Related to income 1,620,985.35 2,424,156.23

Total 2,484,701.69 5,286,783.81

Other notes:

None

12. Risks related to financial instruments

1. Risks of financial instruments

√Applicable □Not applicable

The company's main financial instruments include monetary funds, notes receivable, accounts receivable, other receivables, other current assets, trading financial assets, other equity instrument investments, other non-current financial assets, accounts payable, other payables, trading financial liabilities, non-current liabilities due within one year and lease liabilities. Details of each financial instrument have been disclosed in the relevant notes. The risks associated with these financial instruments, and the risk management policies adopted by the Company to mitigate these risks, are described below. The company's management manages and monitors these risk exposures to ensure that the above risks are controlled within limited limits.

1. Risk management objectives and policies

The main risks caused by the company's financial instruments are credit risk, liquidity risk, and market risk (including exchange rate risk, interest rate risk, and commodity price risk).

The Company's overall risk management program addresses the unpredictability of financial markets and seeks to reduce potential adverse effects on the Company's financial performance.

The Company has formulated risk management policies to identify and analyze the risks faced by the Company, set appropriate risk acceptance levels and design corresponding internal control procedures to monitor the Company's risk levels. The company will regularly re-evaluate these risk management policies and related internal control systems to adapt to changes in market conditions or the company's operating activities. The internal audit department also regularly and irregularly checks whether the implementation of the internal control system complies with the risk management policy.

146/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The company diversifies financial instrument risks through appropriate diversification of investments and business portfolios, and reduces risks concentrated in a single industry, specific region or specific counterparty by formulating corresponding risk management policies.

(1) Credit risk

Credit risk refers to the risk that the counterparty fails to perform its contractual obligations, causing the company to suffer financial losses.

The company manages credit risks by portfolio classification. Credit risk mainly arises from bank deposits, accounts receivable, other receivables, etc.

The company's bank deposits are mainly deposited in financial institutions with good reputations and high credit ratings. The company expects that there will be no significant credit risk in bank deposits.

For notes receivable, accounts receivable and other receivables, the company sets relevant policies to control credit risk exposure. The company evaluates the customer's credit qualifications and sets corresponding credit periods based on the customer's financial status, credit history and other factors such as current market conditions. The company will regularly monitor customer credit records. For customers with poor credit records, the company will use written reminders, shorten the credit period or cancel the credit period to ensure that the company's overall credit risk is within a controllable range.

The debtors of the company's accounts receivable are customers located in different industries and regions. The company continues to conduct credit assessments on the financial status of accounts receivable and purchases credit guarantee insurance when appropriate.

A company's maximum exposure to credit risk is the carrying amount of each financial asset on its balance sheet. The Company has not provided any other guarantees that may expose the Company to credit risk.

Among the company's accounts receivable, the accounts receivable of the top five customers accounted for 28.82% of the company's total accounts receivable (2025: 29.77%); among the company's other receivables, the other receivables of the top five companies in arrears accounted for 81.96% of the company's total other receivables (2024: 83.56%).

(2) Liquidity risk

Liquidity risk refers to the risk that a company encounters a shortage of funds when fulfilling its obligations to settle in cash or other financial assets. When managing liquidity risk, the Company maintains and monitors cash and cash equivalents that management considers sufficient to meet the Company's operating needs and reduce the impact of cash flow fluctuations. Company management monitors the use of bank borrowings and ensures compliance with borrowing agreements. At the same time, obtain commitments from major financial institutions to provide sufficient backup funds to meet short-term and long-term funding needs. The company raises working capital through funds generated from operating operations and bank and other borrowings.

At the end of the reporting period, the financial liabilities and off-balance sheet guarantee items held by the company are analyzed based on the maturity period of the undiscounted remaining contract cash flows as follows (unit: 10,000 yuan):

Ending balance

Project

Within one year Within one to five years More than five years Total financial liabilities:

Trading financial liabilities 1,214.50 1,214.50Accounts payable 8,229.98 8,229.98Other payables 142.19 142.19Non-current liabilities due within one year 86.90 86.90Other current liabilities (excluding deferred income) 53.00 53.00

147/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Ending balance

Project

Within one year Within one to five years More than five years Total lease liabilities 616.26 616.26 Total financial liabilities and contingent liabilities 9,726.58 616.26 - 10,342.84

At the end of last year, the financial liabilities and off-balance sheet guarantee items held by the company were analyzed based on the maturity period of the undiscounted remaining contract cash flows as follows (unit: 10,000 yuan):

Ending balance

Project

Within one year Within one to five years More than five years Total financial liabilities:

Trading financial liabilities 1,980.90 1,980.90 Accounts payable 12,004.56 12,004.56 Other payables 91.03 91.03 Non-current liabilities due within one year 54.47 54.47 Other current liabilities (excluding deferred income) 31.62 31.62 Lease liabilities 686.73 686.73 Total financial liabilities and contingent liabilities 14,162.58 686.73 - 14,849.31

The amounts of financial liabilities disclosed in the table above represent undiscounted contractual cash flows and therefore may differ from the carrying amounts in the balance sheet.

The maximum guarantee amount of a signed guarantee contract does not represent the amount to be paid.

(3) Market risk

Market risk of financial instruments refers to the risk that the fair value or future cash flows of financial instruments fluctuate due to market price changes, including interest rate risk, exchange rate risk and other price risks.

interest rate risk

Interest rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market interest rates. Interest rate risk can arise from both recognized interest-bearing financial instruments and unrecognized financial instruments (such as certain loan commitments).

For financial instruments held on the balance sheet date that expose the company to fair value interest rate risk, the impact on net profit and shareholders' equity in the above sensitivity analysis is the impact after assuming that interest rates change on the balance sheet date and the above financial instruments are remeasured according to the new interest rate. For floating rate non-derivative instruments held on the balance sheet date that expose the company to cash flow interest rate risk, the impact on net profit and shareholders' equity in the above sensitivity analysis is the impact of the above interest rate changes on annual estimated interest expenses or income. The previous year's analysis was based on the same assumptions and methodology.

Exchange rate risk

Exchange rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in foreign exchange rates. Exchange rate risk can arise from financial instruments denominated in foreign currencies other than the functional currency of accounting.

148/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

The company's main customers are located outside China. The company's confirmed foreign currency assets and liabilities and future foreign currency transactions (the denominated currencies of foreign currency assets and liabilities and foreign currency transactions are mainly US dollars, euros, pounds, Canadian dollars, etc.) still have foreign exchange risks. At the end of the reporting period, the amounts of foreign currency financial assets and foreign currency financial liabilities held by the company converted into RMB are listed in Note 5, 56 (1) Foreign currency monetary items.

The company continues to monitor the scale of the group's foreign currency transactions and foreign currency assets and liabilities to minimize the foreign exchange risks it faces; to this end, the company may sign forward foreign exchange contracts or currency swap contracts to avoid foreign exchange risks. At the end of the reporting period, for the company's monetary funds, accounts receivable, other receivables, accounts payable, and other payables denominated in foreign currencies, assuming that the RMB appreciates or depreciates by 10% against foreign currencies (mainly against the U.S. dollar and the euro), and other factors remain unchanged, the company's shareholders' equity and net profit will both increase or decrease by approximately 114.0977 million yuan (the end of the previous year: approximately 83.7447 million yuan).

2. Capital management

The goal of the company's capital management policy is to ensure that the company can continue to operate, thereby providing returns to shareholders and benefiting other stakeholders, while maintaining an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the company may adjust its financing methods, adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares and other equity instruments, or sell assets to reduce debt.

The company monitors its capital structure based on the gearing ratio (that is, total liabilities divided by total assets). At the end of the reporting period, the company's asset-liability ratio was 5.93% (at the end of the previous year: 6.98%).

2. Hedging

(1) The company carries out hedging business for risk management

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

(2) The company carries out qualified hedging business and applies hedging accounting

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

(3) The company carries out hedging business for risk management and expects to achieve risk management objectives but does not apply hedging accounting

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

3. Transfer of financial assets

(1) Classification of transfer methods

□Applicable √Not applicable

(2) Financial assets derecognized due to transfer

□Applicable √Not applicable

149/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(3) Transferred financial assets with continued involvement

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

13. Disclosure of fair value

1. Closing fair value of assets and liabilities measured at fair value

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing fair value

Item Level 1 Fair Price Level 2 Fair Price Level 3 Fair Price

total

value measurement value measurement value measurement

1. Continuous fair value measurement

(1) Trading financial assets 276,186,261.64 276,186,261.64 1. Measured at fair value with changes

276,186,261.64 276,186,261.64 Financial assets included in current profits and losses

(1) Financial products 226,152,700.00 226,152,700.00 (2) Structured deposits 50,033,561.64 50,033,561.64

(2) Other debt investments

(3) Investment in other equity instruments 24,750,356.60 24,750,356.60

(4) Other non-current financial assets 18,000,000.00 18,000,000.00 Assets continuously measured at fair value

276,186,261.64 42,750,356.60 318,936,618.24 Total output

(5) Trading financial liabilities 12,145,021.00 12,145,021.00 1. Measured at fair value with changes

12,145,021.00 12,145,021.00 Financial liabilities included in current profits and losses

Including: foreign exchange options 12,145,021.00 12,145,021.00 Negative liabilities continuously measured at fair value

12,145,021.00 12,145,021.00 Total debt

2. Basis for determining the market price of continuous and non-continuous first-level fair value measurement items

√Applicable □Not applicable

A quoted price (unadjusted) in an active market for identical assets or liabilities.

3. Continuous and non-continuous second-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters √ Applicable □ Not applicable

The use of observable inputs other than quoted market prices for the asset or liability within Level 1, either directly (that is, as prices) or indirectly (that is, as derived from prices).

4. Continuous and non-continuous third-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters √ Applicable □ Not applicable

The asset or liability uses any inputs that are not based on observable market data (unobservable inputs).

5. For ongoing third-level fair value measurement items, the reconciliation information and unobservable parameters between the opening and closing book values are sensitive

sexual analysis

□Applicable √Not applicable

150/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

6. For ongoing fair value measurement items, if there is a conversion between levels during the current period, the reasons for the conversion and the policy for determining the time of conversion.

policy

□Applicable √Not applicable

7. Valuation technology changes and reasons for changes during the period

□Applicable √Not applicable

8. Fair value of financial assets and financial liabilities not measured at fair value

□Applicable √Not applicable

9. Others

□Applicable √Not applicable

14. Related parties and related transactions

1. Information about the parent company of this enterprise

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB

Parent company's name, registered place, nature of business, registered capital, shareholding of the enterprise, voting of the enterprise

Proportion (%) Rights Proportion (%) Hangzhou Jingguan Investment Xiasha, Qiantang District, Hangzhou City, Zhejiang Province

Investment Management Co., Ltd. 2, East District, Wanjing Lakeside Center, Sub-district Investment Management 1,249.50 23.33 23.33 Room 402, Company Building

Hangzhou Qunze Investment

Wanjing, Qiantang District, Hangzhou City, Zhejiang Province

Asset Management Co., Ltd. Investment Management 1,015.00 18.95 18.95

Room 402, Building 2, East District, Lakeside Center

company

Description of the parent company of this enterprise

The company has no related transactions with its parent company

The ultimate controlling parties of this enterprise are Gao Fei and Zhao Huafang

Other notes:

Jingguan Investment is a company controlled by the actual controller Zhao Huafang; Qunze Investment and Saida Investment are companies controlled by the actual controller Gao Fei. Gao Fei directly holds 7.84% of the company's shares, indirectly controls 18.95% of the company's shares through Qunze Investment, indirectly controls 2.64% of the company's shares through Saida Investment, and controls a total of 29.43% of the company's shares; Zhao Huafang indirectly controls 23.33% of the company's shares through Jingguan Investment, and the two control a total of 52.76% of the company's shares through direct and indirect means.

2. Information about the company’s subsidiaries

Please refer to the notes for details of the company’s subsidiaries.

√Applicable □Not applicable

For details on subsidiaries, please refer to (1) "Construction of Enterprise Groups" in X. "Equity in Other Entities".

3. Information about the company’s joint ventures and associated enterprises

Please refer to the notes for details of important joint ventures or associates of this company.

□Applicable √Not applicable

The details of other joint ventures or associates that have related party transactions with the company in the current period, or have balances from related party transactions with the company in previous periods are as follows:

□Applicable √Not applicable

151/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

4. Other related parties

√Applicable □Not applicable

Names of other related parties Relationship between other related parties and the company Xu Jianming Shareholder Hangzhou Hongtai Biotechnology Co., Ltd. Others

Hangzhou Ruichi Biotechnology Co., Ltd. Others

Hangzhou Yile Biotechnology Co., Ltd. Others

Hangzhou Saichuang Equity Investment Partnership (Limited Partnership) Others

Hangzhou Yingjian Biotechnology Co., Ltd. Others

Hangzhou Visbo Medical Technology Co., Ltd. Others

Other instructions

None

5. Related transactions

(1) Related transactions related to the purchase and sale of goods, provision and receipt of services

Procurement of goods/service acceptance form

√Applicable □Not applicable

Unit: Yuan Currency: RMB related-party transactions Approved transaction amount exceeds the amount of related parties in the current period The amount of the previous period

Tolerance (if applicable) Amount (if applicable) Yile Biotechnology Processing fee 814,216.00 5 million No 2,041,751.80 Ruichi Biotechnology Processing fee 1,067,422.00 5 million No 1,943,999.64 Hongtai Biotechnology Raw materials 1,551,380.38 4 million No 1,997,352.06 Yingjian Biological Raw Materials 69,831.70 10 million No 267,261.04

List of goods sold/services provided

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Related parties Contents of related transactions Amount incurred in the current period Amount incurred in the previous period Yile Biotech Sales of goods 1,668,847.39 13,671,546.02 Ruichi Biotech Sales of goods 27,185.84 62,744.27

Description of related transactions for purchasing and selling goods, providing and receiving services

□Applicable √Not applicable

(2) Related entrusted management/contracting and entrusted management/outsourcing situation

The company's entrusted management/contracting status table:

□Applicable √Not applicable

Description of associated hosting/contracting situations

□Applicable √Not applicable

The company’s entrusted management/outsourcing status table:

□Applicable √Not applicable

Description of association management/outsourcing situation

□Applicable √Not applicable

152/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(3) Related lease situation

As a lessor, our company:

√Applicable □Not applicable

Unit: Yuan Currency: RMB Lessee Name Type of leased assets Lease income recognized in the current period Lease income recognized in the previous period

Yingjian Biological Real Estate 144,344.04 144,344.04

As a lessee, our company:

□Applicable √Not applicable

Description of related leasing situation

□Applicable √Not applicable

(4) Related guarantees

The company acts as a guarantor

□Applicable √Not applicable

The company as the guaranteed party

□Applicable √Not applicable

Description of related guarantees

□Applicable √Not applicable

(5) Fund lending from related parties

□Applicable √Not applicable

(6) Asset transfer and debt restructuring of related parties

□Applicable √Not applicable

(7) Remuneration of key management personnel

√Applicable □Not applicable

Unit: 10,000 yuan Currency: RMB

Item Amount for the current period Amount for the previous period Remuneration of key management personnel 119.74 132.58

(8) Other related transactions

□Applicable √Not applicable

6. Unsettled items such as receivables and payables to related parties

(1) Items receivable

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance Item name Related parties

Book balance Bad debt provision Book balance Bad debt provision Accounts receivable Yile Biotech 4,685,183.07 785,447.77 7,842,254.21 448,093.53 Other receivables Yingjian Biotech 574,061.90 28,703.10 507,485.28 35,769.86

153/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) Items payable

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Project name Related party Book balance at the end of the period Book balance at the beginning of the period Accounts payable Yile Biotechnology 187,845.68 243,789.04 Accounts payable Ruichi Biotechnology 242,538.12 250,579.78 Accounts payable Hongtai Biotechnology 524,483.30 217,818.26 Accounts payable Yingjian Biotechnology 16,831.70 -

(3) Other items

□Applicable √Not applicable

7. Related party commitments

□Applicable √Not applicable

8. Others

□Applicable √Not applicable

15. Share-based payment

1. Various equity instruments

(1) Details

□Applicable √Not applicable

(2) Stock options or other equity instruments outstanding at the end of the period

□Applicable √Not applicable

2. Equity-settled share-based payment

√Applicable □Not applicable

Unit: Yuan Currency: RMB Equity-settled share-based payment objects Corporate employees

Method for determining the fair value of equity instruments on the date of grant. Important parameters of the second type of restricted stock-BS model fair value of equity instruments on the date of grant: stock closing price, historical volatility, annualized risk-free profit

The basis for determining the number of exercisable equity instruments such as interest rate, dividend yield, grant price, etc. The equity instruments corresponding to the in-service incentive objects, the company level of the assessment year, and the individual level of the incentive objects are assessed simultaneously

Make your best estimate after reaching the target

Reasons for significant differences between the current period’s estimate and the previous period’s estimate None

The cumulative amount of equity-settled share-based payments included in capital reserves 5,000,192.58 Other notes

None

3. Share-based payment settled in cash

□Applicable √Not applicable

4. Share-based payment expenses for this period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

154/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Category of grant objects Equity-settled share-based payment expenses Cash-settled share-based payment expenses R&D personnel 2,150,263.44 - Sales personnel 1,351,773.96 - Management personnel 791,049.54 - Production personnel 707,105.64 -

Total 5,000,192.58 -

Other instructions

None

5. Modification and termination of share-based payment

□Applicable √Not applicable

6. Others

□Applicable √Not applicable

16. Commitments and contingencies

1. Important commitments

□Applicable √Not applicable

2. Contingencies

(1) Important contingencies existing on the balance sheet date

□Applicable √Not applicable

(2) If the company has no important contingencies that need to be disclosed, it should also explain:

□Applicable √Not applicable

3. Others

□Applicable √Not applicable

17. Events after the balance sheet date

1. Important non-adjustment matters

□Applicable √Not applicable

2. Profit distribution

√Applicable □Not applicable

Unit: Yuan Currency: RMB Profit or dividend to be distributed 0 Profit or dividend declared to be distributed after review and approval 0

3. Sales returns

□Applicable √Not applicable

4. Description of other post-balance sheet events

□Applicable √Not applicable

155/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

18. Other important matters

19. Correction of previous accounting errors

(1) Retrospective restatement method

□Applicable √Not applicable

(2) Prospective applicable law

□Applicable √Not applicable

2. Important debt restructuring

□Applicable √Not applicable

3. Asset replacement

(1) Non-monetary asset exchange □ Applicable √ Not applicable

(2) Other asset swaps

□Applicable √Not applicable

4. Annuity plan

□Applicable √Not applicable

5. Termination of operations

□Applicable √Not applicable

6. Branch information

(1) Determination basis and accounting policies of reporting segments □ Applicable √ Not applicable

(2) Financial information of reportable segments □ Applicable √ Not applicable

(3) If the company has no reportable segments, or cannot disclose the total assets and total liabilities of each reportable segment, the reasons should be stated □Applicable √Not applicable

(4) Other instructions

□Applicable √Not applicable

7. Other important transactions and matters that have an impact on investors’ decision-making □Applicable √Not applicable

8. Others

□Applicable √Not applicable

156/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

19. Notes on main items of the parent company’s financial statements

1. Accounts receivable

(1) Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Aging Book balance at the end of the period Book balance at the beginning of the period Within 1 year (including 1 year) 288,502,175.78 205,799,219.04 1 to 2 years 20,399,410.93 67,399,330.33 2 to 3 years 9,939,051.17 41,181,785.84 More than 3 years 6,750,297.18 3,714,612.66

Total 325,590,935.06 318,094,947.87

(2) Classified disclosure based on bad debt accrual method

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Ending balance Beginning balance

Category Book balance Bad debt provision Book Book balance Bad debt provision Book amount Proportion Amount Provision ratio Value Amount Proportion Amount Provision ratio Value

(%) Example(%) (%) Example(%)

Bad provision based on individual items

1,137,006.20 0.66 1,137,006.20 100.00 - 1,173,382.25 0.37 1,173,382.25 100.00 -Account provision

Among them:

Foreign customers 1,137,006.20 0.66 1,137,006.20 100.00 - 1,173,382.25 0.37 1,173,382.25 100.00 - Provision for bad debts on a portfolio basis

324,453,928.86 100.00 22,439,438.47 30.17 302,014,490.39 316,921,565.62 99.63 19,897,742.95 6.28 297,023,822.67Account preparation

Among them:

Foreign customers 113,191,102.24 34.89 20,510,757.54 18.12 92,680,344.70 135,691,305.78 42.66 19,117,298.43 14.09 116,574,007.35 Domestic customers 16,002,077.28 4.93 1,928,680.93 12.05 14,073,396.35 13,445,094.33 4.23 780,444.52 5.80 12,664,649.81Within the consolidated scope

195,260,749.34 60.18 - - 195,260,749.34 167,785,165.51 52.74 - - 167,785,165.51 Related parties

Total 325,590,935.06 / 23,576,444.67 / 302,014,490.39 318,094,947.87 / 21,071,125.20 / 297,023,822.67

Provision for bad debts is made individually:

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion of provision (%) Reason for provision Other non-important individual items

1,137,006.20 1,137,006.20 100.00 It is expected that the account cannot be collected

Total 1,137,006.20 1,137,006.20 100.00 /

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

√Applicable □Not applicable

Combined accrual items: foreign customers

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Ratio of provision (%) Within 1 year 85,761,444.09 3,584,828.36 4.18 1 to 2 years 12,297,150.11 4,390,082.59 35.70 2 to 3 years 8,427,982.62 5,831,321.17 69.19 More than 3 years 6,704,525.42 6,704,525.42 100.00

157/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Total 113,191,102.24 20,510,757.54 18.12 Instructions on the provision of bad debt provisions by group:

□Applicable √Not applicable

Combined accrual items: domestic customers

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion of provision (%) Within 1 year 6,342,976.15 317,148.81 5.00 1 to 2 years 8,102,260.82 810,226.08 10.00 2 to 3 years 1,511,068.55 755,534.28 50.00 More than 3 years 45,771.76 45,771.76 100.00

Total 16,002,077.28 1,928,680.93 12.05 Instructions on the provision of bad debt provisions by group:

□Applicable √Not applicable

Combined accrual items: Related parties within the scope of consolidation

Unit: Yuan Currency: RMB Closing balance

Name

Book balance Bad debt provision Proportion of provision (%) Within 1 year 85,070,788.06 - - 1 to 2 years 56,425,947.51 - - 2 to 3 years 40,091,340.32 - - More than 3 years 13,672,673.45 - -

Total 195,260,749.34 - -Explanation of provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

Basis for division of each stage and provision ratio for bad debts

Not applicable

Explanation of significant changes in the book balance of accounts receivable that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

(3) Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Opening balance Recovery or write-off or approval Other changes Ending balance accrual

Turn back pin

Accounts receivable

21,071,125.20 2,522,722.98 17,403.51 23,576,444.67 Bad debt provision

Total 21,071,125.20 2,522,722.98 17,403.51 23,576,444.67

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable √Not applicable

158/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Other instructions

None

(4) Accounts receivable actually written off in the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Write-off Amount

Accounts receivable actually written off 17,403.51

Among them, the important write-off of accounts receivable

□Applicable √Not applicable

Instructions for writing off accounts receivable:

□Applicable √Not applicable

(5) Accounts receivable and contract assets of the top five ending balances by debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB in accounts receivable

Accounts receivable and contract assets

Accounts receivable at the end of the period Contract asset period Bad debt provision at the end of the period Unit name Same assets at the end of the period Total balance at the end of the period

Balance Ending Balance Balance Amount Count Ratio

(%)

First place 18,928,330.34 18,928,330.34 5.81 6,498,533.65 Second place 12,750,459.36 12,750,459.36 3.92 2,710,903.37 Third place 8,230,756.27 8,230,756.27 2.53 344,045.61 Fourth place 4,743,795.05 4,743,795.05 1.46 198,290.63 Fifth place 4,685,183.07 4,685,183.07 1.44 785,447.77

Total 49,338,524.09 49,338,524.09 15.15 10,537,221.03Other instructions

None

Other notes:

□Applicable √Not applicable

2. Other receivables

Item list

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Closing balance Opening balance Other receivables 859,904,434.30 804,199,211.82

Total 859,904,434.30 804,199,211.82

Other notes:

□Applicable √Not applicable

159/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

interest receivable

(1) Classification of interest receivable

□Applicable √Not applicable

(2) Important overdue interest

□Applicable √Not applicable

(3) Classified disclosure according to bad debt accrual method □Applicable √Not applicable

Provision for bad debts on an individual basis: □ Applicable √ Not applicable

Explanation on the provision of bad debt provisions by individual items: □ Applicable √ Not applicable

Provision for bad debts by combination: □ Applicable √ Not applicable

Provision for bad debts based on the general expected credit loss model □ Applicable √ Not applicable

(4) Bad debt provision □Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(5) Interest receivable actually written off in the current period □ Applicable √ Not applicable

Among them, the important write-off of interest receivable □ Applicable √ Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Dividends receivable

(1) Dividends receivable

□Applicable √Not applicable

(2) Important dividends receivable aged more than 1 year □ Applicable √ Not applicable

160/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(3) Classified disclosure based on bad debt accrual method

□Applicable √Not applicable

Provision for bad debts is made individually:

□Applicable √Not applicable

Instructions on accruing bad debt provisions individually:

□Applicable √Not applicable

Provision for bad debts by group:

□Applicable √Not applicable

Provision for bad debts based on the general expected credit loss model

□Applicable √Not applicable

(4) Bad debt provisions

□Applicable √Not applicable

Among them, the amount of bad debt provision recovery or reversal in the current period is important: □ Applicable √ Not applicable

Other notes:

None

(5) Dividends receivable actually written off in the current period

□Applicable √Not applicable

Among them, the important write-off of dividends receivable

□Applicable √Not applicable

Write-off instructions:

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

Other receivables

(1) Disclosure based on aging

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Aging Book balance at the end of the period Book balance at the beginning of the period Within 1 year (including 1 year) 150,227,402.27 209,830,229.85 1 to 2 years 196,797,687.36 148,722,070.77 2 to 3 years 371,799,684.79 322,174,047.12 More than 3 years 141,361,472.21 123,712,253.21 Total 860,186,246.63 804,438,600.95

161/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

(2) Classification by nature of payment

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Nature of payment Book balance at the end of the period Book balance at the beginning of the period Related parties within the scope of consolidation 854,550,000.00 800,551,751.50 Rent and collection 4,544,732.18 3,094,937.45 Security deposit and deposit 205,438.00 397,438.00 Others 886,076.45 394,474.00

Total 860,186,246.63 804,438,600.95

(3) Bad debt provision accrual

√Applicable □Not applicable

Unit: Yuan Currency: RMB Phase 1 Phase 2 Phase 3

Lifetime expectations letter Lifetime forecast letter

Provision for bad debts Total expected losses in the next 12 months (credit losses that have not occurred (credit losses that have occurred)

period credit losses

Use impairment) Use impairment)

January 1, 2026

239,389.13 239,389.13 amount

January 1, 2026

239,389.13 239,389.13 amount in this period

--Transfer to the second stage

--Transfer to the third stage

--Return to the second stage

--Return to the first stage

Provision in this period 42,423.20 42,423.20 Transferred in this period

Sales in this period

Write-off in this period

Other changes

June 30, 2026

281,812.33 281,812.33 amount

Basis for division of each stage and provision ratio for bad debts

Not applicable

Explanation of significant changes in the book balance of other receivables that have experienced changes in loss provisions during the current period:

□Applicable √Not applicable

The amount of bad debt provision for the current period and the basis for assessing whether the credit risk of financial instruments has increased significantly:

□Applicable √Not applicable

(4) Bad debt provisions

√Applicable □Not applicable

Unit: Yuan Currency: RMB Change amount in the current period

Category Beginning Balance Ending Balance

Provision Write-off or write-off Other changes

Other receivables

239,389.13 42,423.20 281,812.33 Bad debt provision

162/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Total 239,389.13 42,423.20 281,812.33 Among them, the amount of bad debt provision for the current period that is reversed or recovered is important:

□Applicable √Not applicable

Other instructions

None

(5) Other receivables actually written off in the current period

□Applicable √Not applicable

Important write-offs of other receivables:

□Applicable √Not applicable

Instructions for writing off other receivables:

□Applicable √Not applicable

(6) Other receivables with top five closing balances based on debtors

√Applicable □Not applicable

Unit: Yuan Currency: RMB as a share of other receivables at the end of the period

Name of the bad debt provision unit of the payment Ending balance Proportion of total balance Aging

Nature Closing balance (%)

Within 1 year; 1-2 years; Aokai Biotechnology 526,350,000 61.19 Current account - 2-3 years; more than 3 years

Within 1 year; 1-2 years; Tongzhou Biotech 148,500,000 17.26 Current account - 2-3 years; more than 3 years

Within 1 year; 1-2 years; Saiye Technology 93,000,000 10.81 Current account - more than 3 years

Within 1 year; 1-2 years; Yinghai Medical 86,700,000 10.08 Current funds - 2-3 years; more than 3 years

Rent and agency

Shuguang Technology 3,845,689.58 0.45 Within 1 year; 1-2 years 192,284.48 Receipt

Total 858,395,689.58 99.79 / / 192,284.48

(7) Presented in other receivables due to centralized management of funds

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

163/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

3. Long-term equity investment

√Applicable □Not applicable

Unit: Yuan Currency: RMB Closing balance Opening balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Investment in subsidiaries 110,111,655.16 110,111,655.16 109,297,700.14 109,297,700.14 Investment in associates and joint ventures 21,068,308.34 21,068,308.34 21,224,269.55 21,224,269.55

Total 131,179,963.50 131,179,963.50 130,521,969.69 130,521,969.69

(1) Investment in subsidiaries

√Applicable □Not applicable

Unit: Yuan Currency: RMB Increase or decrease in the current period

The opening balance (book impairment provision at the beginning of the period) and the ending balance (book impairment provision at the end of the period) of the invested unit.

Value) Balance Additional investment Decrease investment Others Value) Balance

Prepare

Mortal Creatures 37,191,625.66 - 37,191,625.66 - Tongzhou Creatures 22,554,983.67 153,269.34 22,708,253.01 - Aokai Creatures 21,232,130.39 437,647.14 21,669,777.53 -Saiye Technology 20,000,000.00 20,000,000.00 -Aorui Biotech 7,104,255.81 174,125.34 7,278,381.15 -Hangzhou Jiesuda 1,000,000.00 - 1,000,000.00 - Yinghai Medical 148,903.75 - 148,903.75 - Tianyu Biotechnology 22,561.18 - 22,561.18 - Yingxin Medical 43,239.68 48,913.20 92,152.88 -

Total 109,297,700.14 813,955.02 110,111,655.16 -

(2) Investment in associates and joint ventures

√Applicable □Not applicable

Unit: Yuan Currency: RMB investment Beginning of the period Impairment allowance Increase or decrease in the current period Closing balance Impairment allowance

164/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Unit Balance (Book value at the beginning of the preparation period Other comprehensive declarations of distribution under the equity method (Book price at the end of the preparation period Reduced investment and other rights accrued impairment value) Balance Additional investment Recognized investment income Cash dividends Other values) Balance changes in assets Provision

Capital gains and losses adjustments or profits

1. Joint ventures

None

Subtotal

2. Joint ventures

Weisbo Medical 21,224,269.55 -155,961.21 21,068,308.34 Subtotal 21,224,269.55 -155,961.21 21,068,308.34

Total 21,224,269.55 -155,961.21 21,068,308.34

(3) Impairment testing of long-term equity investments

□Applicable √Not applicable

Other notes:

□Applicable √Not applicable

165/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

4. Operating income and operating costs

(1) Operating income and operating costs

√Applicable □Not applicable

Unit: Yuan Currency: RMB Amount for the current period Amount for the previous period Items

Revenue Cost Revenue Cost Main business 333,856,043.11 166,969,708.44 397,949,451.48 181,866,634.10 Other business 1,036,521.27 264,864.24 945,325.06 570,106.91

Total 334,892,564.38 167,234,572.68 398,894,776.54 182,436,741.01

(2) Decomposition information of operating income and operating costs

□Applicable √Not applicable

Other instructions

□Applicable √Not applicable

(3) Description of performance obligations

□Applicable √Not applicable

(4) Description of apportionment to remaining performance obligations

□Applicable √Not applicable

(5)Major contract changes or major transaction price adjustments

□Applicable √Not applicable

Other notes:

None

5. Investment income

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount incurred in the current period Long-term equity investment income calculated using the cost method Amount incurred in the previous period

Income from long-term equity investments accounted for using the equity method -155,961.21 -215,248.83 Investment income from disposal of long-term equity investments

Investment income from trading financial assets during the holding period 596,516.57 6,236,747.88 Dividend income from other equity instrument investments during the holding period

Interest income earned from debt investments during the holding period

Interest income earned from other debt investments during the holding period

Investment income from the disposal of trading financial assets -6,376,392.00 -Investment income from the disposal of other equity instrument investments

Investment income from disposal of debt investments

Investment income from disposal of other debt investments

Debt restructuring proceeds

Total -5,935,836.64 6,021,499.05

Other notes:

None

166/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

6. Others

□Applicable √Not applicable

20. Supplementary information

1. Detailed statement of non-recurring profits and losses for the current period

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item Amount Description of profits and losses from the disposal of non-current assets, including the write-off portion of asset impairment provisions 48,941.77 Government subsidies included in the current profit and loss, except for government subsidies that are closely related to the company's normal operating business, in compliance with national policies and regulations, enjoyed in accordance with determined standards, and have a continuing impact on the company's profits and losses 2,484,701.69

In addition to the effective hedging business related to the company's normal operating business, non-financial enterprises have gains and losses from changes in fair value arising from the holding of financial assets and financial liabilities and gains and losses from the disposal of financial assets and financial liabilities.

Fund occupation fees charged to non-financial enterprises included in current profits and losses

Gains and losses from entrusting others to invest or manage assets

Profit and loss from external entrusted loans

Loss of various assets due to force majeure factors, such as natural disasters

Reversal of impairment provision for accounts receivable that has been individually tested for impairment

The investment cost of the enterprise in acquiring subsidiaries, associates and joint ventures is less than the income generated from the fair value of the investee's identifiable net assets when acquiring the investment.

Net profit and loss for the current period from the beginning of the period to the date of merger of subsidiaries resulting from business combinations under common control. Non-monetary asset exchange profits and losses

Debt restructuring gains and losses

One-time expenses incurred by the enterprise due to the cessation of relevant business activities, such as expenses for relocating employees, etc.

One-time impact on current profits and losses due to adjustments in taxation, accounting and other laws and regulations. One-time recognition of share-based payment expenses due to cancellation or modification of equity incentive plans.

For cash-settled share-based payments, gains and losses arising from changes in the fair value of employee compensation payable after the vesting date

Gains and losses arising from changes in the fair value of investment properties that are subsequently measured using the fair value model

Gains from transactions where the transaction price appears to be unfair

Profit and loss arising from contingencies unrelated to the company's normal business operations

Custody fee income from entrusted operations

Other non-operating income and expenses other than the above items 48,897.19 Other profit and loss items that meet the definition of non-recurring profits and losses

Less: Impact on income tax 1,663,667.63 Impact on minority shareholders’ equity (after tax)

Total 9,072,335.50

If a company determines items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and is significant in amount, and if it defines the non-recurring gain or loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as recurring gains and losses, the reasons should be explained. □Applicable √Not applicable

167/168

Hangzhou Aotai Biotechnology Co., Ltd. 2026 Semi-Annual Report

Other instructions

□Applicable √Not applicable

2. Return on net assets and earnings per share

√Applicable □Not applicable

Weighted average net assets Earnings per share Profit for the reporting period

Yield (%) Basic earnings per share Diluted earnings per share Net attributable to the company’s ordinary shareholders

1.30 0.64 0.64Profit

After deducting non-recurring gains and losses, attributable to

1.07 0.53 0.53 Net profit of the company’s common shareholders

3. Differences in accounting data under domestic and foreign accounting standards

□Applicable √Not applicable

4. Others

□Applicable √Not applicable

Legal representative: Gao Fei

Board approval submission date: August 28, 2026

Revision information

□Applicable √Not applicable

168/168